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Abstract 
Acute Myeloid Leukemia (AML) is a cancer of the myeloid lineage of blood cells 
characterized by rapid growth of undifferentiated myeloid precursors that 
accumulate in the bone marrow and suppress normal hematopoiesis. It is the 
most common adult leukemia with an estimated number of more than 60’000 
new cases for the US in 2016. Despite the high rates of complete remissions 
achieved after treatment (60-80% in young adults), the number of patient that will 
result cured after induction and consolidation therapy is very low (~12%). The 
molecular basis of relapsing disease is still unclear and the small number of 
identified predictive factors has small predictive power. To date, chemotherapy 
induction treatment is similar for all patients and consists in the administration of 
mainly three drugs (fludarabine, cytarabine, and idarubicin). Prediction markers for 
the outcome of chemotherapy would instead reduce useless treatments and 
direct research through new possible therapeutic targets that would enhance 
AML treatment. In three successive studies, Ding et al., Corces-Zimmerman et al. 
and Krönke et al., described four possible behaviors for relapse patients: the 
return of the first leukaemia (dominant clone or a subclone), with or without 
additional evolution, or the emergence of ancestral clones, also in this case, with 
or without additional mutations. In this thesis, endowed of the NGS technologies 
advancement, we decided to delineate the possible process of relapse formation 
in order to be able in the future to predict which patients are more susceptible to 
relapse. Our experimental plan includes the whole exome analysis of 30 pairs of 
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primary/relapsed AML samples using NGS to identify relapse-specific mutations, 
the bioinformatics analysis of the clonal evolution of the disease and the 
identification of pathways that correlate with the relapsing disease.  
The methods for the analysis of NGS data, at present, are still in a refinement 
phase, especially for the high level analysis (detection of variants and definition of 
their role in the pathogenesis). We broadly analysed the existing methods for the 
treatment of NGS data (aligners, mutation callers, CNV callers and methods to 
reconstruct clonal composition) in order to determine those better fitting to our 
cohort of patients and purposes: occasionally, we had the possibility to choose 
the best tool meeting our investigative needs, discovering that other methods 
were valuable as well, in other cases we verified that more improvements are 
needed to obtain reliable results.  
Our analysis shows that the genomic landscapes of primary and relapse AMLs are 
similar and in the majority of the patients (76%) some relapse clones were already 
present in the primary tumour and reappeared after chemotherapy at similar or 
augmented cellular frequencies. We also identified some functional gene 
categories (DNA methylation pathway, cohesin complex and chromatin modifiers) 
more prone to resistance and peculiar genes (e.g. ASXL1, TET2) presenting 
growing VAFs at relapse. In 4 out of 29 patients (14%) we were able to identify 
driver mutations in the blood sample of the complete remission at low frequency; 
we hypothesize that more sophisticated diagnostic tools, based on NGS analysis, 
would help in driving the treatment to obtain better outcomes for patients. 
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1. Introduction 
In the past two decades, the emergence of new technologies for DNA re-
sequencing prepared the ground for a deeper knowledge on the characteristics 
of tumours and the mechanisms of cancer development. In many cases this 
allowed to opt for more adequate and efficient treatments and better outcome 
for patients1,2. Despite many advances in the Acute Myeloid Leukaemia (AML) 
genomic characteristics have been disclosed, the treatment and outcome for the 
majority of patients has not improved. In this chapter we will describe the AML 
pathology and its emerging characteristics in order to put into context our study 
on the origin of relapsing leukaemia. 
 
1.0 The blood and the hematopoietic stem cells 
The blood serves all the cells of the body for nutrients and oxygen and is 
responsible for their immune protection. Blood cells have many distinct functions 
and characteristic morphologies that arise during hematopoietic cell 
differentiation. Since their lifespan is quite short, ranging from 4-6 days for the 
platelets to 110-120 days3 for the red blood cells, there is a continuous need for 
production of hematopoietic cells by the bone marrow that results in a turnover of 
~1 trillion cells per day (for an healthy man of 70 kg4) and takes place trough the 
maturation of the hematopoietic stem cells. 
The hematopoietic stem cells (HSCs) are located in the bone marrow and show 
the typical stem cell characteristics: 
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- self-renewal: through the mechanism of asymmetric cell division, HSCs are 
capable of producing new blood cells without the consumption of the stem cell 
pool, because one of the two daughter cells will differentiate loosing the self-
renewal potential while the other will retain all the characteristics of HSCs; 
- dormancy: the majority of the stem cells remain in the G0 (dormant) state of the 
cell cycle and only a small fraction participate to the active production of blood 
cells5 (cytokines are responsible for the activation signal); 
- non specialization: they do not have specific characteristics that allow them to 
accomplish functions like carrying oxygen molecules or recognize external 
antigens, but HSCs are capable of giving rise to mature cells. 
It is not yet clear whether the differentiation of HSCs is guided by a deterministic 
or a stochastic mechanism. The former assumption ascribes to the niche the 
induction of differentiation trough the secretion of specific factors or signalling 
(e.g. cell-cell interactions or cytokines), whereas the latter envisages complete 
randomness in the process limiting the role of the niche only to the regulation of 
which cells are going to progress and which other are dying via apoptosis.6,7 
The differentiation of HSCs takes place through the expression of a set of genes. 
The maturation state of a cell is recognizable by the membrane proteins 
expressed (differentiation markers) and the more it progresses, the more it will be 
difficult to turning it back to its multipotent primitive state. The cell proliferation is 
determined by specific growth factors that activate transcription factors via signal 
transduction pathways. Every depicted branch in Figure 1.1 is associated to 
specific growth factors (many of which are interleukins) activating the signalling 
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cascade that leads to a specific mature cell type. Interestingly, some of these 
growth factors, as erythropoietin and thrombopoietin, find application in the 
clinics for their capacity to stimulate the production of specific cell types8. 
Successively, transcription factors activate the coordinated expression of groups 
of proteins; their fundamental role can be gathered by the fact that their 
mutations are associated to many tumours (MYC is one of the most notorious and 
studied; for leukaemia, well-known examples are NF-kB and CEBPα). 
Figure 1.1: Haematopoiesis in humans. In the graph is depicted the whole lineage of 
hematopoietic cells along with the factors that promote differentiation at each step. 
(Adapted from A. Rad9) 
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1.1 Leukaemia 
Leukaemia is the cancer of the blood-forming tissue, arising from the abnormal 
production of blood cells in the bone marrow that divide continuously and 
eventually substitute normal cells in the blood stream, impeding oxygen 
distribution to the tissues, immunity functioning and bleeding control.  
The estimated number of new leukaemia cases in 2016 in the US is 60’140 (3.6% 
of all new cancer cases, data obtained from NIH10); in Europe in 2012 was more 
than 80’000 cases of which more than 8’000 coming from Italy11 (as reported by 
EUCAN). The mortality rate is very high: respectively of 24’000, 54’000, and 6’000 
patients per year.  
The program of differentiation defined in normal haematopoiesis is significantly 
modified in leukaemia. In normal haematopoiesis HSC differentiate in all the 
cellular components of the blood, in leukaemia the stem cells are blocked in their 
maturation program in a state defined as blasts. The subgroup of the blasts owing 
all the stemness characteristics is called Leukemic Stem Cells (LSCs) and is 
thought to serve as a reservoir of leukemic cells acting similarly to SCs for normal 
tissues. Theoretically, these cells are responsible to repopulate the leukaemia in 
immunodeficient mice upon transplantation. Additionally, it is believed that their 
quiescent phenotype in some cases provides them the capacity to survive 
chemotherapy and relapse. Gene expression defines the phenotypical nature of a 
cell, and maturation is pursued switching on and off specific groups of genes. As 
depicted in Figure 1.2, in normal haematopoiesis (left panel) there is a clear 
	  18	  
definition of biological pathway activation that leads from stem cells to 
progenitors; the same happens in leukemic cells although in a drastically different 
manner.12 LSCs have simultaneously strong similarities with HSCs and normal 
progenitors; again, differentiated blasts share many pathway characteristics with 
normal hematopoietic cells at diverse maturation stages. In leukaemia the 
organization of modules activation and inactivation is mixed. 
Figure 1.2: Activation and inactivation of cellular function pathways in normal HSCs 
and LSCs. Differentiation from stem cells to progenitors in the bone marrow follows a 
specific pattern of activation/inactivation of biological processes that leads to a certain 
transcriptional program. In LSCs that pattern is consistently modified in the maturation 
from stem cells to leukemic blasts. 
(Adapted from Vedi et al., 201612) 
 
Leukaemias are grouped into 5 major types, based on the cell type that became 
cancerous (lymphoid or myeloid) and on the progression of the disease, that can 
be rapid (acute) or slow (chronic): 
• Acute Lymphoblastic Leukaemia (ALL), 
• Acute Myelogenous Leukaemia (AML), 
• Chronic Lymphocytic Leukaemia (CLL), 
• Chronic Myelogenous Leukaemia (CML), 
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• Other leukaemias. 
Relative percentages of these 5 groups, as estimated for USA in 2014, are shown 
in Figure 1.3. 
Figure 1.3: Proportion of new leukaemia cases, divided per type, in USA in 2014: an 
estimation done by the American Cancer Society. 
(Adapted from Cancer Facts and Figures, 2014) 
 
In this study we are focusing our attention on the AML subgroup, which is the 
most frequent among adults; therefore, we are describing its characteristics more 
in detail. AML involves the myeloid lineage of hematopoietic cells and is 
characterized by the rapid growth of white blood cells in the bone marrow. Even 
though great advances have been made in the genetic characterization of this 
tumour, the disease entities are defined predominantly on cytogenetic and 
molecular markers. Two major classifications have been proposed and are used 
today to classify AML patients, the former is the French-American-British (FAB) 
classification firstly delineated in 1976, that groups AML subtypes based on cell-
type and maturation of the cell of origin13 (Table 1.1); the latter was produced by 
the World Health Organization (WHO) in 200814 and revised in 201615 and aims at 
a major relevance to the clinics and treatment (Table 1.2). 
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Table 1.1: French-American-British categorization of AMLs with cell-type and 
maturation of the cell that originated the disease and typical cytogenetic traits for each 
group. 
FAB subtype Name Cytogenetics 
M0 Undifferentiated AML  
M1 AML with minimal maturation  
M2 AML with maturation t(8;21)(q22;q22), t(6;9) 
M3 APL t(15;17) 
M4 Acute myelomonocytyc leukaemia inv(16)(p13q22), 
del(16q) 
M4 eos Acute myelomonocytic leukaemia 
with eosinophilia 
inv(16), t(16;16) 
M5 Acute monocytic leukaemia del(11q), t(9;11), 
t(11;19) 
M6 Acute erythroid leukaemia  
M7 Acute megakaryoblastic leukaemia t(1;22) 
 
Table 1.2: WHO schematic representation of subclasses of AML (2016). 
Acute myeloid leukaemia (AML) and related neoplasms 
 AML with recurrent genetic abnormalities 
  AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
  APL with PML-RARA 
  AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
  AML with t(6;9)(p23;q34.1);DEK-NUP214 
  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
  Provisional entity: AML with BCR-ABL1 
  AML with mutated NPM1 
  AML with biallelic mutations of CEBPA 
  Provisional entity: AML with mutated RUNX1 
 AML with myelodysplasia-related changes 
 Therapy-related myeloid neoplasms 
 AML, NOS 
  AML with minimal differentiation 
  AML without maturation 
  AML with maturation 
  Acute myelomonocytic leukaemia 
  Acute monoblastic/monocytic leukaemia 
  Pure erythroid leukaemia 
  Acute megakaryoblastic leukaemia 
  Acute basophilic leukaemia 
  Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
 Myeloid proliferations related to Down syndrome 
  Transient abnormal myelopoiesis (TAM) 
  Myeloid leukaemia associated with Down syndrome 
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Cytogenetic is used for classification but serves also as a prognostic factor. In fact, 
cytogenetic abnormalities have been associated to different relapse risks and 
overall survival. Grimwade et al.16 defined 3 risk classes: favourable, intermediate 
and adverse risk, based on the AML cytogenetics. Also genetic mutations have 
been associated with AML risk and principal markers are described in the next 
paragraphs. 
 
1.2 Next Generation Sequencing 
The advent of Next Generation Sequencing (NGS) allowed researchers to 
sequence genomes of already assembled organisms in a more rapid and cheaper 
manner than before. It is often referred as high throughput sequencing because 
its approach endeavours at the repeated sequencing of the same regions in order 
to strengthen the power of base calls. It can be used only for already assembled 
or very little genomes because it produces short reads that need to be aligned to 
a reference in order to map their position. In particular, the technology we used 
to sequence the human genome is the Illumina platform (Solexa), the bases of 
which are schematized in Figure 1.4. The genomic DNA is fragmented in small 
pieces (generally, it is sonicated and the fragments have a maximum size of 500 
bp); after fragmentation, specific adapters are ligated to each end of the DNA 
fragments. Through the adapters, each fragment is fixed on the sequencing flow 
cell and clusters of fragments are formed by PCR. The sequencing can be 
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performed twice, starting from both ends of each fragment for a specified 
number of nucleotides. The sequencing output consists of millions of sequencing 
reads of a given length (75, 100 or 150). The sequencing technique uses 
reversible terminator nucleotides: at each base the four nucleotides labelled with 
different fluorochromes can be incorporated, after wash out of the not 
incorporated nucleotides, the luminescence is registered. By subsequent rounds 
of sequencing, for every cluster present in the flow cell, forward and reverse 
sequences are produced. The sequencing can be pursued throughout all the 
genome (whole genome sequencing, WGS) or on targeted regions. Whole exome 
sequencing (WES), for example, targets all the known exons in the genome 
thanks to a specific capture enrichment step that uses oligonucleotides 
specifically designed to select only the portions of the genome of interest. 
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Figure 1.4: Illumina sequencing. In the figure are depicted the steps needed to perform 
Next Generation Sequencing through the Illumina platform. The genomic DNA is 
fragmented and adaptors are ligated to each end. The fragments are fixed to the flow 
cell trough the adapters and the clusters are generated by successive PCR cycles. 
Afterwards, both end of the fragments are sequenced. 
(Adapted from Illumina) 
  
The output of the machine consists in raw files containing all the reads 
information. The mutational analysis follows successive steps, starting with the 
mapping of all those reads to the reference genome through alignment 
algorithms. The reference genome derives from the sequencing of the genome of 
a single individual and, although many enhancements have been made, reads 
coming from another healthy individual aligned to the reference genome will, 
naturally, differ from it in many positions. These positions are called Single 
Nucleotide Polymorphisms (SNPs): they are the portions of the genome that 
characterize the phenotypical differences between individuals and, aside for some 
cases in which they are predisposing for some diseases, they do not have a 
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malignant potential. On the contrary, it happens in cancer that a genomic 
position differs somatically in the tumour cells from the correspondent germline 
position of the same individual: these positions are called single nucleotide 
variants (SNVs) and can be responsible for malignant phenotypes. The same 
applies for small insertions or deletions (indels) meaning that one or more bases 
can be gained or lost somatically. In the cancer context, the frequency at which 
this allelic differences are found is fundamental because it reflects the portion of 
cells carrying that variant in the tumour. The Variant allele frequency (VAF) is 
calculated as the number of reads carrying the alternative variants among all the 
reads spanning that genomic position. 
 
1.3 AML genomic landscapes 
As well as in many other cancer types, mutations implicated in the 
pathophysiology of AML may cause the activation of a proto-oncogene, the 
inactivation of a tumour suppressor gene or can alter the transcription of a gene 
through the mutation of the transcription factors binding sites. Thanks to the 
rapid evolution of technology in the last twenty-five years the mutational status 
and the levels of expression of many genes have been linked to acute myeloid 
leukaemia, however their exact coordination in the development of the disease 
still needs to be uncovered. We are, here, describing what is known up to date 
about the AML genome, retracing the milestone discoveries of almost thirty years 
of cancer research. 
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1.3.1 Established alterations in AML 
Cytogenetic alterations has been used for a long time as the major distinctive 
factor between AML subgroups, yet around half of AMLs have normal 
karyotype.17 In this paragraph we describe the major genetic alterations that have 
been discovered in AML through molecular biology before the advent of NGS. 
Since this study focuses on SNVs and indels landscapes, we are not explaining 
relevant translocations like AML1-ETO and PML-RARa, which are distinctive for 
AML subgroups. 
 
1.3.1.1 FLT3 
At the beginning of the 90’s a novel receptor tyrosine kinase was discovered to 
be specific of murine haematopoietic stem cells with enriched stem cell activity18. 
Further studies showed that the Fms-Related Tyrosine Kinase 3 (FLT3) is a growth 
factor receptor that promotes autologous proliferation, and it is quite commonly 
found constitutively activated in leukaemia patients. The most common mutations 
of FLT3 consist in an internal tandem duplication (ITD) that is found in 20-25% of 
the patients, and in a point mutation in the tyrosine kinase domain, that occurs in 
7.7% of the patients. The mutated allele is not always expressed and patients with 
a high mutant versus wild type ratio display a shorter overall and disease free 
survival19. 
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1.3.1.2 NPM1 
Nucleophosmin (NPM1) is a nucleolar phosphoprotein that shuttles between the 
nucleus and the cytoplasm. In 2002 NPM1 was described as a crucial regulator of 
the tumour suppressor p5320. Variants in NPM1 genes are generally insertions of 4 
bp in the 12th exon, causing a frame-shift that alter the C-terminal of the protein. 
The insertions most frequently observed, in descending prevalence order, are: 
variant B (960insCATG), variant C (960insCGTG) and variant D (960insCCTG). 
NPM1 variants are specifically observed in AML (35.2% of cases) and not in other 
neoplasms (both haematopoietic or extrahaematopoietic)21 and they confer 
distinct features to the mutated patients from a genetic, clinical, pathologic, 
immunophenotypic and cytogenetic point of view22 (Table 1.3). In particular, they 
are associated with a specific AML subgroup and display a gene-specific 
homeobox expression signature.23 NPM1 mutations can occur together with FLT3 
mutations, in this case the prognosis for the patient is better than for FLT3 
mutation alone. 
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Table 1.3: Characteristic features of NPM-mutated AML as reported by Falini et al.21 
Genetic features 
    NPM1 mutation is specific for AML, mostly “de novo” 
    Usually all leukemic cells carry the NPM1 mutation 
    Mutually exclusive with other “AML with recurrent genetic abnormalities” 
    NPM1 mutation is stable (consistently retained at relapse) 
    NPM1 mutation usually precedes other associated mutations (e.g. FLT3-ITD) 
    Unique GEP signature (↓ CD34 gene; ↑ HOX genes) 
    Distinct microRNA profile 
Clinical, pathologic, immunophenotypic, and cytogenetic features 
    Common in adult AML (∼ 30% of cases), less frequent in children (6.5%-8.4%)† 
    Higher incidence in female 
    Close association with normal karyotype (∼ 85% of cases) 
    ∼ 15% of cases carry chromosome aberrations, especially +8, del9(q), +4 
    Wide morphologic spectrum (more often M4 and M5) 
    Frequent multilineage involvement 
    Negativity for CD34 (90%-95% of cases) 
    Good response to induction therapy 
    Relatively good prognosis (in the absence of FLT3-ITD) 
 
 
1.3.1.3 RAS family 
The Ras family is a group of proteins with GTPase activity that play a vital role 
contributing in regulation of cell proliferation. In fact, several members of the 
family are mutated in many cancer types and they have been associated also to 
leukaemia in the late eighties as an infrequent mutation (~25% of the 
patients).24,25 Three notorious proto-oncogenes, that express the p21RAS protein, 
are part of this family: HRAS, KRAS and NRAS.26 Ras-family mutations generally 
affect codons 12, 13 and 61 of the gene transcript causing the amino acid change 
of a glycine into a bigger residue (valine, aspartate, cysteine, serine).27 KRAS 
mutated patients respond better to high cytarabine doses than not mutated 
patients28; its pathway or its regulating components are often associated with MLL 
rearrangements29 and are probably the result of genomic instability that causes 
damages in the most fragile portions of the genome. 
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1.3.1.4 CEBPA 
CEBPA is a transcription factor that coordinates proliferation and differentiation in 
myeloid progenitors, fine-tuning the activity of cyclin-dependent kinases. CEBPA 
variants often result in the disruption of the leucine zipper domain or in the 
premature protein termination and can be generated both by indels or point 
mutations affecting protein translation.30,31 Also a familial mutation has been 
reported for CEBPA, consisting in the deletion of the 212C.32 Variants in CEBPA 
occur in 16% of the patients30 and are associated with a good prognosis. 
 
1.3.1.5 RB1 
RB1 gene has a role in regulation of proliferation and differentiation, acting 
directly on the cell cycle and interacting with p53, MDM2 and the polycombs. Its 
role in cancer was primarily assessed for the retinoblastoma neoplasms, but 
mutations of RB1 are found also in AML. However, in contrast with the point 
mutations associated to the retinoblastoma phenotype, in leukaemia the RB1 
gene is often target of gross rearrangements and has been associated to poor 
prognosis.33  
 
1.3.1.6 TP53 
TP53 is probably the most notorious tumour suppressor gene. Its role is 
fundamental in senescence and apoptotic responses. Cells with dysfunctional p53 
can be subjected to wrong rearrangements of short chromosomes that lead to 
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the production of circular chromosomes and eventually to the wrong 
redistribution of genomic DNA after cell duplication. In fact, in leukaemia p53 
mutations are often associated to complex karyotypes.33 As long as the majority 
of tumour suppressors, mutations in TP53 do not need to be positioned exactly at 
one specific nucleotide of the gene: generally they are sparse and located 
between exon 5 and 8 (especially on the last). Mutated TP53 usually confer a 
worse prognosis in AML34. 
 
1.3.2 The genomic era 
In 2008 the DNA from a patient affected by AML has been the first cancer 
genome to be completely sequenced. For this study, the authors chose one 
patient presenting an AML belonging to the M1 subtype, which is the most 
common, representing approximately the 20% of all cases. The authors selected 
this particular subtype, thinking that its genome would be easier to analyse, as 
first attempt, because it is not associated with common genetic abnormalities.  
The authors identified the mutations by comparing the DNA coming from the 
tumour sample to its correspondent skin sample, used as normal counterpart, and 
discarding all the variants hitting non-genic regions to slim down the list. The 
resulting 11’192 variants were again refined to exclude introns, not-translated and 
synonymous variants (i.e. variants that do not results in changes of the amino 
acidic composition of a protein) to obtain a final list of 181 possible mutations. 
The majority of them resulted to be false positives. Indeed, the authors were able 
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to validate by PCR and Sanger sequencing only a list of 8 single nucleotide 
mutations and 2 small indels. These variants were present both in the tumour and 
the relapse sample (not sequenced, but tested for these variants) and were nearly 
absent in the skin sample, as expected. 
The two indels were common mutations in leukaemia, thus found in the FLT3 and 
the NPM1 genes. On the contrary, the eight Single Nucleotide Variants (SNVs) 
had not been previously identified in any leukemic genome and were absent in a 
cohort of 187 leukemic patients that were analysed for these mutations by PCR. 
However, the authors speculated that the inability to retrieve these mutations in 
other AML patients was mainly due to the small dimension of the test cohort and 
speculated on the possibility for PTPRT, CDH24, PCLKC and SLC15A1 to be 
implicated in the pathogenesis of AML, on the basis of the recurrence of 
mutations in these genes in cancers other than leukaemia. Also the other 4 genes, 
KNDC1, GPR123, EBI2 and GRINL1B, were interesting for their potential function. 
Notably, the skin sample, sequenced as normal reference, was found 
contaminated by leukemic cells, anticipating the important issue of the choice of 
which tissue to use as normal sample for genome and exome analysis of blood 
tumours36.  
After this seminal paper, many others studied the genomic landscape of AMLs 
and uncovered the relationships between genes and this pathology. The most 
important players newly identified are IDH1, IDH2,37 TET2,38 DNMT3A,39 EZH240 
and UTX41. Recently, also the spliceosome machinery have been associated to 
leukemogenesis42: mutations of spliceosomal genes, which fall in the class of 
	   31	  
tumour suppressors, may cause defective splicing, resulting in  accumulation and, 
as a consequence, unbalanced ratios of isoforms of crucial genes in the cells (e.g. 
RUNX1) that lead to leukaemia43. 
There are many groups worldwide aiming to characterize AML at a genomic, 
epigenomic and transcriptomic level and a joined effort has been made to build 
public databases of samples and clinical information from haematological 
patients. An example is the GIMEMA foundation in Italy, which collects samples 
and information from several haematological units all around the country; started 
with the aim to develop scientific research on haematological malignancies, now 
serves as a reservoir of samples with associated clinical information.  
The first genomic and epigenomic study on a relatively big number of AML 
patients was published by The Cancer Genome Atlas (TCGA), that analysed the 
DNA, either genomic or exomic, from 200 de novo AML patients in order to 
delineate the commonalities and peculiarities of this pathology44. This dataset still 
represents the largest public collection of AML DNA data and many successive 
publications performed further analysis on this same dataset. 
Compared to many other cancer types, AML results to be one of the less 
mutating tumours, with a median mutation frequency across patients of 0.37 per 
Megabase, even if there is a high inner variability among individuals, with the 
range of mutations that spans two orders of magnitude from 0.01 to 10 per 
Megabase45. Lawrence et al. in their 2013 Nature paper45 were able to correlate 
the genomic frequency of mutations both with the replication timing and the 
transcriptional activity across the genome, the overall small number of mutations 
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identified in AML patients may very likely be due to a slow cycling activity of the 
tumour cells of origin. Therefore, considering the natural error rate of the 
replication machinery and the replications time of such cells, a diminished 
mutation frequency can be imputed to a lower probability of accumulating 
mutations. However, the reason for the high variability of mutation rates across 
patients in AML remains still an open issue.  
Despite the cohort of patients was quite small in order to make good association 
studies, the authors observed a significant low number of mutations in patients 
presenting the PML-RARa and the MLL-x translocations compared to other 
leukaemia types, suggesting that these abnormalities do not need many 
cooperating events during the leukemogenic process. On the contrary, AMLs with 
RUNX1-RUNX1T1 fusions, with TP53 mutation and the AML associated to 
unfavourable risk groups present a significantly augmented number of mutations. 
Tier1 mutations are those causing changes in the amino acid coding regions of 
annotated exons, consensus splice-site regions, and RNA genes (including 
microRNAs).44 In the study of the TCGA mentioned above, AML presented from 0 
to 51 Tier1 mutations per patient with an average of 13 mutations. The analysis 
was carried on 200 AML patients for a total of 2315 somatic variants, 1528 (66%) 
of which were missense and 270 small insertion and deletions, which caused 
frameshifts in 192 (71%) cases. 
Recurrent genes are defined as the genes mutated somatically in at least two 
samples: 260 genes presented these characteristics and 154 of them were 
recurrently mutated missense. Among them, the authors scored genes already 
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established to have a role in the pathogenesis of AML from a very long time 
(DNMT3A, FLT3, NPM1, IDH1, IDH2 and CEBPA) and from recent years (U2AF1, 
EZH2, SMC1A and SMC3). 
 
1.3.2.1 Driver and passenger mutations 
It is straightforward that distinct mutations may have disparate relevance for 
cancer formation depending on the base of the codon they affect: they can have 
no effect (synonymous mutations), cause the change in amino acid sequence (non 
synonymous mutations) or determine the complete termination of the amino acid 
chain (nonsense mutations). Furthermore, the gene that has been targeted by the 
mutation can be either expressed or not in the cell type expanding in the tumour 
and the gene can have an essential or irrelevant role for the maintenance of 
regular cellular functions (many cellular pathways enclose redundancies). The 
mutations that are responsible for the tumour phenotype are called “driver”, 
while other mutations that are carried in tumour cells but do not give significant 
contribution to the altered condition are called “passenger”. 
Many tools have been developed to recognize which genes are more likely to 
have a paramount role in cancer development thus including “driver” mutations 
(i.e. “driver” genes). Driver genes are thought to have an enriched frequency in 
the patient population because of their causality. Therefore, algorithms that aim 
at the identification of driver genes use for their predictions the information about 
the frequency of the mutation in the patient populations, in some cases corrected 
for other confounding parameters45 (e.g. gene length), or in other cases 
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associated to other quality information such as the typical mutational patterns of 
an oncogene or a tumour suppressor gene, like DOTS-Finder, a tool developed in 
our laboratory.46 
In Figure 1.5 are reported the 23 genes which resulted to have a significant 
mutation prevalence from the analysis with Mutational Significance in Cancer 
(MuSiC) tool47, that aims at the distinction of true causal mutations from 
passenger events. The majority of them had been previously described as crucial 
players in AML development because they were molecularly identified in AML 
patients.  
Figure 1.5: Genes significantly prevalent in AML according to MuSiC. In the graphic 
is reported the number of mutations observed for the 23 genes identified as drivers using 
the MuSiC tool on the TCGA data on AMLs.  
(Adapted from TCGA, 201244) 
	  
 
1.3.2.2 Functional categories of genes implicated in AML 
The process that drives from mutations to tumour development is due to the 
impairment of essential cellular functions. Different mutations in different genes 
can give the same phenotypical outcome if they affect the same pathway. The 
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investigation of altered pathways may, therefore, uncover the fundamental 
functions that are disregulated in the specific tumour (i.e. AML); consequently, 
genes that would be catalogued as passenger from an approach based uniquely 
on frequencies, can unveil their causal role when investigated in their pathway 
context. HotNet48 is the implementation of an algorithm designed to identify de 
novo subnetworks implicated in tumour development, given a list of mutations 
detected in a cohort of patients. Starting from an interaction network, HotNet 
firstly defines gene neighbourhoods in a diffusion perspective and, subsequently, 
tests the false discovery rate of the identified subnetworks in order to extract the 
more reliable. Using this tool, the TCGA44 described that 99% of AML patients 
carried at least one mutation belonging to one of the 9 clusters identified (Figure 
1.6): 
- transcription-factor fusions, 
- the gene encoding for nucleophosmin (NPM1), 
- tumour suppressor genes,  
- DNA-methylation–related genes,  
- activated signalling genes, 
- chromatin-modifying genes, 
- myeloid transcription-factor genes, 
- cohesin-complex genes, 
- spliceosome-complex genes. 
Furthermore, they were able to assess whether couples of genes were mutated in 
the same patient at the same time (co-occurrent) or significantly rarely found 
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together in the same patient (mutually exclusive). They uncovered the presence of 
co-occurrence patterns between NPM1 and FLT3 and NPM1 and DNMT3A; on 
the other hand, NPM1 and FLT3 resulted mutually exclusive with RUNX1 and 
TP53. All these results can support the definition of a putative mechanism for 
AML development. 
Figure 1.6: Functional categories for mutations identified in AML patients. For every 
patient the box is filled in correspondence of a mutation. Genes are grouped in the 9 
classes detected by HotNet, cytogenetic risk and types of mutation are explicated by the 
colour of the box.  
(Adapted from TCGA, 201244) 
 
 
1.3.2.3 Identification of mutational spectra 
Understanding the origin of the mutations is valuable for many reasons: it can 
pinpoint the patients that have higher risk of developing the disease and 
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anticipate diagnosis, advance new potential therapeutic targets and enforce the 
promotion of healthier life styles. Several environmental factors can foster the 
appearance of new mutations; the use of reverse engineering approaches can 
guide to deduct the causal relationship between mutations and environmental 
factors. Analysing the mutations in a trinucleotide context is a step forward 
analysis that comes after mutation identification. It considers the mutations and 
the flanking basis as a single unit and recognizes typical patterns of mutations 
related to a specific tumour; consequently it is able to suggest a possible 
mechanism for mutation appearance. The mutational spectrum for a pathology is 
represented as a three-dimensional bar plot (Figure 1.7) in which the bars are 
disposed as six rectangles coloured on the basis of the point mutation 
considered; each rectangle contains sixteen bars correspondent to the possible 
trinucleotide contexts for that point mutation. The height of the bar represents 
the number of mutations of that type. The NMF algorithm divides all the TCGA 
patients in six factors characterized by peculiar spectra of the mutational 
landscape described. Tp*A -> T transversion dominates the AML mutational 
spectrum; this type of mutation is mainly found in leukaemias (AMLs and CLLs), 
but its interpretation is not yet clear. 
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Figure 1.7: Mutational spectra. a. Description of the composition of mutational spectra: 
every rectangle on the plane represents a mutation in a trinucleotide context. The six 
different colours are associated to the six possible point mutations and the group of 
boxes of the same colour are linked to all the possible trinucleotide contexts for that 
point mutation. Analysing all the tumours in the TCGA cohort, Lawrence et al. identified 
six typical mutational spectra behaviours; b. AML mutational spectrum is dominated by 
the Tp*A -> T base change  
(Adapted from Lawrence et al., Nature 2013) 
 
 
1.4 AML risk increases with age  
The mutational spectrum analysis described in paragraph 1.3.2.3, grouping 
mutations together by base change and the genomic context in which the 
mutation occurs, gives a first input on the possible mutational process that led to 
the development of the disease. The consequent intriguing question would be 
whether there exist combinations of mutations that can be associated to a specific 
mutational process (mutational signatures). Alexandrov et al.49 developed an 
algorithm able to extract the mutational signatures from groups of patients 
affected by the same cancer. This algorithm considered mutation types in a 
trinucleotide context and found the solution in which the smallest number of 
signatures better explains the observed portion of mutations. Subsequently, the 
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authors used hierarchical clustering to put together the same signature coming 
from different cancer types and end up with 27 signatures for the 30 cancer types 
analysed. They were also able to associate some of these mutational signatures to 
possible mutational mechanisms49. As an example, signatures 1A and 1B (Figure 
1.8.a) are present in the majority of cancers and have been both related to aging, 
because their abundance correlate significantly with the age at diagnosis in many 
cancer types. The strong correlation with age suggests that the mutations 
belonging to these signatures are naturally acquired during the lifetime of an 
individual. Mutation rate heterogeneity among individuals suffering of the same 
cancer type can be due to diverse environmental factor risks (e.g. exposure to 
carcinogens) or to the acquirement of mutations affecting repair mechanism or 
other pathways that promotes mutation accumulation before/after cancer 
initiation (Figure 1.8.b). Because both signatures 1A and 1B are associated with 
age, they are mutually exclusive between cancer types. However, the former is 
always found in copious groups of patients and the latter in smaller groups, 
suggesting that they are just two version of the same signature.  
This type of analysis applied to AML showed that AML patients present only 
signature 1 in both forms (A and B). The majority of the patients show signature 
1B probably due to the fact that AML patients in this study were 200 (Figure 
1.8.b).  
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Figure 1.8: Mutational signatures identified across human cancer types. (a) for every 
signature identified is reported in which (and in how many) cancer types it was found as 
significantly enriched and the probable association with mutation causes and 
mechanisms; (b) for every AML patient is reported the prevalence of mutational 
signatures as the number of mutations for that signature per Megabase.  
(Adapted from LB Alexandrov et al.49) 
 
These results are in line with the fact that AML is typically a cancer of advanced 
age, however unexpectedly also healthy elderly individuals can present signs of 
clonal haematopoiesis. Early studies detected clonal haematopoiesis events in 
23.1% of normal elderly women (mean age 76) through the observation of X 
chromosome inactivation patterns using HUMARA assay 50. The authors 
hypothesized three possible scenarios for these results: the slow selection of 
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differences related to the X chromosome, a stem cell depletion that leads to 
clonal dominance over time or a clonal advantage given by the mutations. The 
last theory was confirmed by the detection of recurrent TET2 somatic mutations in 
normal elderly individuals51. Also copy number alterations resulted to have an 
increased frequency after 75 years: from 0.23% before 50 years to 1.91% 
between 75 and 79 years52.  Moreover, it has been shown that the blood of 
normal individuals with no signs of haematological disorders present one or two 
somatic mutations in genes already described as drivers in haematological 
malignancies. In particular, the most frequently mutated genes are DNMT3A 
(which is largely the most represented and has been found mutated also in the 
blood of remission patients up to 8 years after initial AML diagnosis)53, TET2 and 
ASXL154,55 (Figure 1.9.b). Figure 1.9.a reports the frequency of somatic mutated 
individuals divided in groups according to their age. Since the 17’182 normal 
samples analysed came from a cohort of WES samples collected for other scope 
than haematological malignancies, it turns out clearly the impact of aging, and 
therefore of time, on the occurrence of somatic mutations. Somatic mutations in 
healthy peripheral blood increases tenfold comparing people under 50 and over 
65 years old and, in parallel, also the risk for haematological cancer increases 
(hazard ratio, 11.1; 95% confidence interval [CI], 3.9 to 32.6 and hazard ratio, 
12.9; 95% confidence interval, 5.8 to 28.7 in two different studies54,55). 
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Figure 1.9: Elderly normal individuals present and augmented rate of mutations in 
the peripheral blood cells. a. Frequency of somatic mutations is reported for every 
group of age from a cohort of 17,182 normal samples, the red area refers to the 50th, 75th 
and 90th percentiles; b. Number of mutations identified in the ten most mutated genes in 
normal individuals.  
(Adapted from Jaiswal et al.56) 
 
 
1.5 Leukaemogenesis  
There are many questions regarding leukaemogenesis that at present are still 
unanswered as the characterization of the cell of origin of AML, whether there is a 
predefined order for the appearance of the mutations that lead to the 
development of the leukaemia, the possibility that pre-leukemic cells persist after 
treatment and guide the successive relapse. All these questions have an 
impressive impact on the clinic, the search for new treatments and the outcome 
for patients.  
There is little information about the preleukemic phases of AML, because, of 
course, typically AML is diagnosed after full evolution of the disease. For this 
reason it is difficult to trace the exact consecution of changes that lead a normal 
cell to become leukaemogenic. However, there are some AML patient subtypes 
for which some developmental information has been collected. Myelodisplastic 
Syndrome (MDS) is a malignancy that often precedes AML: at the cellular level 
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the bone marrow becomes clonal but the cells maintain their ability to 
differentiate57 and have a high rate of apoptosis58. In some patients affected by 
MDS, these two latter cellular characteristics are lost and the disease evolves in 
acute leukaemia. The mechanisms at the basis of the development of MDS have 
not been identified yet and there is not a common mutation to all cases that can 
be pointed out as the responsible for this pathology. Furthermore, patients 
present a phenotypic heterogeneity that may have a genetic origin, although 
there is no clear genetic profile associated with the different phenotypic 
categories. Indeed, MDS patients show mutations in many AML genes that are 
associated to poor prognosis: those belonging to the chromatin regulation 
compartment as DNMT3A, TET2, IDH1 and IDH2 involved in the CpG island 
methylation of promoter regions; ASXL1 and EZH2 that are members of the 
polycomb family and act modifying the histone proteins; oncogenes and tumour 
suppressors like RUNX1, ETV6, TP53, EVI1, JAK2. They often present uniparental 
disomy (10-15% of patients) that consists in the acquisition of both copies of a 
chromosome (or part of a chromosome) from the same parent, and in many cases 
small insertions and deletions are present. Finally the genetic lesions that mostly 
characterize MDS patients are spliceosome mutations (e.g. SF3B1, SRSF2, U2AF1, 
ZRSR2) that are present in 85% of the cases. In general, these mutations are 
mutually exclusive and may play a role in the splicing of crucial genes like TET2, 
RUNX1 or act cooperatively with other genes as DNMT3A that often co-occurres 
with SF3B140,59.  
Observation of the MDS patients provides a landscape for the emergence of the 
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leukaemia but it is possible that these mechanisms do not retrace the AML 
development in not myelodisplastic patients. Elderly normal individuals with 
clonal haematopoiesis that eventually evolved in AML are the source of additional 
information on the genesis of the pathology55. Up to date, three cases have been 
reported and two of them developed leukaemia very rapidly: two months after 
clonal haematopoiesis was observed, they were diagnosed respectively of MDS 
and AML. The authors reanalysed by WGS the first blood sample collected and 
identified many AML mutations in the first patient (Figure 1.10.a) at frequencies 
consistent with the presence of a clone. The mutation with highest frequency was 
ASXL1, considered the putative founder of this clone; other known drivers 
identified were RUNX1, TET2, STAG2, SRSF2, all mutations also identified in MDS 
patients. The second patient (Figure 1.10.b) had two different mutations on 
CEBPA that were found also in the bone marrow at diagnosis (together with three 
putatively passenger somatic mutations) at a slightly augmented frequency. The 
prognosis for this patient was favourable and he achieved complete remission 
after treatment. For the third patient, the authors were able to hypothesize the 
sequence of genetic lesions that predisposed the emergence, 34 months after 
the first sampling, of AML (Figure 1.10.c).  In this case they identified a TP53 
mutation, present at 86% of allele fraction at diagnosis. This mutation was present 
at 23% in the precedent blood sample tested. Thanks to the concurrent presence 
of a number of chromosomal rearrangements, they were able to put in a temporal 
sequence the changes described in the Figure below (1.10): the tumour arose 
from a subclone that was present at 3% frequency in the first sample examined 
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and that gained additional aberrations, becoming more aggressive. 
Figure 1.10: The evolution of clonal haematopoiesis in 3 individuals that developed 
haematological malignancies after being sequenced as normal elderly. (a,b) For 
patient 1 and patient 2 are shown the VAFs of the mutations identified in function of the 
sequencing coverage. The –log10 p-value is associated to the probability of each 
mutation of having a VAF lower than 50% (binomial test). Red dots indicate the variants 
that hit known driver genes in leukaemia. Panel c. shows the reconstructed evolution of 
the rearrangements occurrence in patient 3 as indicated by WGS. Percentages have been 
estimated based VAFs, the colours are associated to the genetic lesions depicted in the 
box at the beginning of the shading and its expansion.  
(Adapted from Genovese et al.55) 
 
Majety’s group hypothesized that the leukaemia cell of origin engenders from a 
HSC. Self-renewal capacity and longer lifespan would allow accumulating 
mutations circumventing the low rate of spontaneous mutations. In fact, they 
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were able to identify through WES, leukaemia associated mutations in a 
population of HSCs with normal activity isolated from AML patients. Mutations in 
common between the HSCs and the frank leukaemia hit genes like NPM1, TET2, 
SMC1A and CTCF. Furthermore, in five cases, the authors were able to find some 
mutations of the frank leukaemia but not all, indicating that the cell of origin of 
the leukaemia started from the HSC compartment and accumulated additional 
mutations60. In a successive study61, the authors separated HSCs on the basis of 
the expressed surface markers and divided the leukaemia mutations in: i) pre-
leukemic mutations, mutations present in the HSC population at VAF higher than 
1%; ii) late mutations, mutations absent in the HSC population. They, then, 
stratified the patients by functional categories, based on the function of the 
mutated genes, and uncovered that some categories were preferentially mutated 
in the pre-leukemic phase and some in the late phase (Figure 1.11). In agreement 
with the results already obtained from mutational analysis of MDS and normal 
elderly individuals, the authors found, in the first phase of the disease, an 
implication for “landscaping”61 genes, that include DNA methylation, chromatin 
modification and cohesion complex genes; and for late mutations, mutations that 
affect signalling genes that promote the progression to overt leukaemia. 
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Figure 1.11: Mutations of 16 patients and their occurrence in early or late phase of 
AML development stratified by categories. Mutations that were already detectable in 
the HSCs of the AML patient are considered pre-leukemic, those that do not fulfil these 
requirements are considered late. Mutations were divided in subgroups as described in 
TCGA paper44.  
(Adapted from M. Ryan Corces-Zimmerman et al.61) 
 
In particular, landscaping mutations are thought to prepare the HSC to clonal 
expansion conferring a competitive advantage as it has been demonstrated for 
TET238, DNMT3A62 and IDH137. Therefore, the leukemic transformation appears to 
be the combined effect of two successive alterations that confer first a self-
renewal gain of function followed by a proliferation gain of function (Figure 1.12).  
Figure 1.12: Schematic representation of the synergistic effect of landscaping 
mutations and activated signalling mutations necessary for leukemic transformation. 
The cooperation of these two types of mutations enhances the capacity of a HSC to 
become leukaemogenic.  
(Adapted from Sykes et al.63) 
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1.6 The complexity of clonal architecture 
In paragraph 1.5 we described the emerging evidence on the genesis of AML, 
describing it as a linear process. However, that is an oversimplification that 
allowed us to explain the concepts on the process underlying. Now we can 
examine in depth the context that subtend the events previously described. 
Indeed, in the last decade, with the advent of NGS, the complexity of clonal 
architecture of cancer is becoming more and more evident. In fact, the 
composition of the cancer population, instead of being formed from a single 
clone accumulating successive mutations, is more likely composed of multiple 
clones, characterized by different genetic compositions that exist together at 
different frequencies in the tumour population. An example of this behaviour is 
reported in Figure 1.13 in which it is possible to identify 4 different clones in the 
AML population. The authors filtered out CNVs, keeping only regions with two 
chromosomal copies and, afterwards, clustered the mutations with similar VAF to 
obtain the possible mutational composition of distinct clones. DNMT3A 
mutations, considered the initiating mutations for this patient, appear in the clone 
at highest frequency (considering that frequencies of X-linked mutations in males 
have doubled VAF). This AML clone can be considered the dominant clone, but 
there are at least two other subclones present in the sample at lower frequencies. 
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Figure 1.13: The clonal composition of a leukemic population in a patient. The plot is 
divided in an upper panel, that displays the density of mutations at a specific VAF in the 
sample, and a lower panel in which the VAF is connected to the coverage at each 
position. The colours represent distinct subclones (clusters), as predicted by the 
algorithm SciClone. Numbers highlight the position of driver mutations in the clones. 
(Adapted from C. Kandoth et al.64) 
  
Indeed, heterogeneity has been observed across many cancer types and there 
seems to be a general trend for clonality in cancer: tumours often show the 
presence of more than a single clone per patient and in a study of 1’165 patients 
analysed across 12 cancer types, 86% had at least two clones. Furthermore, the 
number of sub-clones forming the tumour seems to correlate to the mortality risk 
for the patients. When the number of subclones is greater than 2, the hazard ratio 
is 1.49 (95% CI: 1.20–1.87)65, comparing them to tumours formed only by one or 
two clones. Interestingly, there seems to be an upper limit for the number of 
clones in a tumour: when the clones are more than four, genomic instability likely 
becomes problematic for the tumour itself, reducing the risk for the patient. 
The forces that interplay giving rise to intra-tumour heterogeneity are somatic 
mutations, natural selection and adaptation to the tumoural microenvironment. 
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Environments  (like the primary tumour site, the organs target of metastasis or the 
exposure to carcinogens, as UV light, tobacco smoke or chemotherapy) drive the 
selection of some clones in favour of others. In Figure 1.14 is schematized the 
effect of the environment on cancer evolution at different stages. Every new 
mutation in a cell enters in a picture that was already designed and its emergence 
can be neutral, give an advantage or be deleterious for that cell 66. The effect of 
addition of a mutation to a cell is called epistasis and the impact of epistasis on 
tumour evolution is confirmed by the presence of co-occurrence and mutual 
exclusivity of mutations in cancer genes (as already described in paragraph 
1.3.2.2)44. Furthermore, cancer evolution does not always occur stepwise but 
catastrophic events may take place, changing dramatically the genomic 
landscape of a cell (e.g. chromotripsis). 
Figure 1.14: The evolution of cancer genome. This scheme reports a complex 
hierarchical composition of cancer that arises from the emergence of many driver 
mutations in different tumour subclones and can generate relapses and metastasis 
genetically different from the dominant clone in the primary tumour. 
(Adapted from Yates et al.66) 
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Many approaches, both biological and mathematical, have been used in the last 
years to uncover the genetics of heterogeneity in cancer and the main categories 
of these strategies are discussed below. 
 
 
1.6.1 Multi sampling  
Multi sampling consists in the analysis and comparison of repetitive sampling 
from the same patient. Samples can be temporally distinct, as, for example, the 
diagnosis and relapse samples of a patient, or spatially distinct, like the parental 
tumour and the metastases of the same neoplasm or sampling of different 
portions of the same tumour mass. Recently, many groups have started to 
combine these two approaches collecting samples both temporally and spatially 
distinct from each other and analysing them together. 
An example of multiple sampling is reported in the study of Schramm et al.67, in 
which the mutational analysis of a primary neuroblastoma was compared to the 
analysis of its five relapse and metastasis samples. The authors performed WES 
analysis of all the samples and, subsequently, after filtering the positions that 
reached the minimum quality requirements in every sample, they computed a 
table containing all the alleles that showed a different base (e.g. nucleotide 
variant) from the others in at least one sample. Using this table, they simply 
calculated the Hamming distance (i.e. number of substitutions needed to obtain 
one sequence from the other), as the number of positions in which they differed, 
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between each couple of samples. After using neighbour-joining algorithm68 to 
construct the tree of relationships among the samples, they uncovered that every 
relapse contained private mutations and that there were at least two different 
clones at the origin of the very heterogeneous relapse and metastasis samples. 
There is a flourishing publication of methods aiming at the reconstruction of 
clonal composition starting from the variations identified in multiple samples from 
the same patient69–72. Despite the mathematical models at the basis of these 
methods are sometimes very different, all of them use VAFs, corrected for the 
copy number prevalence at the site of the mutation, to group variants into 
clusters in the sample. We describe in details these different methods in the 
Materials and Methods section (paragraph 3.6).  
 
1.6.2 Single-cell sequencing 
Single cell sequencing is the more precise method to infer clonal composition of 
tumours because it effectively permits to determine which variants, indeed, 
belong to the same cells. However, this method is costly, has some bias that still 
need optimization and, for the time being, is not ready for high throughput 
analyses. An example of a study using single cell sequencing in two breast 
cancers to reconstruct the subtended tumour populations was performed by 
Navin et al. in 201173. The authors analysed 100 single cells from two tumours, 
one monogenomic and one polygenomic; in both cases they uncovered the 
presence of a consistent subpopulation of genetically diverse cells that, for the 
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case in which they disposed also of a metastatic sample, were not identified at 
the metastatic sites. 
 
1.6.3 Mathematical and statistical models 
In order to deal with the issue of the resolution of an admixture of cells in a single 
sample, also computational approaches can be exploited that allow to determine 
the genetic makeup of the cell subpopulation and their prevalence in the sample. 
Greenman et al.74 developed a method that employs point mutations and 
genomic rearrangements to reconstruct the sequence of events that took place in 
a sample, building a sort of historical reconstruction with the use of the graph 
theory. In 2012 Nik-Zainal et al.75 used this algorithm to reconstruct “the life 
history” of 21 breast cancers. In their cohort of patients, they were always able to 
identify a dominant clone representing about 50% of the tumour cells. The 
remaining population was formed by a great number of low-frequency subclones 
harbouring hundreds to thousands of mutations (see Figure 1.15 for an example). 
This finding enabled the authors to propose the existence of a quiescent reservoir 
of cells that are potentially capable of repopulating the tumour after the 
acquisition of new proliferative advantaging mutations. 
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Figure 1.15: The phylogenetic tree reconstruction for a breast cancer patient. The 
authors reported the alterations characterizing each clone and sub clone and the 
abundance of the cells in the tumour population (thickness of the grey lines). 
(Adapted from Nik-Zainal et al.76) 
 
 
1.7 State of the art of treatment in AML and 
determination of remission in patients 
With the exception of APL, the specific M3 subtype of AML, which has a distinct 
mechanism of leukaemogenesis and for which has been developed a successful 
molecular treatment, treatment of the other AML subtypes is general and is 
consolidated, with no great changes in the administered drugs since many years. 
The treatment is divided into two main phases: the first aims at the rapid 
eradication of the AML blasts and induction of the remission of the leukemic state 
(remission induction or, simply, induction therapy); the second aims to prevent 
the relapse of the disease (consolidation or post-remission therapy). 
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Since leukaemia is a very fast growing tumour, the induction therapy needs to be 
performed immediately after diagnosis and physicians, generally, choose the 
strongest treatment the patient is able to sustain, in order to have a good 
probability to eradicate the tumour. The general, treatment for the induction 
therapy is known as “3+7” and involves three days of anthracycline administration 
(daunorubicin, idarubicin or anthracenedione mitoxantrone) and seven days of 
cytarabine. Complete remission (CR) is achieved in 60-80% of young patients and 
in 40-60% of elderly patients77. Many other drugs and combination of drugs have 
been used through the years to test their possible advance in treatment outcome, 
however, based on the evaluation of the risks given by toxicity, the CR rate and 
the overall survival, the “3+7” is still the best compromise. After the induction 
therapy the leukaemia population is reduced under the cytogenetically 
detectable threshold (~109 cells); however some leukemic cells can persist after 
treatment and, without a supplementary treatment aimed at maintaining the 
remission state, these cells can eventually lead to relapse. This second phase of 
treatment is called consolidation therapy and comprehends additional drugs 
and/or bone marrow transplantation (or hematopoietic stem cell transplantation, 
HSCT). This second phase of the treatment is more compliant with patient’s and 
AML’s specific characteristics. It has been demonstrated that four cycles of high 
doses of cytarabine  (3 g/m2 per q12h on days 1, 3, 5) give better results than 
lower doses78; similar response should be achieved with other chemotherapeutic 
agents at high doses. Autologous HSCT has effects similar to chemotherapy and 
is recommended only for high risk cytogenetic patients, allogeneic HSCT is 
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associated to low relapse rate both in intermediate and high cytogenetic risk 
patients79. The positive effect of these treatments is given by the graft-versus-
leukaemia effect80 that is an anti-tumour response arising only after 
transplantation. 
Different treatment is reserved for older patients (≥ 60 years) for which the 
standard therapy is more often toxic and have an increased relapse risk; with 
standard “3+7” treatment their life expectation is 8 to 12 months81. It is possible 
that the characteristics of age-related leukaemia, already elucidated in paragraph 
1.4, impart a stronger resistance to the disease and results into poorer outcomes. 
Activation of the RAS, SRC and TNF pathways may play a role in these events.82 
Therefore, suggested treatment for patients between 60 and 74 years of age has 
a “3+7” walk but envisages cytarabine at reduced doses compared to standard 
treatment, doses that need to be adapted to the patient characteristics. The same 
rules applies to the consolidation therapy: only rare cases benefit from dose 
escalation after the first chemotherapy and, usually, allogeneic HSCT offers the 
best results.79 After 75 years of age, the choice of the treatment has to be taken 
together with the patient because low doses of cytarabine can be toxic, resulting 
in a 30 days mortality rate of 26%. Furthermore, cytogenetics and AML type have 
a greater impact on the response to treatment in this age category.79 
The possible outcomes after standard treatment are diverse, because patients 
can be respondent, partially respondent or not respondent to therapy, according 
to achievement of complete remission (CR) after induction therapy. Achievement 
of complete remission is defined by the following criteria: 
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• percentage of blasts in the bone marrow below 5; 
• total absence of blasts with Auer rods; 
• values for neutrophil and platelet count in the normal range: > 1 x 109/l and 
100 x 109/l, respectively; 
• independence from red cell transfusions; 
• absence of extramedullary disease.83  
The remission state of a patient can be established at different levels, based 
on the type of technology used to determine it: 
• Morphologic: comprehends all the parameters discussed above except for 
counts of neutrophils and platelets; 
• Cytogenetic: applicable only in AML cases presenting cytogenetic 
abnormalities, consists in the return to a normal karyotype; 
• Molecular: different molecular markers can be used for testing and, in 
general, remission is achieved when the molecular marker tested at 
diagnosis is below the level of detectability. 
In some cases CR is achieved but the recovery is not complete (incomplete 
Complete Remission, CRi), because the patients present low neutrophil or platelet 
counts. Alternatively, the treatment may give partial results, with a decrease of 
the blast percentage insufficient to achieve CR (partial response), or no results at 
all. In this last case, the disease is defined as resistant because the leukemic cells 
are not affected by the chemotherapy. 
Despite the high rates of CR achieved after treatment, the number of patient that 
will result cured after induction and consolidation therapy is very low (~12%).84 In 
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the next paragraph, we discuss the characteristics of relapsing leukaemias and the 
possible mechanisms that underlay treatment failure. 
  
1.8 Relapsing AML 
Relapsing AML can arise from months to years after the first CR, and the first 
three years after CR are particularly crucial, because, beyond this period of time, 
the risk of relapse reduces steeply.84 The relapse free percentage at 6 years for 
patients, that already reached three years of disease free survival, was estimated 
to be ~86% on an American cohort.85 However, the percentage of relapsing 
patients is very high and understanding which patients have a higher probability 
to relapse would have a great impact on the clinics. 
Several markers have been identified that help the prediction of outcome at 
diagnosis. They are mainly based on cytogenetics, clinical information, clinical 
history or molecular factors. Age, as already discussed, is an important prognostic 
factor; old patients are more difficult to treat and relapse is more frequent in old 
than in younger individuals.86  
Cytogenetic plays an important role in the prediction of the treatment outcome 
and the risk stratification, already described in paragraph 1.3. Grimwade et al.16 
examined the rate of relapse at five years in a group of 1’612 patients; the overall 
percentage of relapse is 49%, but its range changes substantially in the three risk 
groups, as elucidated in Table 1.4. 
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Table 1.4: The influence of cytogenetically defined risk categories on relapse risk at 
5 years.  
Risk category Cytogenetic abnormalities Relapse risk at 5 years 
(range) 
Favourable t(15;17), t(8;21), inv(16) 29% - 42% 
Intermediate NK, +8, 11q23, +21, del(7q), 
del(9q), +22, other numerical 
or structural abnormalities 
39% - 60% 
Adverse Complex karyotype, -7, 
abn(3q), del(5q), -5 
68% - 90% 
 
Independently from the cytogenetic risk groups, the presence of the FLT3 ITD 
mutation is an important predictor for relapse in AML patients. Its presence is, in 
fact, strongly associated with increased relapse risk, adverse disease free survival 
and overall survival.87  
In contrast, NPM1 variants are generally associated to the favourable risk class, 
because the patients harbouring this mutation generally respond well to 
chemotherapy. However, the co-occurrence of NPM1 and FLT3 mutations 
weakens the respondent phenotype and shifts the response to therapy towards 
the adverse prognosis observed in patients harbouring the FLT3 ITD mutation.88 
Considering their impact on disease outcome and response to therapy, both 
FLT3 and NPM1 are used as fundamental markers for CR and their presence is 
tested during the follow up of the patients in order to detect the possible 
presence of residual tumour cells, defined as minimal residual disease. 
All of these markers show strong association with relapse free survival but they, 
even considered all together, are neither necessary nor sufficient for a confident 
forecast. For this reason, it would be of great clinical impact to identify new 
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markers that may allow the prediction of treatment outcome in AML patients at 
time of diagnosis. 
The treatment options for relapsing leukaemia mainly depend on the time in 
which relapse occurs: if relapse occurs within one year after the first CR, it is 
highly probable that the AML is resistant to therapy and the general suggestions 
is to consider the use of experimental drugs, followed by a HSCT, in case 
remission is accomplished; if the relapse occurs later, the first treatment of choice 
is the combination of drugs like daunorubicin, idarubicin and cytarabine89. 
The mechanism that causes relapse is known only for specific cases but for the 
majority of the patients it has not been elucidated yet; it might be possible that 
genetic abnormalities escaping conventional remission assessment techniques 
(i.e. minimal residual disease) can result in the recurrence of the disease months 
later. 
 
1.9 Clonal evolution in AML 
After this excursus on the clinical and biological presentation of relapsing AML, it 
sounds clear that it is of paramount importance to elucidate the mechanisms and 
the causes of relapse of the disease. Therefore, probably, the path that will guide 
us in understanding the molecular players that lead to relapse requires looking at 
relapse from an evolutionary point of view. Also the role of chemotherapy in 
induction of new mutations and in clonal selection needs to be further elucidated. 
The mutagenic effect of cytotoxic agents used to kill the tumour cells, in some 
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cases, can induce new mutations that provide selective advantage to the cancer, 
posing the basis for relapse (Figure 1.16.a). Indeed, chemotherapy may act as a 
selective force and, after treatment, clones resistant to the drug can expand 
(Figure 1.16.b). Alternatively, if the drug has the same effect on all main 
subclones, the empty niche may become the breeding ground for pre-existing 
clones or subclones that best fit to the new environment (Figure 1.16.c).90 These 
possible scenarios highlight the fundamental role played by tumour 
heterogeneity in AMLs: the presence of many subclones in the same patient and 
the possible presence of a reservoir of highly mutated cells enhance the chances 
for tumour regrowth and chemotherapy escape. 
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Figure 1.16: possible AML evolutionary scenarios in case of unsuccessful 
chemotherapy. a. Many drugs used for chemotherapy act through the induction of new 
mutations in the cells, a drawback of this mechanism is the possibility to induce mutation 
favourable for the progress of the disease; b. The sensitivity to chemotherapy can be 
modulated by many genetic and phenotypical features; for this reason cancer 
subpopulations can react differently to treatment; this can result in the emergence at 
relapse of populations that were subclonal in the primary tumour; c. When response to 
therapy is similar for all the clonal subpopulations the new environment is exposed for 
the expansion of the fittest clone, irrespectively of the mutations appearance time. 
(Adapted from Landau et al. 201490) 
 
In this context, many studies compared patient’s DNA at exordium and relapse in 
order to identify possible markers and mechanisms for relapse emergence. In 
2012, Ding et al.91 analysed the whole genome sequence (WGS) of 8 patients and 
described two alternative behaviours for their relapse: in 3 cases the dominant 
clone gained additional mutations at relapse, in 5 cases the relapse arose from a 
subclone already present at exordium that successively accumulated additional 
mutations (Figure 1.17). For model 1 the authors suggest that the patients could 
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be inadequately treated or the founder clone already contained a mutation 
conferring resistance, for model 2 they suggest the presence of resistant 
mutations or the induction of new crucial mutations by cytotoxic agents in a 
specific subclone. 
Figure 1.17: Two scenarios of evolution of the disease that lead to relapse in AML 
patients. In the first model the relapse arises from the dominant clone, which is not killed 
by chemotherapy and further evolved in the relapse. Clusters were identified grouping 
mutations based on their VAF at exordium and relapse, as shown in the graph at the right 
of the model. In the three patients presenting this type of relapse, we observe the 
presence of just two clones: the grey clone was already present at exordium and survived 
chemotherapy; the second clone, coloured in red, arises after chemotherapy. In model 
two many subclones are present in the primary tumour that can vanish, survive or even 
expand after treatment. 
(Adapted from L. Ding et al.91) 
 
The authors highlighted a significantly higher rate of transversions in the relapse 
compared to primary mutations. Compared to transitions, transversions are a kind 
of mutations more difficult to arise in the genome spontaneously and have been 
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associated to mutagenic factors such as tobacco smoke92 and cytotoxic agents.93 
Thus, the relapse specific mutations identified may be actively induced by the 
chemotherapeutic treatment. However, an alternative hypothesis could be that 
the low coverage they used to perform WGS (25X) is insufficient to identify low 
frequency mutations at exordium. 
In seven out of the eight patients the primary tumours contained mutations 
associated to preleukemic state of the leukaemia like DNMT3A, IDH1, IDH2, 
PHF6 and RUNX1. These “landscaping” mutations were also found in some 
remission samples by R. Corces-Zimmerman et al.61 In particular, this study shows 
that the preleukemic HSCs persisted in remission. Using targeted amplicon 
sequencing to detect the mutations at exordium and relapse in their three 
patients, the authors highlighted three different scenarios (Figure 1.18): in one 
patient the relapse probably originated from a preleukemic clone that persisted 
after chemotherapy and gained additional activating mutations leading to relapse 
formation; in the second patient a resistant subclone gained new mutations; in 
the third patient the relapse contained the same mutations identified in primary 
leukaemia, suggesting that the treatment was not completely effective. 
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Figure 1.18: three patients exhibit different patterns of evolution from the primary 
tumour to the relapse leukaemias. In the first patient, the relapse evolved from a 
preleukemic cell that acquired new proliferating mutations. In the second patient, the 
tumour arose from a subclone (like model 2 in Figure n.). In the third patient, the relapse 
leukaemia is the genetically identical to the primary AML, unveiling the survival of 
leukemic cells also at remission (MRD). 
(Adapted from Corces-Zimmerman et al.61) 
 
Krönke et al.94 in 2013 used, instead, SNP array techniques to analyse a cohort of 
53 adults with NPM1 mutated AML. They were able to observe all 4 possible 
combinations of the evolutionary behaviours described by the previous studies 
mentioned above: half of the NPM1 mutated AMLs appear to evolve from the 
dominant clone of the primary leukaemia, half from an ancestral clone containing 
only early “landscaping” mutations and without late events (Figure 1.19); in both 
cases, they observe the clone with or without the acquisition of new mutations. 
Similarly to the two studies previously described, new mutations are found in the 
evolution of the dominant clone or subclones, but, at the same time, they 
disclose the occurrence of relapse without acquisition of additional mutations in 
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the primary tumour clones. The mutations acquired at relapse were landscaping 
(e.g IDH1) and activating (e.g. NRAS). They never observed relapse originating 
from clones unrelated to the primary leukaemia.  
Interestingly, they uncovered the presence of an inverse correlation between the 
number of mutations shared by the primary and relapse disease and the time to 
relapse, suggesting that more time is needed for relapse when additional 
evolution is needed to restart the disease. 
Figure 1.19: Evolution of relapse in a cohort of 53 AML patients with mutated 
NPM1. Below is depicted the summary of the observations made by Krönke et al. in their 
study on the evolution of relapse. They observed 4 main categories of evolution: the 
major AML clone is present at relapse with or without evolution or an ancestral clone 
(that lacks late events from the primary clone) is present at relapse with or without 
additional mutations. Early events, in general, consist of mutations that affect so-called 
“landscaping” genes while late events consists of activating mutations. Mutations 
acquired at relapse can be of both types. 
(Adapted from J. Krönke et al.94) 
 
We think that these three studies glimpse the mechanism of AML relapse 
emergence that still needs to be further elucidated. Indeed, they highlight some 
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patterns in AML evolution but, at the same time, have some weak points that 
need to be solved. Ding et al.95 use WGS for their analysis, which gives a very 
broad look at the genome, but at low coverage, we believe that, at higher 
sequencing depth, some of the relapse specific mutations might be found also in 
the primary tumour. On the other hand, Corces-Zimmerman et al.61 and Kronke et 
al.94 use microarray for their studies: this technology gives results at higher 
definition but restricts the analysis exclusively to mutations already identified and 
inserted in the array a priori; furthermore, the former study had a very little 
cohort, only 3 patients, and the latter examined only a subset of all AMLs, AML 
harbouring NPM1 mutations. Indeed the combination of the strong points of each 
study described would give a more thorough representation of the relapsing AML 
genomic features. 
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2. Aim of the project 
After first remission, about three out of four AML patients relapse within 5 years 
from the original diagnosis. Relapse can be the result of persistence of leukemic 
clones or subclones and effective molecular markers would aid both in the 
identification of patients more prone to relapse and the determination of 
remission. The aim of our study is, therefore, to combine the strong points of all 
the studies described in paragraph 1.8 and to identify, through next generation 
sequencing (NGS), a group of mutations or a signature that might allow the 
prediction of the treatment outcome at the exordium of AML and to test the 
hypothesis that the chemoresistant phenotype is characterized by mutations that 
enable the cells to survive the pharmacological treatment and expand in the 
secondary tumour. Our experimental plan includes the whole exome analysis of 
30 pairs of primary/relapsed AML samples using NGS, to identify relapse-specific 
mutations, the clonal-evolution bioinformatics analysis to determine the evolution 
scenario that best fits the observed data and the identification of patterns of 
mutations or pathways that correlate with the relapsing disease.  
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3. Materials and methods 
In this section we describe all the methods we tested and effectively used for our 
analysis. We present multiple datasets because these analyses have been 
performed through the years while the data collection advanced. Paragraphs from 
3.2 to 3.6 are dedicated to methods refinement. Lastly, in Paragraph 3.7, we 
describe the cohort of samples and the pipeline of analysis effectively used for 
our project and in paragraph 3.8 we define the list of AML driver genes we used 
to highlight the possible players for tumour formation. 
 
3.1 The dataset 
The human AML and APL samples were collected at the University of Bologna, 
University of Rome Tor Vergata, University of Torino and University of Udine 
(Italy), and genomic DNA was isolated using standard protocols. In order to 
identify tumour-specific mutations, we compared each leukemic sample (bone 
marrow) to the corresponding normal DNA, isolated from blood cells at the time 
of clinical and molecular remission of the disease. Exome-capture was performed 
using the SureSelectXT Human All Exon v.1, v.2, v.4 and v.5 (Agilent 
Technologies) following the manufacturer’s specifications. For 25 samples a 
different exome capture was used for the analysis: for the primary and remission 
samples of BO6, BO7, BO9, BO10, BO11, BO13, BO14, BO16, BO21, BO22, 
BO23, BO24, BO27, BO28 TrueSeq rapid capture kit (Illumina) was used for 
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exome enrichment; on the contrary for primary and remission samples of BO5, 
BO8, BO12, BO15, BO17, BO18, BO19, BO20, BO25, BO26 and BO29 the 
capture has been performed with NextEra (Illumina). Whole-exome sequencing 
was performed with the Illumina Hiseq 2000 platform with 101 bp paired-end 
reads for all the patients except for UD14 that was sequenced on the Illumina 
NextSeq machine. General characteristics of the patients are reported in the 
Results section (Paragraph 4.2.1). 
 
3.1.1 Dataset for alignment testing 
Patients analysed in this context were 3 APLs and 2 AMLs collected at the 
University of Rome Tor Vergata. WES was performed through Illumina GAIIx with 
76 bp paired-end reads after DNA isolation with standard protocols; for capture 
we used SureSelectXT Human All Exon capture kit v.1 and v.2, respectively for 
AMLs and APLs. 
 
3.1.2 Cohort of samples for mutation calling 
Human AML samples used for this analysis are described in Table 3.1. We didn’t 
use hAPL#Mi1 and hAPL#Mi4 samples because of their low quality. Alignment to 
the reference genomes (hg19) was performed using the Burrows-Wheeler Aligner 
(BWA)96. 
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Table 3.1: Mutation calling cohort – patient characteristics. 
Sample ID Cytogenetic analysis FAB classification NPM1 FLT3 Age at Diagnosis 
AMLp6 NK NA wt wt 45 
AMLp7 NK NA mut wt 53 
hAML#Mi3 NK NA mut wt 71 
BO1 NK M1 wt wt 32 
BO2 +8, t(2;10)(q33;p13) M5 wt wt 42 
BO3 NK M1 mut mut 34 
hAML#Mi7 inv(9)(p11q13) M5 mut mut 50 
TO1 NK M5 wt wt 67 
TO2 NK M5 mut mut 73 
TO3 NK M1 wt wt 58 
UD1 del(6); del(11) M0 wt wt 33 
APLp2 t(15;17) M3 NA NA 61 
APLp3 t(15;17) M3 NA wt 42 
hAPL#Mi6 t(15;17) M3 NA mut 54 
hAPL#Mi7 t(15;17) M3 NA mut 56 
hAPL#Mi8 t(15;17) M3 NA NA 24 
hAPL#Mi9 t(15;17) M3 NA NA 38 
hAPL#Mi10 t(15;17) M3 NA mut 68 
hAPL#Mi11 t(15;17) M3 NA NA 43 
sAML#Mi1 t(15;17) M3 NA wt 24 
 
3.1.3 The “Bologna cohort”  
The cohort of coupled samples used to test the performances of CNV calling 
algorithms was composed of 23 leukaemia patients. For these patients the group 
of Prof. G. Martinelli at the University of Bologna sequenced (WES) the primary 
tumour and the normal sample (except for one case) and at the same time 
performed SNP array analysis on the tumour sample. In Table 3.2 are reported 
the quality of the SNP array platform, the presence/absence of WES sequencing 
of tumour and normal samples and the platform used for the SNP array analysis. 
We decided to exclude some patients from the analysis: BO9 and BO10 because 
they were analysed on a different SNP array platform, BO12 because the normal 
was not sequenced by WES; BO14, BO16 and BO22 because they did not pass 
the quality filters.  
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Table 3.2: Summary of the sequencing data available for the samples from the 
Bologna cohort. For every patient we report the quality of the SNP array platform, the 
eventual WES sequencing for the tumour (TUM) or the normal (NORM) samples and the 
platform used for the SNP array analysis. 
	  
 
3.2 Comparing mappers of the sequencing reads to the 
genome 
Alignment of the short reads produced by the NGS technology consists in the 
mapping on the human reference genome (in our case hg19/Grch37) of each 
read, defining its exact genomic coordinates. This task is performed comparing 
each base belonging to the read with the bases of the reference genome in order 
to detect the region with the highest similarities. This step is tricky in 
Bioinformatics because it is time consuming and memory consuming (the genome 
is 3X109 bp long and the sequencing platforms usually produce hundreds of 
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millions reads for each sample). We compared the performances of two methods 
in the alignment of short reads to the genome, approaching the problem from 
diverse perspectives: BWA96 and Novoalign97. BWA uses the Burrows-Wheeler 
transformed (BWT)98 algorithm. Thanks to the BWT indexing technique, it is very 
efficient and allows the presence of mismatches and gaps. Novoalign97 uses the 
Needleman-Wunsch99 global alignment with gap penalties, an old method that 
the authors were able to adapt for alignment optimization.  
In order to compare the output of the two methods, we used SEAL100, a 
comparative tool primarily designed to evaluate short read aligners. Given a set 
of parameters (sequencing error, indels, coverage, …), SEAL is able to simulate 
the sequencing data, producing fastq files that contain reads which resemble an 
NGS output. The reference genome can be either already existing or created by 
the program and the reads are generated choosing positions on that reference 
genome from a uniform distribution and fragment sizes (for paired end 
experiments) from a normal, in order to simulate the characteristics of real reads. 
Afterwards, the chosen alignment methods (in our case BWA and Novoalign) are 
run on the simulated fastq files in order to permit the comparison of the results 
obtained through alignment with the simulated genome of origin. 
 
3.2.1 Pre-processing for alignment testing 
Reads were filtered along machine quality assessment keeping only reads marked 
as ‘N’ by the machine (N: Not failing the quality filter, with a quality score 
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threshold of 2), the alignment was performed in parallel with BWA and Novoalign 
with standard parameters. After alignment, we applied the GATK pipeline101 
including realignment, duplicates identification (Picard)102 and quality 
recalibration. Mutations were called using MuTect103 and annotated with 
ANNOVAR.104 
 
3.3 Comparing mutation calling algorithms in WES-AML 
samples 
We decided to measure the differences among MuTect103 and SomaticSniper105 
because the former is widely used in WES analysis in the literature and the latter 
was primarily used for the definition of single nucleotide variants in AML44 
resulting in two distinct landscapes on the same cohort of leukaemia patients. The 
approach of the two methods is rather analogous: given the reads observations at 
that site, MuTect calculates for each not-reference site the likelihood for the 
tumour to carry or not that variant, SomaticSniper calculates the probability of all 
the possible genotypes. The main divergence between the two methods locates 
in the reads filtering procedure for the tumour and control samples (see Results 
section 4.1.2). For both algorithms we functionally annotated SNVs using the 
MutationAssessor database106 and filtered out synonymous variants or those 
falling in non-coding regions. 
 
3.3.1 Mutation calling with SomaticSniper 
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We followed the pipeline guidelines for SomaticSniper105, removing duplicated 
reads before mutation calling with the MarkDuplicates software present in Picard 
version 1.68102. Only variants with mapping quality and somatic quality values 
over 40 were included in the successive analysis. 
 
3.3.2 Mutation calling with MuTect 
WES data have been pre-processed according to GATK best practices101,107 
through local realignment, duplicate marking and base quality recalibration. We 
identified SNVs in our samples using MuTect version 1.1.4.5 with the initial 
tumour Log Odd Discovery set to 6.8 (calculated on the basis of the expected 
number of mutations per Megabase in the TCGA 2013 publication44). An 
additional filter was applied to the output SNVs on the minimum read depth: a 
minimum of 8 reads should be present in the normal samples and 14 in the 
tumours, as suggested by the authors. 
 
3.3.3 Validation 
We validated high-frequency mutations (≥ 25%) through Sanger sequencing, after 
PCR amplification with custom primer pairs for each mutation. All PCR products 
were evaluated on a 2% agarose gel, then sequenced in both directions with Big 
Dye Terminator reactions and loaded on an ABI PRISM 3730xl DNA analyser. To 
analyse the sequences we used the Sequencing Analysis 5.2 software. 
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For low frequency variants, Sanger sequencing was ineffective because it has low 
sensitivity and is unable to validate variants present in less than ~25% of the reads 
(our experimental data). For these reasons, we validated variants with VAFs <25% 
using the IonTorrent platform, choosing the regions in order to explore all the 
possible groups of frequencies and, when possible, selecting both variants 
detected only by MuTect or by SomaticSniper and variants detected in common 
by both algorithms. Ion Torrent sequencing data were aligned to the reference 
genome (hg19) with BWA. For each SNV, we counted the number of reads 
carrying the variant in the tumour and in the remission. We considered validated 
the variants with a p-value <0.001, calculated with the one-sided test on equality 
of proportions in the comparison between the number of reads carrying the 
variant in the normal or the tumour samples (with a maximum number of reads in 
the normal supporting the variant allele ≤3). 
 
3.4 Comparing CNVs detection methods 
Copy number variants are usually easier to be detected in WGS data than in WES. 
In fact, WES data are characterized by the discontinuity of the regions tested and 
are affected by the capture of the target regions, which is susceptible to diverse 
affinity of the probes. Nonetheless, many tools have been developed for the 
detection of CNVs from NGS data and we decided to compare some of the most 
used methods for CNV identification in WES samples: 
• Cn.mops108: the acronym stands for Copy Number estimation by a Mixture 
	   77	  
Of PoissonS. In order to uncouple the copy number detection from the 
inner variability of exome coverage across the genes, this tool models the 
coverage at each genomic position. Through a Bayesian approach it 
decouples the real signal and the noise and uses Poisson mixture models 
to detect noise and reduce false discovery rates (FDR); 
• CONTRA109: the COpy Number Targeted Resequencing Analysis tool uses 
the ratio of coverage depth in tumour and control samples to detect 
regions that vary in the number of copies. To overcome the general bias 
produced by this approach, CONTRA: i) normalizes the coverage depth in 
the two samples; ii) uses the log-ratios at the base level to circumvent 
errors due to GC-content; iii) corrects for imbalanced library size; iv) 
estimates the log-ratio variation binning the regions and using 
interpolation; 
• ExomeCNV110: uses depth of coverage and alternative allele frequencies to 
detect CN regions. The ratio of coverage depth in the tumour and normal 
samples is normalized for the total number of reads in each sample and 
adjusted to have a total median of 1. CNVs are, then, recognized through 
hypothesis testing: when the Poisson distribution of one region’s 
coverages can not be associated to a normal distribution, a CNV can 
explain this deviation. A ρ parameter is used to distinguish between 
deletions and amplifications; 
• Control-FREEC111: this tool is similar to the abovementioned ExomeCNV, 
but it adds finer normalization steps, adjusting for GC-content and 
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handling also contaminated control samples; 
• VarScan2112: uses Fisher’s exact test to extract the regions where the log2 
ratio of depth of coverage in the two samples undergoes a significant 
change. It, then, uses circular binary segmentation (CBS, part of DNAcopy 
R package) to identify the exact regions that have alterations in the number 
of copies. 
In particular, to call copy number variant regions from WES data in our cohort 
of patients, we used the Control-FREEC tool, adjusting for contamination and 
using a minimum read count threshold of 50 reads. The window used to 
compare regions was set to 50’000 and the target region was restricted to the 
portion of the genome covered by the capture design of the Sure Select kit 
version 5 (Agilent) plus the complete sequence of exons covered only partially 
by that regions (without UTRs). 
 
3.4.1 SNP array analysis 
Aroma113 suite (CRMAv2 R package) was run with default parameters and GLAD 
segmentation; for our patients only the leukemic sample was analysed and, 
because we lacked the SNP array of remission samples, a summary of all the 
samples was used as normal reference. 
Nexus114 suite, provided by BioDiscovery, used as control sample HapMap 
counts.  
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3.5 Gillespie’s stochastic simulation algorithm 
It is of paramount value the possibility to describe the behaviour of a system over 
time, given defined constraints. Stochastic time evolution equations that describe 
a finite system are unmanageable analytically (except for very simple cases) and 
also numerical solutions can be difficult. Simulations allow studying the complex 
dynamics of finite states that evolve in time designing variable trajectories. They 
start from a set of given probabilities for variables, and randomly change; 
simulations can be repeated many times in order to observe the distribution of 
results. 
The Gillespie’s algorithm115 is capable of simulating numerically the evolution in 
time of a model in an exact manner. In origin, it was designed for chemical 
systems but it can be extended to all phenomena that can be represented with 
reactions following the laws of mass action. Here, we present the description of 
the procedure that directly solves the time simulation described in paragraph 
4.1.5.1 of the Results. Given a population i=N at time t, the number of individuals 
in state x is 𝑋! 𝑡 . At each time point of the simulation, we calculate the vector 𝑿(𝑡) ≡ (𝑿! 𝑡 ,… ,𝑿! 𝑡 ). Starting from time 0 when 𝑋!! = 𝑥!, the system changes 
over time on the basis of a set of reactions (𝑅! ,with  𝑗 = 1,… ,𝑀) that introduces 
birth, death, changes of state (…) in the existing population. At each step, the 
system is updated following the state change vector (𝑣!, that describes all the 
possible population changes introduced by the reactions in the system) and the 
propensity function (𝑎!(𝑥), which is the probability of occurrence of a reaction in 
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the infinitesimal time step [𝑡, 𝑡 + 𝜕𝑡)) with values sampled at that particular step. 
At each step, the direct method substitutes t with the successive time step 𝑡 + 𝜏 
and x with 𝑥 + 𝑣! . 𝜏  is defined as follows: 𝑟!  and 𝑟!  are sampled such that 
𝜏 = !!!(!) ln !!!  with 𝑎! 𝑥 =    𝑎! (𝑥)  and 𝑗 = min   𝑎! 𝑥 >   𝑟!𝑎!(𝑥)!!!! . In this 
way, the more the population or the reaction rate increases, the more the time-
step decreases to better describe what is happening in the system. 
In our study we reproduced the evolution of the tumours and their relapses in 
order to know a priori the subgroups forming the tumour populations in the two 
cases and to be able to retrace the steps that led to that result. The R package 
used to run the Gillespie’s method in order to obtain model solutions is 
GillespieSSA116; we used the direct method “D” to get the exact Monte Carlo 
procedure. The seed has been sampled at every cycle in the interval [-1’000’000, 
1’000’000] and is reported in the output. 
 
3.6 Clonal analysis methods 
For every solution identified with the Gillespie’s algorithm for the tumour and 
relapse couples, we built a dataset reporting the position, the base change, the 
number of reference and alternative reads in the three samples (primary tumour, 
relapse and the normal) and their relative copy number. Further description of the 
model and how the dataset information was extracted is reported in the Results 
section, paragraph 4.1.5.1. On the datasets produced by the Gillespie’s 
algorithm, we were able to test four clonal reconstruction methods taken from the 
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most important papers published in the field: 
• Clomial70:  is the compression of “Clonal decomposition using binomial 
models”. This algorithm is able to handle multiple samples at the same 
time in order to increase the statistical power. To estimate clonal 
genotypes and their frequencies uses an expectation maximization 
algorithm. We used the Clomial R package with random seed set to 1. We 
ran Clomial with a suggested number of clones from 1 to 5, the best model 
was chosen as the one with the lowest value of BIC (Bayesian Information 
Criterion, used to select the model with the highest likelihood). We 
decided to limit our research in the range [1,5] because the amount of time 
needed by the algorithm grew significantly with the number of expected 
clones given in input. Furthermore, in the majority of the examples, the 
best models resulted to be those with 2 expected clones; 
• Expands69: is the acronym for “Expanding Ploidy and Allele Frequency on 
nested Subpopulations”. This algorithm models cellular frequencies as 
probability distributions and, then, uses hierarchical clustering to group 
mutations with similar probabilities. In this way the mutations with similar 
behaviour (in the probability distribution) should be grouped also if they 
have different frequencies, as for the CNV regions. We used the Expands R 
package with random seed set to 11. We used the parameters suggested 
by the authors and, in particular, we set the number of amplicons per 
mutated cell to 50, the precision to 0.018 and the minimum cell frequency 
to 0.01. For clustering, we restricted the dataset to those variants having 
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finite cell frequency distributions; 
• PyClone117: uses a hierarchical Bayesian statistical model to estimate cellular 
prevalence together with allelic imbalance introduced by CNVs. The group of 
mutations and the number of groups in the populations are computed 
simultaneously through Bayesian non-parametric clustering. Interestingly, it 
uses beta binomial emission densities stating that it overcomes simple 
binomials for high variability in the prevalence of mutations. Since allelic 
prevalence and number of copies are strictly connected to each other it also 
uses flexible prior probabilities for the genotypes. Beta binomial density 
distribution was the statistics chosen to run PyClone for 10’000 Monte Carlo 
Markov Chain iterations. Alpha and beta parameters for Dirichelet Process 
were set to 1. Tumour content was set to 1, because, for the majority of 
samples in our analysis, we do not have the information about purity. 
Expected sequencing error rate was set to 0.005, which is the upper bound for 
the error rate in our analyses. All the other parameters were set to default 
values; 
• SciClone118: uses Bayesian mixture modelling of beta distributions to cluster 
the mutations by VAFs similarity. It uses only variants falling in copy number 
neutral regions of the genome. We used sciClone R package with random 
seed set to 11. We used the default parameters: the minimum depth of the 
region was set to 60, the maximum number of clusters to 10 and the copy 
number margins to 0.25. 
All the pieces of information retrieved at the precedent steps were necessary to 
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perform a good analysis of the clones in our cohort of patients. For every patient 
we ran PyClone, analysing the triplet of the samples all together. In particular, the 
random seed was set to 7 and the burning region to 1000, as suggested by the 
authors. 
 
3.7 The pipeline defined for our analysis 
In the first part of the results we surveyed a group of methods to define the ones 
that would better apply to our specific cohort of relapsing AMLs. The pipeline 
used to preprocess the sequencing data is reported in Figure 3.1. Starting from 
the FASTQ given in output by the Illumina platform, we firstly filtered the reads 
that passed the quality test, performed inline during the sequencing. We retained 
only the reads marked with ‘N’ (those not failing the quality filter with a threshold 
of 2) by the sequencer. We, then, aligned all the reads to the human genome 
(hg19) with BWA mem, the latest version enhanced for time consumption and 
precision. We did not filter out unmapped reads, we, instead, marked (but not 
removed) the duplicates with Picard MarkDuplicates version 1.84, using lenient 
validation stringency. The reads were, then, realigned to the genome to improve 
the precision around indels. The realignment was performed through GATK 
version 2.8, with stringency set to lenient, using as known databases for the indels 
1000 genomes phase 1 and Mills and 1000 genome gold standard. The base 
qualities were recalibrated, in order to have more reliable values, using the 
recalibration tool from GATK (version 2.8) with dbSNP137 as gold standard. This 
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pipeline was applied to every sample following GATK guidelines. However, we 
integrated this pipeline in a Python script in order to automatize the process and 
reduce the computational time for the analysis. Once all the triplets of samples 
completed this first part of the pipeline, they were jointly used for the search of 
variants. 
Figure 3.1: Schematic representation of the analysis pipeline. 
 
 
3.7.1 Mutation calling with MuTect 
Identification of the single nucleotide variants (SNVs) was performed running 
MuTect (version 1.0.27783), with reference databases COSMIC version 54 and 
dbSNP version 135. We performed the MuTect analysis 6 times for every patient 
in the following combinations of comparisons: tumour versus remission, relapse 
versus tumour, relapse versus remission and the vice versa comparisons. The 
MuTect results were filtered retaining only mutations marked as KEEP and 
removing both not covered positions (UNCOVERED) and SNPs (DBSNP) for every 
comparison. For each patient we, then, built a unique file containing all the 
positions identified as mutated at least once. For each mutated position we used 
a Python script to restart from the bam files and count again the reads carrying or 
not the variant in all the three samples. Afterwards, an R script was used to label 
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every mutation, as described in the Results section (paragraph 4.1.3), on the basis 
of their presence in the primary, the remission and/or the relapse samples after 
recounting. 
 
3.7.2 Calling of Indels with Pindel 
Pindel was run on the following couples of tumours: primary versus remission, 
relapse versus primary and relapse versus remission. We filtered only regions with 
coverage greater or equal to 10, more than 3 alternative reads and BWA quality 
score greater or equal to 20. Annotation was performed with ANNOVAR. 
 
3.7.3 Cleaning the contaminated samples 
As described in paragraph 4.2.2 of the Results, four relapse samples in our cohort 
(UD1, UD4, UD11, UD12) were contaminated with the DNA of the donor for the 
heterologous bone marrow transplant. Likely, we were able to retrieve the DNA 
of the donors. Therefore, for the contaminated relapse samples we needed to 
subtract the SNVs, indels and CNVs detected in the donors DNA. For this reason, 
we sequenced for WES analysis the donor DNA and ran the abovementioned 
pipelines to identify the variants. We, then, eliminated all the SNPs and the indels 
identified in the donors from the relapse sample of each corresponding recipient 
patient. For the CNVs we, instead, removed from the results the regions 
overlapping for more than 10% with the donor CNVs. Though harsh, this action 
was necessary to produce reliable results in the successive analysis.  
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3.8 A list of AML driver genes 
The list of AML driver genes, reported in Table 3.3, was built considering the 
output of many driver-calling tools from the literature: MutSig45, MuSiC47, 
OncodriveFM119, TUSON120, DOTS-Finder46 and “Vogelstein” (a list of driver 
genes reported in Vogelstein et al. 2013 paper 121). All those methods were run 
on a set of 200 AMLs and all the genes identified as drivers by at least one of 
those methods were retained in our dataset. 
The functional categories for AML drivers were derived from the TCGA paper44 
and covered the 90% of the drivers in our list described above. 
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Table 3.3: The list of driver genes used for our analysis. 
Gene 
Symbol MutSig MuSiC 
Oncodri
ve TUSON 
DOTS_Fi
nder 
Vogelstei
n 
PipelineCall
s 
ASXL1 x x x x x x 6 
BCL2 
   
x 
 
x 2 
BCOR 
    
x x 2 
CALR 
    
x 
 
1 
CBFB 
    
x 
 
1 
CBX7 
    
x 
 
1 
CEBPA x x x x x x 6 
CREBBP 
   
x 
 
x 2 
DNMT3A x x x x x x 6 
EZH2 x x 
 
x x x 5 
FLT3 x x x 
 
x x 5 
HNRNPK 
    
x 
 
1 
ID3 
   
x 
  
1 
IDH1 x x x 
 
x x 5 
IDH2 x x x 
 
x x 5 
KIT x x x 
  
x 4 
KMT2D 
   
x 
 
x 2 
KRAS x x 
   
x 3 
MEF2B 
   
x 
  
1 
MEF2BNB 
-MEF2B  
  
x 
  
1 
MIR142 
 
x 
    
1 
MXRA5 x 
     
1 
MYC 
   
x 
  
1 
MYD88 
   
x 
 
x 2 
NPM1 x x x x x x 6 
NRAS x x x 
 
x x 5 
PAPD5 x 
     
1 
PDSS2 x 
     
1 
PHF6 x x x 
 
x x 5 
PTPN11 x x x 
  
x 4 
RAD21 x x 
  
x 
 
3 
RUNX1 x x x x x x 6 
SF3B2 
   
x 
 
x 2 
SMC1A x x 
    
2 
SMC3 x x 
    
2 
SRSF2 x 
    
x 2 
STAG2 x x 
  
x x 4 
TET2 x x x 
 
x x 5 
TP53 x x x x x x 6 
U2AF1 x x x 
 
x x 5 
WT1 x x x x x x 6 
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4. Results 
The main aim of this thesis is the investigation of the evolution of the mutational 
landscape of AMLs from the exordium to the relapse in order to identify possible 
drug resistant lesions that might allow the prediction of patient’s outcome if they 
are present in the primary disease. We characterised of a dataset composed by 
30 patients for whom we collected the leukemic blasts of the primary tumour and 
the relapse tumour and the blood cells at the remission phase of the disease. We 
sequenced the whole exome of all the samples and then compared the triplets of 
samples to uncover possible commonalities and differences that would explain 
the underling evolution of the disease. In particular, we divide the Results section 
in two main parts. In the former, we assess the performances of different available 
bioinformatics methods and choose the best methods for our purposes. In the 
latter we show the results obtained on our cohort of patient with the selected 
methods.  
 
4.1 Selection and refinement of methods to improve WES 
data interpretation 
Undeniably, there is an expanding quantity of NGS analysis tools for all the steps 
that need to be executed to interpret exome sequencing data (e.g. alignment, 
point mutation mutation callers). These tools exploit slightly different needs and 
have different performances. The first task of our bioinformatics endeavour is, 
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therefore, to compare and select the best methods able to portray our cohort of 
patients.  
 
4.1.1 BWA is more suitable than Novoalign for mapping reads in 
our cohort of leukaemia patients 
Burrows-Wheeler Aligner (BWA)122 is, nowadays, the most commonly used 
method to map sequencing reads to the reference genome in WES studies and it 
is the recommended mapper in the GATK guidelines for DNA high throughput 
sequencing.107 Even though this method is generally recognized to have high 
performances, it is possible that, on specific datasets, other methods may 
perform better. We had the possibility to test Novoalign97, which is a mapper 
under license and has been used by other groups in our field123. We compared 
the performances of these two methods using two approaches: 
• SEAL124: a tool that allows to test alignment methods, creating an in silico 
dataset with parameters set by the user; 
• we analysed a in house set of WES sequencing of APL and AML samples (not 
validated) in order to unveil the overlap of the results obtained with the two 
methods and eventually highlight whether one of the two was more 
comprehensive than the other. 
SEAL produces fastq files containing reads with specific characteristics chosen by 
the user (see Methods section 3.2); in particular our custom set had a ”genome” 
length of 38’000’000 bp, we selected this length because it corresponded to the 
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exons covered by the SureSelect kit version 1, the fragment-length was of 76bp 
and the fragment-count of 36’000’000 bp. The program only allows changing the 
genome indels size and indels frequency and we decided to evaluate the changes 
in alignment performance modifying each condition separately. The results of our 
analysis are reported in Figure 4.1. We used the F-measure as a parameter for the 
quality of alignment, it was calculated as follows: 
𝐹 −𝑀𝐸𝐴𝑆𝑈𝑅𝐸   =   2 ∗ 𝑃𝑅𝐸𝐶𝐼𝑆𝐼𝑂𝑁   ∗   𝑅𝐸𝐶𝐴𝐿𝐿𝑃𝑅𝐸𝐶𝐼𝑆𝐼𝑂𝑁  +   𝑅𝐸𝐶𝐴𝐿𝐿  
where Precision is the rate of true positives over all the positive calls !"!"!!"  and 
Recall is the rate of true positives over all the real positives !"!"!!" : higher results 
correspond to better performances. 
Varying the size of the insertions or deletions, we observed that BWA performs 
better than Novoalign when the indels are small (< 10 bp), while Novoalign have 
higher F-measure when the indels are bigger than 16 bp. In contrast, the 
frequency of the indels has a minor impact on the goodness of the alignment and 
both methods perform very well for frequencies lower than 3×10−3. 
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Figure 4.1: BWA and Novoalign performances differ on an in silico dataset. We 
maintained fixed the indels frequency and vary their size (a) or, alternatively, maintained 
fixed the indels length and vary their frequency (b). We simulated the alignment to the 
reference genome with BWA (green boxes) or Novoalign (pink boxes) and evaluated the 
correctness (F-measure) of the mapping with SEAL.  
 
We, then, decided to test the two methods on a real dataset (pipeline depicted in 
Figure 4.2.a). For this purpose, we used coupled tumour and remission WES 
samples from 5 leukaemia patients: three APLs and two AMLs (for a description of 
the dataset see Materials and Methods section). For every patient, both samples 
were mapped to the reference genome using BWA or Novoalign. Afterwards, 
following the downstream analysis suggested by GATK, mutations were called 
using the MuTect pipeline, comparing remission and tumour samples aligned 
with the same mapper. As shown in Figure 4.2.b, we observed that, in the 
majority of cases, the mutations identified after alignment with the two 
independent methods are not highly concordant and the overlap of the results is 
often lower than 50%. For each of the two alignment algorithms, the private 
mutations identified (i.e. the mutations identified specifically only by one method) 
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are many and BWA seems to identify better low frequency mutations. Only a vast 
validation of the identified mutations would really allow determining the effective 
performances of the two aligners; however, we performed a validation analysis of 
the mutations called only after alignment with BWA. The validation rate we 
obtained is high; therefore, we know that, in our hands, BWA works well (see 
results described in detail in the next paragraph). 
Figure 4.2: Comparison of BWA and Novoalign on a real dataset of AMLs. a. 
Workflow used for this comparison. b. Each bar indicates the number of mutations 
identified in common by both programs (dark blue) and, alternatively, only by one of the 
two (grey: BWA; pink: Novoalign). The results of the analysis are shown both for 
mutations identified at high frequency (VAF > 25%) and at low frequency (VAF > 5%). P2, 
p3, p5, p6 and p7 are the patients used for the analysis: the first three were diagnosed 
with Acute Promyelocytic Leukaemia (APL) and the last two with Acute Myelogenous 
Leukaemia (AML). For every patient we grouped together mutations at high frequency 
(having a VAF over 25%) and all mutations (having a VAF higher than 5%). 
 
Another useful and important parameter to take into consideration when 
evaluating an alignment tool is the coverage of the mapped reads within the 
targeted region of interest. Since, in order to perform WES enrichment, we used 
the SureSelect Human All Exome V1 kit (Agilent Technologies), we were able to 
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calculate this parameter, in terms of percentage of the targeted region covered 
by the mapped reads in our sequencing dataset for AML patients. The 
performances are reported in Figure 4.3: despite BWA has always a slightly better 
coverage than Novoalign, the two methods are nearly comparable and there is no 
striking difference. 
Figure 4.3: Percentage of the coverage on target of the reads mapped with BWA 
and Novoalign on our 5 leukaemia patients. The coverage is reported as percentage 
of the total amount of bases covered by the SureSelect Human All Exon kit V1 (Agilent 
technologies). P2, p3, p5, p6 and p7 are the patients analysed in this circumstance: the 
first three were Acute Promyelocytic Leukaemia (APL) patients; the last two were Acute 
Myelogenous Leukaemia patients (AML). For every patient we report the coverage of the 
samples collected at exordium of the leukaemia (leu) and remission (rem). 
 
We compared the performances of BWA and Novoalign considering three 
capacities required to define a good aligner: 
• The capacity to manage small indels: for frequencies of 1 x 10-3 and lower, 
the two methods are almost comparable and very good in the alignment 
task. On the contrary, varying the indels size, the two tools show opposed 
capabilities: BWA is significantly better than Novoalign at mapping reads 
when the indels size is less than or equal to 10 bp; they perform similarly 
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indels between 20 and 50 bp of size. In our project, we want to study the 
presence in our patients only of small indels and we decided not to search 
for structural variants (i.e. indels of big size), for which the methods 
developed up to now are actually still unsatisfactory. Based on these 
observations BWA is more suitable in the context of small indels alignment; 
• The SNVs called after alignment: the two methods result in about half 
common mutations and half aligner-private mutations; in particular, BWA 
seems to manage more efficiently low frequency mutations. We did not 
expect a similar discrepancy of identified variants originating by the used 
aligner. However, since, in our hands, mutations identified at the bottom of 
the pipeline using BWA as mapper, have high validation rates, we think 
that it is a good mapper for our study; 
• The coverage of the target regions: this parameter was comparable for the 
two tools and BWA gave slightly better results than Novoalign. 
For all the argumentations mentioned above and because it was not under 
licence, we decided to use BWA for all our further analyses. 
 
4.1.2 MuTect allows mutation calling at low Variant Allele 
Frequency 
Accurate mutation calling in WES of tumour-control couples of samples is still a 
challenge in cancer studies, because there are many sources of error that may 
arise both during the preparation (PCR amplification, enrichment capture), the 
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sequencing of the samples (machine error) and the bioinformatics analysis of the 
mutations (mapping to the reference genome, correct quality assessment). 
Moreover, intrinsic peculiarities of some tumours, in particular blood tumours, 
such as the heterogeneity of the population and the contamination by the tumour 
of the normal sample, used as control, pose an additional layer of complexity. 
Growing evidence of the high variability in the mutations called through different 
algorithms125 has encouraged the scientific community, firstly, to try to develop 
new outstanding tools for mutations detection126 and, secondly, to build methods 
that combine the results of multiple tools in order to obtain more complete and 
reliable results. 
 
4.1.2.1 Two analysis pipelines strongly disagree in mutation calling over a 
set of leukaemia patients 
We noticed that two successive studies44,45 on the same cohort of patients gave 
very discrepant results (Figure 4.4). We used the supplementary information of 
the two papers in order to collect the number of mutations and the type of 
substitutions (i.e. the detected base change) identified for each patient. We 
uncovered a substantial difference in the variants identified by two different 
pipelines. The first study44, performed at the Washington University, used 
SomaticSniper as variant caller; the second study45, a pan-cancer analysis made at 
the Broad Institute, used MuTect. The two studies report very different numbers 
of mutations from the WES analysis of the same 133 AML patients (Fig 4.4.a), with 
an average of 11 vs 24 mutations (0.03-1.7 per Mb vs 0-13.53 per Mb) per 
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patient, respectively. Particularly different was the maximum number of mutations 
identified in single patients: 33 vs 406, with seven patients showing a very high 
number of mutations detected by MuTect, never highlighted before in AML. We 
called these patients “hypermutated” because they are conform to the 
hypermutation definition127 having a number of somatic mutations in the coding 
regions dramatically above the median mutation rate of the other AMLs.  
Correlation coefficients calculated for the number of mutations per patient, 
including or excluding these outliers, are 0.08 and 0.3, respectively, underlining 
the little similarity in the results obtained by the two analyses. Furthermore, also 
the type of mutation changes, identified in the two studies (Fig 4.4.b), shows two 
different genomic landscapes for the same pathology and the same cohort of 
patients. 
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Figure 4.4: Two mutation callers give significantly different results on a public 
dataset. a. Number of mutations identified for each patient by SomaticSniper on the x 
axis and MuTect on the y axis. The red dots identify patients with a very high number of 
mutations when analysed with MuTect (outliers). Pearson’s correlation coefficients were 
calculated including (red square) and excluding (green square) these patient outliers. The 
black dashed trend line indicates the expected number of identified mutations assuming 
that the analysis with the 2 pipelines gives exactly the same number of mutations. b. 
Percentage of each type of mutations listed (Mutation-Type) on the total number of 
mutations identified by each pipeline. Also in this case the analysis was performed 
including or excluding outlier patients (no Outliers).  
(Adapted from Bodini et al.128) 
  
 
We, then, selected all the datasets that were analysed with the same 
preprocessing pipeline and were available from the TCGA data portal and re-
analysed 131 AML WES datasets using MuTect. Considering the union of the 
SNVs identified with the new MuTect analysis and the previous set of 
SomaticSniper mutations, we characterised a new and more comprehensive AML 
mutational landscape. Indeed, analysing the TCGA bam files with MuTect, we 
could detect the presence of many more SNVs in the AML tumours than the ones 
identified by the TCGA project. In particular, we identified 9150 putative false 
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scored in multiple patients the presence of recurrent SNVs in the same position, 
never described before in leukaemia patients, for the following genes: RNF2, 
TP53BP2 and RASA1 (Tab 4.1). Again, also the SNVs identified in these genes 
were usually present at VAFs <10%. These genes encode for proteins involved in 
regulation of cell proliferation or differentiation. Moreover, using DOTS-finder46, a 
tool developed in our laboratory aiming at the identification of driver genes from 
a list of patient’s mutations, they were classified as putative drivers. These results 
underscore that the genes we found mutated at low frequency may play a 
relevant role in cancer progression.   
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Table 4.1: Putative driver genes identified by two pipelines, found recurrently 
mutated in the AML cohort analysed. The table shows the percentage of patients 
carrying a mutation in each listed gene as identified by one (TCGA) or both pipelines 
(TCGA+MuTect). The genes reported have been pinpointed by DOTS-Finder as putative 
driver. 
  
Percentage of mutated 
patients   
  
Percentage of mutated 
patients 
Hugo gene 
symbol 
TCGA + 
MuTect 
TCGA 
  
Hugo gene 
symbol 
TCGA + 
MuTect 
TCGA 
DNMT3A 29% 29%   MYH11 2% 0% 
FLT3 12% 10%   NACA 2% 0% 
IDH2 11% 11%   NUP214 2% 0% 
TP53 11% 11%   PHF6 2% 2% 
KMT2C 11% 1%   PRDM1 2% 0% 
IDH1 10% 8%   THRAP3 2% 2% 
NRAS 10% 8%   TPR 2% 0% 
RUNX1 8% 6%   TSC1 2% 0% 
KRAS 7% 5%   ABL2 2% 0% 
ATP2B3 5% 2%   ASXL1 2% 1% 
EP300 5% 0%   ATM 2% 0% 
KIT 5% 5%   ATP1A1 2% 0% 
MED12 5% 1%   BCL11A 2% 0% 
NF1 5% 1%   BRCA2 2% 0% 
PTPN11 5% 5%   BUB1B 2% 0% 
HIP1 5% 0%   CACNA1D 2% 0% 
TET2 5% 5%   CD74 2% 2% 
U2AF1 5% 4%   CLTCL1 2% 0% 
AKAP9 4% 0%   EBF1 2% 0% 
ALK 4% 0%   ERG 2% 0% 
CREBBP 4% 0%   EZH2 2% 2% 
KDR 4% 2%   FANCA 2% 0% 
ROS1 4% 0%   FUBP1 2% 0% 
SF3B1 4% 1%   GAS7 2% 1% 
TCF12 4% 0%   GMPS 2% 0% 
WIF1 4% 0%   GPHN 2% 0% 
APC 3% 0%   KDM5A 2% 0% 
ELF4 3% 1%   KIF5B 2% 0% 
GATA2 3% 2%   LCP1 2% 0% 
KMT2D 3% 0%   MAX 2% 0% 
MSN 3% 0%   MLLT4 2% 1% 
NCOA2 3% 0%   MYB 2% 1% 
NOTCH2 3% 1%   MYC 2% 1% 
PBRM1 3% 0%   MYD88 2% 0% 
SETBP1 3% 2%   MYH9 2% 0% 
TRRAP 3% 0%   NFE2L2 2% 0% 
WT1 3% 2%   NTRK3 2% 2% 
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ARID1A 2% 1%   NUMA1 2% 0% 
BCR 2% 0%   NUP98 2% 0% 
BRD4 2% 0%   PAX3 2% 1% 
CHEK2 2% 0%   PAX5 2% 0% 
CIC 2% 1%   POU5F1 2% 1% 
CNOT3 2% 0%   RAP1GDS1 2% 1% 
CSF3R 2% 1%   SETD2 2% 0% 
EGFR 2% 2%   SLC34A2 2% 0% 
ETV6 2% 1%   SRSF2 2% 0% 
EXT1 2% 0%   STAG2 2% 2% 
FANCD2 2% 0%   STAT5B 2% 0% 
JAK2 2% 1%   SYK 2% 0% 
KDM6A 2% 2%   TRIP11 2% 0% 
LPP 2% 0%   TSHR 2% 0% 
MSH6 2% 1%   USP6 2% 1% 
 
As shown in Table 4.1, for all genes harbouring non silent SNVs and present in 
the Cancer Gene Census database, we could not score differences in the 
frequency of mutations in our patients cohort for well known AML drivers (e.g. 
DNMT3A, IDH1, IDH2, FLT3, RUNX1, TP53, NRAS). However, combining the 
results of the two pipelines, we identified 58 novel recurrent SNVs in genes 
present in the Cancer Gene Census database, even if they were present in 5% of 
the patients at most. However, though novel mutations were infrequent among 
patients, 43% of the patients carried at least one of them, pinpointing their 
relevance in this dataset.  
Furthermore, we analysed the new results using the Fisher’s exact test in order to 
define which genes are mutated in a mutually exclusive fashion (mutually 
exclusive genes) and which genes are mutated simultaneously in the same 
patients (co-occurring genes). If we do not correct for multiple hypothesis testing 
(as in Ley et al.44), we can recapitulate the same results of the TCGA publication44 
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for mutual exclusivity. In contrast, we can find many more co-occurring genes (542 
vs 12, considering only genes and not gene functional cathegories). However, if 
we correct for multiple hypothesis testing, almost no genes show significant co-
occurrence or mutual exclusivity. In agreement with our observations, a 
subsequent publication by the same authors described an identical scenario64. 
Indeed, applying a multiple hypothesis testing correction the authors found only 
two couples of co-occurring genes. We think that these results are given to the 
low frequency of the new mutations we identified in these patients. Likely, the 
analysis of a larger cohort would deliver more reliable results for testing co-
occurrence and mutual-exclusivity. 
Furthermore, as stated above we identified a very high number of mutations in 7 
patients. For 3 cases this is very likely due to the presence of non silent SNVs in 
mismatch repair genes: MSH6 in two hypermutated patients and PMS1 for the 
third patient. In contrast, there are no evident or easy explanations for the 
remaining 4 cases. However, we have to underline that our analysis is restricted to 
SNVs, so we cannot exclude the presence of other types of mutations, such as 
indels or structural variants in mismatch repair genes also for the remaining 
patients.  
 
4.1.2.2 Testing and validating the two mutation calling pipelines on a cohort 
of 20 leukemic patients 
Considering all the discrepancies that were highlighted by our comparison in the 
results obtained with the two pipelines, we decided to try to investigate further 
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the reasons underlying these discrepancies.  Therefore, we performed a thorough 
validation of the mutations identified by both methods in order to determine if 
one of the two had a greater error rate and, possibly, the rationale for such errors. 
To this aim, we analysed by WES a cohort of 20 leukemic patients containing 19 
primary AMLs (8 of which APLs) and one secondary APL. In agreement with the 
data we reported using the TCGA dataset, also on our cohort of patients, the 
SNV landscapes identified by the 2 pipelines were largely different: 
SomaticSniper revealed a total of 194 SNVs and 178 mutated genes, versus 463 
SNVs and 412 mutated genes revealed by MuTect. The commonalities amounted 
for 161 SNVs and 150 mutated genes. Indeed, the frequencies of SNVs per 
patient are different: 9.7 in SomaticSniper vs 23.2 for MuTect (0-0.6 per Mb vs 
0.1-4.37 per Mb). Moreover, similarly to the paper mentioned above45, MuTect 
characterized one hypermutated patient: the secondary APL, harbouring 131 
mutations. In this patient we did not detect mutations in mismatch repair genes, 
but the hypermutated phenotype could have been induced by the external 
chemotherapeutic agents used for treatment. 
The genes that were previously known to be cancer genes (as reported by The 
Cancer gene census, CGC129,130) identified by the two pipelines were 14 for 
SomaticSniper and 21 for MuTect (Table 4.2), underling again the impact of the 
discrepancies found and the importance of using a good mutation caller. 
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Table 4.2: Number of mutations identified by SomaticSniper and MuTect in our 
cohort of 20 leukaemias. For each patient (sample), we report the number of SNVs 
uncovered by SomatiSniper, by MuTect, by both pipelines (Common). Moreover, for 
each group we report the genes already known to play a role in cancer development that 
are part of the Cancer Gene Census (CGC). 
 
For the variants identified in common, the two algorithms have a high rate of 
agreement on the VAF of the mutations (Figure 4.5), with high Pearson’s 
correlation coefficient both for the frequencies of the variants identified in the 
Sample  SomaticSniper  MuTect  Common  
CGC genes only 
in SomaticSniper  
CGC genes 
only in 
MuTect  
CGC genes in 
Common  
AMLp6  0 3 0       
AMLp7  8 23 7     IDH1  
hAML#Mi3  7 17 5     IDH2  
BO1  13 17 8 NRAS  KRAS    
BO2  8 10 7     IDH1  
BO3  13 13 5 DNMT3A    IDH1  
hAML#Mi7  7 7 6     FLT3, IDH1  
TO1 16 20 15     
JAK2, PHF6, 
RUNX1  
TO2  11 17 10     
DNMT3A, 
FLT3  
TO3  15 23 14 TET2  
MLL3, 
NRAS  
EZH2, NRAS, 
RUNX1, 
TET2  
UD1  17 24 16     EZH2  
APLp2  14 26 12 IL21R      
APLp3  3 22 3   CHECK2    
hAPL#Mi6  11 21 6   ETV6    
hAPL#Mi7  18 43 16   TRIM33  ARID1A  
hAPL#Mi8  3 9 3   FGFR2  KRAS  
hAPL#Mi9  5 5 5       
hAPL#Mi10  7 10 7     FLT3  
hAPL#Mi11  8 22 7   
FLT3, 
NRAS, WT1  
KDM6A  
sAPL#Mi1  10 131 9   
ERBB2, 
KIAA1549  
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tumour (0.99) and in the normal sample (0.81). The average difference of 
frequency assignment was around 1.1% (range 0 - 7%). Indeed, these SNVs were 
easy to be uncovered having little frequency of reads carrying the variant in the 
normal (about less than 1.5%) and high frequency in the tumour sample (the 
smallest around 20%). The normal samples show a slightly lower correlation rate 
because they are at very low frequencies and one read difference results in 
bigger discrepancies. 
Figure 4.5: Variant Allele Frequency of mutations identified by both algorithms. 
Common mutations generally have very low VAFs in the normal sample (panel b., ~≤ 
1.5%) and higher in the tumour sample (panel a., ~> 20%). The Pearson’s correlation 
coefficient calculated for VAFs in SomaticSniper and MuTect of tumour and normal 
samples are respectively 0.99 and 0.81, reflecting high similarity of counts. Note that in 
the two panels there is a different scale in order to magnify the differences of normal 
samples.  
 
The two pipelines especially differ on their capacity to call SNVs with low VAFs: 
MuTect in our dataset is able to call mutations with as low as 2% VAF, while the 
lower limit for detection with SomaticSniper is bound at 10% VAF. For this reason, 
we grouped mutations based on their frequencies: we considered high frequency 
mutations (HF) those having a VAF >10% and low frequency mutations (LF) those 
having a VAF ≤10%. SomaticSniper was able to identify 194 HF SNVs and MuTect 
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found 245 HF SNVs (9.7 and 12.3 SNVs per patient, respectively) (Table 4.3); 161 
of these SNVs were common, accounting for around 83% and 66% of the total 
SNVs identified by each pipeline, respectively. The validation of HF SNVs 
revealed that both methods are very precise with validation rates higher than 
89%; in particular the common mutations had a validation rate of 98% (78/161 
tested positions).  
The SNVs distinguished by only one of the two methods are 33 for SomaticSniper 
and 84 for MuTect (Table 4.3). SomaticSniper unique SNVs were verified in 43% 
of the cases (6/14 positions tested) and MuTect unique HF SNVs were always 
validated (17 positions tested). These results underline that both pipelines leave a 
portion of mutations undetected (i.e. the mutations that are unique to the other 
pipeline). Probably, refinement of the methods, aiming at reducing the detection 
of false positives, conducted to high rates of false negative mutations.  
Furthermore, nearly half of the SNVs identified by MuTect were LF SNVs, never 
detected by SomaticSniper. The validation rate for these LF SNVs was around 
80% (48/60 positions tested).  LF mutated genes include also 13 known drivers as 
reported by CGC130: CHEK2, ERBB2, ETV6, FGFR2, FLT3, KIAA1549, KRAS, 
MLL3, NRAS, PDE4DIP, RUNDC2A, TRIM33 and WT1. 
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Table 4.3: Mutations identified by the two pipelines and corresponding validation 
rates. In the table are reported all the mutations identified by the two pipelines 
(SomaticSniper-ALL and MuTect-ALL) and grouped by identification (COMMON: 
identified by both pipelines, SomaticSniper-ONLY, MuTect-ONLY). We tested only a 
portion of all the mutations identified and the numbers are reported for every group. We 
also separated the results by frequency (higher or equal to 10% and lower than 10%) in 
order to highlight differences of the methods used. 
 
LF SNVs identified through WES were tested on two different sequencing 
platforms, Ion Torrent and MiSeq, to ensure the reliability of the results (see 
Materials and Methods chapter, paragraph 3.3.3). Comparing Illumina WES 
frequencies with the output of our validation datasets, we determined that the 
average distance between VAFs was: for Ion Torrent 6 percentage points (with a 
minimum of 0.1 and a maximum of 16 percentage points), for MiSeq the average 
distance was smaller and equal to 3 percentage points but with larger variability 
(from a minimum of 0.06 to a maximum of 21 percentage points). Compared to 
the WES data, VAFs resulted decreased in Ion Torrent validation and very similar 
in MiSeq validation. The validated mutations have frequencies that span from 4% 
to 10% with a median around 6% in Illumina (both for WES and MiSeq targeted 
resequencing) and a median of 2% in Ion Torrent. In Figure 4.6, we show the 
number of mutations we validated, grouped for VAFs in the three experiments. In 
conclusion, though there is no outstanding correlation, WES seems to 
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approximate validation frequencies and, indeed, low frequency mutations (<10%, 
median of 6%) in WES appear at VAFs lower than 10% in IonTorrent (median of 
2%) and in MiSeq (median of 6%). We deliberately tested mutations that 
appeared at more than 4% in WES analysis; both validation technologies 
confirmed that these were LF mutations, probably at VAFs even lower than 
estimated through WES. Because the higher the coverage, the more precise can 
be the VAF determination, with a coverage below 200X (typical of WES analysis), 
the determination of LF VAFs is restricted to few reads and is more prone to 
fluctuations. 
Figure 4.6: Variant Allele Frequencies of low frequency validated mutations. The 
three panels show the VAFs of the LF mutations detected respectively through WES (a.), 
Ion Torrent (b.) and MiSeq (c.). We deliberately tested mutations that appeared at more 
than 4% in WES analysis; validation technologies confirmed that these were LF 
mutations, probably at VAF even lower than observed through WES. 
 
 
In order to ascertain the accuracy of detection of mutations at very low VAFs, we 
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defined as the most called base and reads that differ from the “correct” base 
were considered as errors. Based on this consensus strategy, we calculated the 
empirical error rate as the total number of bases that differ from the consensus 
bases divided by the total number of read bases.  The empirical error rate for Ion 
Torrent was 0.33% and for MiSeq was 0.61% for the control samples (normal) and 
0.29% and 0.62% for the tumour samples, respectively. Based on these results, 
we can be reasonably confident in the trueness of variations appearing at rates 
above 1%. 
Moreover, the possibility of calling an SNV depends on the presence of mutated 
allele in the tumour sample and its absence in the normal sample: these are the 
prerequisites of a somatic mutation. Thus, it is possible to find the tumoural 
variant in the normal sample for technical reasons, caused by mosaicism of the 
normal or by normal contamination with the tumour sample, in particular when 
the normal is a remission sample. Pløen et al.53 described DNMT3A mutations 
persisting in the normal sample up to 8 years after initial diagnosis (at frequencies 
up to 50%); those mutations were after represented in the relapse or in a 
secondary myelodisplastic syndrome revealing the preleukemic nature of the cells 
harbouring them. As discussed before, the persistence of tumour or preleukemic 
cells at remission, with frequencies under the detectability level, can eventually 
cause the relapse in some patients. The evaluation of mutation calling tools in the 
AML context needs, therefore, to consider this aspect and it is fundamental a 
certain leniency in the calling test that allows to identify leukemic mutations in the 
primary also when they are retained in the remission; otherwise the analysis would 
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loose the most ancient mutations of the leukaemia. Actually, the frequency of 
variant alleles in normal samples is significantly higher for SNVs unique to one 
pipeline (Figure 4.7). The average frequency was of 0.001 in the common, 0.004 
in the MuTect-ONLY (Welch 2-tailed test, P-value: 0.0004), and 0.1 in the 
SomaticSniper-ONLY (P-value: 0.005). Notably, common mutations have very low 
VAFs in the normal, therefore, not validated mutations in SomaticSniper could be 
the result of a contamination by leukemic cells of the normal sample. 
SomaticSniper, in fact, was originally designed to call mutations in leukaemias 
and we noticed that it allows higher VAFs for alternative allele in the normal 
(Figure 4.7.c). Despite a higher rate of false positives, this leniency allows for the 
discovery of SNVs that have the “landscaping” characteristics and can result in 
successive relapse. In our set of patients, we pinpointed mutations with these 
characteristics in TET2 and DNMT3A that were called “not validated” but 
necessarily needed to be taken into consideration.  
In conclusion, SomaticSniper is more able than MuTect to detect variants present 
in the normal sample but, at the same time, this characteristic makes it more 
prone to false positive calls. 
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Figure 4.7: Normal and Tumour VAFs in called variants. We reported the VAF for 
tumour (x-axis) and normal (y-axis) for mutations that were commonly identified (panel a) 
or respectively unique to MuTect (panel b) or SomaticSniper (panel c). Points 
correspondent to validated mutations are filled in black, not validated mutations are 
represented with a surrounding black circle.  
 
 
We retrieved the VAFs reported by MuTect for the SNVs uniquely called by 
SomaticSniper (vice versa was impossible) and we noticed a difference in the 
frequencies reported by the two algorithms. Indeed, they apply different filters to 
the reads that result, at the end, in the differences observed in mutation calling. 
In particular, MuTect applies distinct filters to normal and tumour reads: while the 
filters applied to the normal are very similar to the filter applied by SomaticSniper, 
the filters applied to the tumour are stricter in order to increase the possibilities of 
calling real variants increasing reliability. However, in some cases, we observe 
VAF counts in contrast to the indicated hypothesis: this can be due to minor 
differences in filter parameters that in fact are reflected in changes of smaller size 
(Figure 4.8). 
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Figure 4.8: Differences in Variant Allele Frequency for the mutations identified only 
by SomaticSniper. In the graph are reported the VAFs for the tumour (x-axis) and the 
normal (y-axis) samples for the mutations that were called uniquely by SomaticSniper. 
Dotted lines connect the points relative to SomaticSniper values (blue) to the points 
relative to MuTect values (yellow) for the same mutation. 
 
 
 
4.1.2.3 The impact of false negatives in the AML data analysis and the choice 
of a mutation calling method 
We compared two mutation-calling methods that have been previously used in 
the literature to describe AML mutational landscape. The most surprising result 
was the presence of many false negatives that result in an under evaluation of 
AML somatic mutations. From the clinical point of view, this can leave concealed 
patterns of clonal evolution or the presence of prognostic marker that would 
guide the therapeutic strategies. Indeed, we discovered that a consistent part of 
the AML mutational landscape has to be uncovered; in particular many mutations 
at low frequency can be present in leukemic patients that were not characterized 
with SomaticSniper. It has been demonstrated that oxidative DNA damage during 
sample preparation can induce artefacts in the mutations131,132; therefore we 
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estimated the possibility for the mutations identified with MuTect to be artefacts 
calculating the percentage of C>A and G>T transversions on the total mutation 
number. We verified that some patients present an unexpected high proportion 
of possible artefact mutations; in particular two patients (pt2856 and pt2931) have 
more than 50% of C>A and G>T mutations (see Figure 4.9). In these cases a 
deeper validation should reveal the reliability of the results. 
Also the identification of AML hypermutated samples is novel; we still do not 
know whether the observed mutations can be imputed to technical errors, arise 
simply by a sample preparation artefact as described above, or are real. Indeed 
the probability that they are due to oxidative stress is very low since the median 
percentage of C>A and G>T transversions is 10% (ranging from 7% to 21%). 
Certainly the presence of hypermutated patients raises many questions on the 
possible mechanism giving birth to the leukemic phenotype. 
Figure 4.9: Percentage of possible artefact mutations in TCGA patients called by 
MuTect. Each bar in the plot refers to a TCGA patient, on the y axis is reported the 
percentage of mutations of the C>A and G>T type (red) compared to all the other 
possible mutations (light blue). 
 
We tested only two of the many somatic mutation callers developed for NGS data 
analysis; accordingly, our estimate of the number of false negative mutations is 
likely a limited estimate of the real situation. Nevertheless, the scientific 
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community already knew this complication and a big effort has been made to find 
new outstanding method that would outperform the others or that would 
incorporate the capabilities of multiple tools126.  
Considering all the data obtained and the speculations reported above, we 
decided to pursue the analysis on our cohort of patients using MuTect, because it 
allows us to uncover low frequency mutations and have higher validation rates. 
Although, of course, we must keep in mind the false negatives that also this 
analysis will bring along. 
 
4.1.3 Calling mutations on triplets of samples 
In order to characterize the genetic patterns of relapse formation in AML, we 
collected, for our cohort of patients, triplets of samples, consisting in exordium, 
remission and relapse samples. The mutation calling entanglement is even more 
complex if the analysis is going to be performed on multiple samples collected 
from the same patient. In this case, calling a mutation in one sample raises the 
intrinsic probability for the presence of the same mutation in a related sample 
from the same patient even at very low frequency. Since the purpose of our study 
is to determine the origin of relapse in AML patients, great relevance is 
demanded to relapse mutations that were previously existent in primary tumours 
or remission samples. Therefore, the remission samples in our analysis have not 
been formally considered simply as normal DNA, and instead we treated them as 
temporally distinct samples collected during the evolution of the disease. 
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Practically, we proceeded analysing all the possible couples of samples (tumour 
vs remission, relapse vs remission, relapse vs tumour and vice versa) and calling 
the variants using MuTect. For all resulting SNVs, we recovered the counts of 
reads carrying the reference base and the variant base and labelled the variants 
as: 
- Primary tumour specific or Relapse specific when the variant harboured less 
than two reads or had a VAF lower than 1% (which we consider, as 
explained in paragraph 4.1.2.2, the lower boundary to distinguish 
mutations from noise in Illumina HiSeq Sequencing) in the relapse or in the 
primary tumour sample, respectively; 
- Common decreasing or Common increasing if the variant was present in 
both samples but the difference in the read counts was statistically 
significant: greater in the primary tumour for the former, greater in the 
relapse for the latter. We tested the difference in read counts trough two 
sided Fisher’s exact test, using 0.05 as a threshold for significant calls; 
- Common Primary – Remission or Common Relapse – Remission in case at 
least two reads and a VAF of 1% were reached in the remission and one 
other sample, while the third contained less than two alternative reads; 
- Common when the variant was present both in the primary tumour and 
relapse samples and there was no significant difference in the read counts 
for the two samples. 
This is a simple but effective way to label mutations taking advantage of the 
joining of multiple samples and looking at the samples as a whole in an 
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evolutionary context. 
 
4.1.4 Control-FREEC and ExomeCNV outperform other methods 
in CNV calling  
The call of copy number alterations from WES data is to date a challenging issue, 
mainly because the different affinities for their targets of the probes used for 
capturing results in coverage fluctuations and because the gaps between the 
covered regions make even harder the identification of the exact segments with 
different copy numbers in the tumour cells. Furthermore, it has been recently 
discovered that not only tumour cells contain copy number alterations but also 
normal cells, in some cases, present peculiar alterations in the number of copies 
of genomic regions. 
In order to evaluate the performances of different CNV callers from WES data, we 
took advantage of an additional dataset available in our laboratory. This dataset is 
only partially overlapping with our main dataset and it is composed by primary 
tumour and remission samples, which were analysed both by WES and SNP-array 
analysis. We refer to this dataset as the “Bologna cohort”. Of course, in this 
context, we use the SNP-array analysis as a positive control for the calls of CNVs 
from WES data, because the sensitivity of this technique, in the regions analysed, 
is very high and is well established. 
Concerning the SNP-array analysis, we disposed of the results of Nexus, the 
proprietary algorithm for the analysis of CytoscanHD arrays, and we used Nexus’ 
	  116	  
output as positive control for the evaluation of WES derived CNVs. 
 
4.1.4.2 Control-FREEC and ExomeCNV have higher accuracies in calling 
CNVs from WES data 
We used five methods to extract CNVs from WES data in order to define which 
approximates better SNP-array results: cn.mops, CONTRA, ExomeCNV, Control-
FREEC, VarScan + DNACopy. For this purpose, we analysed 17 patients from the 
“Bologna cohort” described in paragraph 3.1.3. For each method, we compared 
the bed files given in output and containing the calls with the bed files obtained 
by the Nexus analysis. 
First of all, we evaluated if the methods starting from WES data were able to 
recapitulate the copy numbers variations identified through SNP-array. To 
address this question, we computed the number of basis of the genome both 
present in the array output and in the output of each method independently (we 
called it “coverage”, Figure 3.10.a). Nexus output contains only the regions 
carrying variants in the number of copies (i.e. the number of copies differs from 
2), while the tested methods report the information also for copy number neutral 
regions; as a consequence the “coverage” parameter disclose the extent of the 
regions containing CNVs effectively targeted by each method (remember that all 
the methods start from the same reads file). Concerning the coverage, we 
observed a ranking of performances of the different tested methods: VarScan2 
and ExomeCNV gave the best results; Control-FREEC an intermediate 
performance; cn.mops and CONTRA gave the lowest coverage (Figure 4.10a). 
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Filtering for exclusively high quality Nexus results, the coverage decreases 
significantly but not uniformly: some patients have big coverage drops (e.g. 
BO11), others do not change (BO19), suggesting the absence of association 
between WES coverage and array quality (Figure 4.10b).  
Figure 4.10: Coverage of the overlap of the SNP-array output with the CNV calling 
obtained from WES data. We calculated the number of bases of the genome present 
simultaneously in the SNP-array output and in each of the WES-CNV calling pipelines 
both for raw Nexus results (a) and for quality filter Nexus results (b). Colours of the bars 
correspond to the methods tested; the dotted line serves as a reference because the two 
plots have different scales on the y-axis. 
 
Considering the percentage of basis covered by the SNP array and present in the 
output of each method instead of the absolute number of covered basis, we 
recapitulate the same results: CONTRA has the lowest coverage performances, 
cn.mops is slightly better and variable among patients, Control-FREEC has 
middle performances and the best results are scored by ExomeCNV and VarScan. 
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Figure 4.11: Percentage of the overlap regions of the SNP-array output with the 
CNV calling obtained from WES data. We calculated the percentage of bases of the 
genome present simultaneously in the SNP-array output retrieved by each of the WES-
CNV calling pipelines for raw Nexus results. Colours of the bars correspond to the 
methods tested. 
 
Indeed, the Pearson’s correlation coefficient calculated for WES and array 
coverage was very low: 0.048 and 0.0015 for tumour and normal samples, 
respectively, and the distribution of the patients in the plot is sparse (Figure 4.12). 
In general, for samples with good coverage, the WES coverage does not impact 
on CNV detection. 
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Figure 4.12: Correlation between the coverage of the WES regions and the 
coverage of the SNP-array for tumour (a) and normal (b) samples. Each dot in the 
plots identifies one patient. The Pearson’s correlation coefficient of the distribution is 
indicated. 
 
In order to compare the CNVs identified by the calling pipelines to the Nexus 
results, we transformed the absolute copy numbers identified from WES 
according to these criteria: i) regions with 2 copies were labelled “neutral”; ii) 
regions with more than 2 copies were labelled “gains”; iii) regions with less than 2 
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copies were labelled “loss”. Afterwards, we were able to produce two confusion 
matrices for every CNV calling method: one for the GAIN calls and one for the 
LOSS calls, as described in Table 4.4. However, since Nexus reports only aberrant 
regions and automatically discards neutral regions, we will lack all the true 
negatives (TNs) and some false positives (FPs). 
Table 4.4: Labels for the construction of the two confusion matrices. Written in grey 
are the classes missing in our analysis, due to the absence of neutral regions in Nexus 
output. 
 
In this context, to measure the closeness of predicted CNVs identified in WES 
data to SNP array results, we used accuracy. Accuracy is calculated as: 
𝐴𝐶𝐶𝑈𝑅𝐴𝐶𝑌   = !"  !  !"!"  !  !"  !  !"  !  !"   
As already discussed above, the lack of neutral reads in the Nexus outputs allows 
calculating only partial accuracy. The level of accuracy (reported in Figure 4.13 
and summarized in Table 4.5) results very variable among patients: the smallest 
range for accuracy was obtained with cn.mops on losses going from 0.002 to 
0.046 (always presenting very low levels of accuracy), the bigger range was 
obtained with ExomeCNV for the gains going from 0 to 0.986. The results 
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obtained from Nexus quality filtered output show higher accuracy variability also 
for the less performing methods in the detection of copy number losses: 
CONTRA, the smallest, has an accuracy range going from 0 to 0.22, ExomeCNV 
in the best case reaches almost 1. Despite, in general, the performances on 
filtered data do not show very high differences (the median is not strongly 
affected), the maximum values are significantly improved both for methods 
showing good CNV prediction capacities (ExomeCNV, Control-FREEC, VarScan2) 
and for the worse tools (cn.mops, CONTRA). VarScan2 gives unbalanced results: 
when accuracy is high in CN loss, it is low in CN gain and viceversa. On the 
contrary, ExomeCNV and FREEC seem to be more balanced and they both 
display good performances. Finally, with our dataset, Cn.mops and CONTRA do 
not give satisfactory results. 
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Figure 4.13: Measurements of accuracy of the five WES-CNV calling methods 
compared to SNP-array results both for LOSS and GAIN CNVs. Using the 
aforementioned contingency tables, both for gain and loss CNVs, we calculated the 
accuracy for each method, as shown in the legend, for every patient. The same analysis 
was performed before and after applying Nexus quality filters to the SNP-array data. 
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Table 4.5: Summary of accuracy levels identified by the different methods. For every 
method is reported the median and maximum values obtained on the “Bologna cohort” 
both for gains and losses. The same set of results was calculated with (Nexus quality 
filtered) or without (Nexus no filters) filtering the quality of Nexus output. 
 
Another parameter used to measure the quality of calling is the F-measure, 
calculated through the following equation: 
𝐹 −𝑀𝐸𝐴𝑆𝑈𝑅𝐸   =   2 ∗ 𝑃𝑅𝐸𝐶𝐼𝑆𝐼𝑂𝑁   ∗   𝑅𝐸𝐶𝐴𝐿𝐿𝑃𝑅𝐸𝐶𝐼𝑆𝐼𝑂𝑁  +   𝑅𝐸𝐶𝐴𝐿𝐿  
where Precision is the rate of true positives over all the positive calls !"!"!!"  and 
Recall is the rate of true positives over all the real positives !"!"!!" : higher results 
correspond to better performances. 
In absence of True Negatives, F-Measure is nearly equivalent to Accuracy and, 
indeed, as expected in our context, calculating F-measures for our dataset, we 
obtained results very similar to the one obtained measuring accuracy (data not 
shown). 
Since we observed that the CNVs of some patients resulted problematic (e.g. 
none method is able to reach 0.1 of accuracy on BO5), we speculated that some 
intrinsic characteristic of the sample could impair the capacity to identify CNVs in 
Method Median Max Method Median Max
cn.mops 0.005 0.058 cn.mops 0.006 0.06
CONTRA 0.004 0.055 CONTRA 0.004 0.06
ExomeCNV 0.42 0.995 ExomeCNV 0.31 0.996
FREEC 0.23 0.97 FREEC 0.248 0.99
VarScan 0.009 0.73 VarScan 0.009 0.94
cn.mops 0.01 0.046 cn.mops 0.017 0.27
CONTRA 0.0004 0.162 CONTRA 0 0.22
ExomeCNV 0.057 0.929 ExomeCNV 0.186 0.99
FREEC 0.03 0.693 FREEC 0.024 0.98
VarScan 0.03 0.83 VarScan 0.054 0.93
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those samples either biological characteristics (i.e. GC content) or technical (poor 
quality of the sampled material). If this is the case, we expect to observe a similar 
impact also on the analysis of SNP-array. We therefore checked for correlation of 
SNP-array quality scores that refer to noise (MAPD) and fluctuation (waviness) of 
probes binding (Figure 4.14). However, we could detect a little association of 
these three scores (Pearson’s correlation coefficients between -0.25 and 0.34). We 
concluded that the CNV calling might be challenged by technical and biological 
problems that asymmetrically affect SNP array and WES. 
Figure 4.14: Quality scores for SNP-array do not correlate with accuracy in our 
analysis. CNV identified through SNP array technique or WES analyses are not 
concordant in high quality positions. In the table are reported the Pearson’s correlation 
coefficients for the four comparisons. Following the distribution of patients’ values in for 
the accuracy compared to SNP array quality measures are sparse. 
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appeared very difficult to call CNVs. On the basis of the parameters considered, 
the best method for our analysis appeared to be Control-FREEC for two main 
reasons: i) though it displays intermediate performances on coverage, it provides 
good accuracy on our cohort of samples; ii) it is less susceptible to coverage 
variability. Even if Exome CNV showed similar performances, it always gave an 
aberrantly high number of variants called. These calls may very likely be false 
positives because this pipeline misses a normalization step. 
 
4.1.5 The choice of an adequate method to reconstruct clonal 
composition in tumour samples 
At present, the scientific community is lacking a gold standard dataset that would 
allow assessing the performance of computational tools used for the 
reconstruction of the subclonal composition of complex cellular populations from 
genomic data. The ideal dataset would come from a controlled experiment in 
which the subpopulations present in the sample and their relative abundances are 
set and known a priori, in order to be able to test all the possible sources of error 
(e.g. capture phase, sequencing phase, bioinformatics pipeline). With the 
announcement of the ICGC-TCGA-DREAM somatic mutation calling challenge, 
on Tumour heterogeneity and evolution, a test dataset has been published 
containing simulated tumour data derived from real tumour data; to date, only a 4 
of the 50 tumours are disposable for testing. Since the dataset is not complete, it 
is difficult to assess methods performances based only on 4 cases, leaving the 
	  126	  
need unanswered. 
To address this open question, we built a mathematical model for tumour and the 
corresponding relapse evolution. We, consequently, constructed 90 in silico 
datasets varying standard error and purity of the samples. Standard error was 
used to simulate the possible fluctuations in the determination of the real VAF of 
a mutation, because, as already stated above, the sampling of the cell population 
made through the WES can lead to errors in the VAF estimates. To delineate the 
impact of VAF variability we introduced standard error at increasing rates of 0, 
0.01, 0.05 and 0.09. Of course, also the purity of the tumour samples can affect 
the clonal reconstruction: we set a purity of 1 to correspond to a tumour sample 
100% pure, therefore, without contamination of normal cells. We created 5 
datasets for each model with purity ranging from 0.6 to 1.We tested on these 
datasets four tools for the reconstruction of tumour population, among the most 
commonly used in the literature. This experimental strategy should allow us to 
assess which analytical tool is able to better reconstruct the real cellular clonal 
structure underling the genomic data. 
 
4.1.5.1 Construction of the benchmark in silico dataset for clonal analysis  
The ideal benchmark should recapitulate: 
• the biological conditions: tumour arises in a somatic heterogeneous context and 
relapse can be the consequence of cells present at exordium and successively 
evolving; 
• the characteristics of the data: AML has generally low mutation rate and, in our 
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dataset, CNV rates are different in primary and relapse tumours; 
• all the possible sources of errors: sequencing errors and purity of the sample 
can have a great impact on the reconstruction of the clonal population. 
Therefore, we decided to proceed building a model with constrains conceptually 
based on our knowledge. 
 
4.1.5.1.1 Model characteristics 
The computational model is defined through a series of matrices and vectors that 
contain all the parameters that will be used to compute the solution. In particular, 
we want to describe a situation in which from a normal population of cells, 
through the accumulation of successive damaging mutations, a tumour expands 
and, after some time, we are able to capture a timeframe of this evolution, in our 
case corresponding to the primary tumour sample. 
The model is defined by the following parameters: 
1. the number of the inspected genomic positions (N): here, we describe in more 
details only the simplest model that takes into consideration only two genomic 
positions. However, the model we built consists of a more complicated simulation 
with 5 inspected genomic positions. In reality, the code is written in order to let 
the user choose the number of positions to be analysed. It is important to 
underline that, of course, adding a single genomic position to the simulation 
increases substantially the computational load for the solution; 
2. the code for the identification of the mutation at the inspected genomic 
position: every position can be in the original state (i.e. not mutated), identified 
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with a 0, or mutated, identified with a 1;  
3. all the possible “genomic” states: the mutational condition of an entire genome 
is described by a vector of zeros and ones, that reports for every genomic 
position the presence or absence of the mutation. All the possible states for a 
model with two genomic positions are:  
 
4. the initial population (x0): considering the primary tumour, the initial population 
is composed of only normal cells. We arbitrary set the number of cells of the initial 
population at 100 cells. Because normal cells are all in the s1 state, the vector is:  
 
• the allowed transitions: in order to avoid inconsistent situations and to better 
guide the model to the desired solution, it is necessary to put some restrictions to 
the transitions among the different mutational states that can be observed. For 
this reason, we allowed only the transitions that involve the acquisition of a single 
mutation (the summary of allowed and refused transitions for a two genomic 
positions model is reported in Figure 4.15). 
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Figure 4.15: Scheme of transitions allowed in our model. Only transitions indicated 
with a blue arrow can arise in the model, the occurrence of red transitions is avoided 
through model constraints.  
 
• the model reactions: on the basis of the allowed transitions, the model is 
defined with a series of reactions that describes the birth, the death and all the 
transitions that can take place in the model (see propensity vector for the 
mathematical definition of each reaction); 
• the propensity vector: it defines the actors that will interplay in the model 
equations. The reactions of changes among states and the associated equations 
are the following: 
 
where cn defines the constant of association for the reaction (i.e. “death rate”, 
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“birth rate” or “transition rate”), cc defines the total number of cells at the 
previous step, used to impart a spatial constraint to the group of cells that are 
dividing. The first group of four equations describes the death of the cells in a 
determined state; the second group of four equations describes the birth of the 
cells in a determined state; the last group of four equations describes all the 
possible transitions of allowed mutational states; 
• the parameters that define the rates of birth and death: these values are 
reported in a vector that contains the rates associated to the equations that 
define the model. The state transition rate is fixed, all the other parameters, 
instead, depend on the mutations present in that particular state: the state s0 has 
death rate and birth rate fixed to 1, every mutation has an associated δ death rate 
and δ birth rate randomly chosen in these ranges: 
. 
where N is the number of inspected genomic positions in the model. 
Note that both these parameters can either be positive or negative and that the 
presence of two mutations together will not always necessarily result in an 
increased birth rate or a decreased death rate. 
 
4.1.5.1.2 Definition of the time-points that resemble our set of samples 
In order to reconstruct in silico the same set of leukemic samples we analysed in 
practice, which is composed of primary, remission and relapse samples for each 
tumour, we ran the model with specific parameters and took a snapshot of the 
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results generated by the model at three different time-points:  
• PRIMARY TUMOUR: five genomic positions (N = 5), the initial population is 
set to 100 normal cells and we let the model run for 30 (t=30) iterations. The 
primary tumour sample corresponds to the snapshot of the model at time t=30;  
• REMISSION: the whole population is formed by 100 normal cells (to 
resemble the normal state) plus 5 cells that survived the chemotherapy, chosen 
randomly in the possible states (Ns(t)) present in the primary tumour at the end of 
the simulation (t=30). Ns is the number of states presented at least by one cell in 
the tumour population at time t.  The probability for a state to be represented in 
each of the 5 cells surviving the treatment is equal to !!!(!)  . 
• RELAPSING TUMOUR: in this case the starting population is the one that 
has been constructed for the remission; the number of states is five plus the 
number of not normal states (nns) present at remission (N = 5 + nns). Assuming 
that it is impossible to loose acquired mutations in a cell, we collapse genetic 
makeup of cells surviving chemotherapy to a single mutation in the new 
framework (each corresponding to a nns). In order to avoid transitions between 
”surviving states” the transition matrix has been modified with additional 
restrictions. The number of iterations was set empirically to 10 (see next 
paragraph for the explanation). 
To better understand the process described by the model we report in Figure 
4.16 a practical example of the three time points. We are analysing a genome 
that in the primary tumour can present mutations at 5 genomic positions (A, B, C, 
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D and E). At the end of the first simulation, 3 clones form the primary tumour: s29, 
s30 and s31; the first is antecedent to the other two, having only 3 mutations on the 
genes C, D and E; the other two evolved differently acquiring respectively a A 
and a B mutations. Ns(30) for the primary tumour is, therefore, equal to 3 in this 
case; the 5 cells surviving the therapy will be then extracted with a probability of !!   
from the group s29, s30 and s31. In fact, we extracted 2 cells for the states s29 and s30 
and 1 cell for the state s31. For evolution of the relapse we, then, launched the 
simulation on N genomic position where N=5+nns, in our case the number of not 
normal states at remission was 3 (nns=3), therefore the total genomic positions 
will be 8. Assuming that it is impossible to acquire 2 independent mutations at 
the same genomic position, we modified the transition matrix in order to avoid 
transitions between s29, s30 and s31. At the end of the simulation for the relapse 
sample, we observed that the clone s30 expanded overcoming the others and 
acquired two mutations (G and H) that became dominant plus 3 more subclonal 
mutations (F, I and J). 
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Figure 4.16: The output of our model at the three defined time points and 
reconstruction of the biological framework described. a. For every time-point, we 
report only the populated states. In the primary tumour we identify three states where s29 
is antecedent to s30 and s31 having only mutations C, D and E. At remission all the three 
states survive at very low frequencies. In the relapse s30 expands overcoming the other 
clones and gaining new mutations. b. A scheme of the biological snapshot at the three 
time-points with cellular frequencies of the clones carrying the mutations. 
 
 
4.1.5.1.3 Setting of the parameters for resembling relapse formation 
We did not challenge our model from a mathematical point of view, testing all the 
parameters in order to choose the better ranges for our framework, because this 
was not the aim of our study. However, we attempted three combinations of 
mutation rates and time to relapse to obtain a good output in a reasonable time.  
Firstly, we set the parameters for the primary tumour and let the model run for 30 
steps, considering a mutation rate of 0.05, which is extremely high compared to 
the real mutation rate of the human genome. These settings were thought in 
order to increase the probabilities for the model to develop a tumour. We ended 
up with a population of cells where one state overcame the others, thus resulting 
in a tumour. 
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From a theoretical point of view, in order to mimic a physiological situation, it 
would be better to use a time to relapse smaller than 30 and lower mutation 
rates. In fact, considering that the primary tumour, in reality, have a mean 
exordium age around 60, a time to relapse of 30 would be very long compared to 
the one observed in reality. Indeed, a patient is considered cured if he/she did 
not develop the disease ten years after the first leukaemia. Therefore, as for the 
primary tumour, also for the relapse we challenged our model using three 
different combinations of settings for time to relapse and mutation rates, in order 
to investigate which conditions better replicates reality, allowing, at the same 
time, for relapse formation (Table 4.6).  
In the first attempt, we used a number of steps for the relapse of 7. We run the 
model ten times and observed that, with these settings, at the end of the run too 
many cellular species compose both the tumour and the normal population in the 
relapse (Figure 4.17.b). Nevertheless, the maximum number of iterations of the 
model to get a solution showing a tumour population was low (4 iterations). We, 
therefore, tested the same time to relapse, considering a mutation rate of 0.006. 
A mutation rate of 0.006 is lower than the one previously tested, but it is still 
higher than in reality. In fact, it is the rate expected if any mutation occurring in 
the exome of the cell would behave as a driver mutation, which is clearly very far 
from reality. In this case the time for simulation increased substantially and the 
model had to run many times before observing the formation of a relapse tumour 
(median of 115.5, with a maximum of 1247 iterations, Figure 4.17.b). We needed 
to run the simulation many times with different set of parameters for birth and 
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death rates, as explained in paragraph 4.1.5.1.1, because a mutation rate of 0.006 
and a t=7 did not allow a cell population to outgrowth the others. Finally, using 
10 steps to mimic the time to relapse formation and a high mutation rate of 0.05, 
we obtained a defined relapse in a reasonable amount of time (Figure 4.17). 
Therefore, after these tests, we decided to adopt as final parameters a mutation 
rate of 0.05 and t=10 and modelled ten couples of primary and relapse tumour 
using these settings to be used to test several clonal analysis methods tools. 
Table 4.6: The parameters tested in our model. The parameters were adjusted in order 
to find a good compromise between the need to obtain results in a reasonable 
timeframe and the approximation of the real conditions for development of the disease. 
Observations report the model output characteristics and the time needed to obtain the 
results by running the model with the parameters listed. 
Relapse steps Mutation rate Observations 
7 0.05 Relapse is not well defined (many cellular 
species both in relapse and normal cells) 
7 0.006 Mutation rate is still higher than real; very 
time consuming  
10 0.05 Relapse is well defined and can be obtained 
in reasonable time 
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Figure 4.17: In our model, different mutation rates and times to relapse (t) largely 
impact the number of iterations needed to obtain a tumour population and the 
composition of the observed tumour populations. For every set of parameters, we 
report: a. the boxplot of the number of times the simulation was ran, resetting the birth 
and death parameters in order to be able to observe a cellular population in output with 
tumoural characteristics (the dominant clone harbours at least 3 mutations). We produced 
10 primary-relapse couples of samples for every set. Note we report a different scale for 
the boxplot with mutation rate 0.006 and t equal to 7 to make the graphic more 
readable; b. an example of evolution of the states during time for relapse. For mutation 
rate equal to 0.05 and time set to 7 the final snapshot results noisier than for the other 
two examples. 
 
 
4.1.5.1.4 From model solutions to actual input datasets 
The model solutions, described in the previous paragraph (4.1.5.1.3), were 
calculated in a discrete manner through the Gillespie’s method (GillespieSSA R 
package) and we ran the model resampling the δ death rate and δ birth rate until 
the expansion of the dominant clone has a minimum number of mutations 
defined by the user (3 in our case). In Figure 4.18 is reported the composition of 
the cellular population developed at each time-point during one of the ten 
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simulations performed with the chosen set of parameters. It is clear that the 
normal population size decreases gradually in favour of the expansion of the 
tumour clones. For example, in the primary tumour, the tumour population at the 
time of diagnosis (t=30) consists of a dominant clone and eight subclones. The 
relapse, instead, appears more heterogeneous, with more subconal populations 
compared to the primary tumour, because it starts already with some mutations 
and can reach a higher number of states. 
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Figure 4.18: Cellular composition of the primary and relapse populations at each 
step of our model running: solution 1. Each stacked bar shows the number of cells for 
all the states (Time) forming the tumour population. Each colour identifies an 
independent clone and the height of each bar indicates the number of cells for each 
clone. The first bar (Time 1) represents the normal cellular population and it is composed 
by the 100% of normal cells, successively the fraction of the normal population decreases 
and new cells harbouring mutations arise and expand over time.  
 
 
Once defined the solution of the model, in order to use the information obtained 
about the tumour populations as a benchmark to test the performances of the 
different computational methods available for clonal analysis composition, we 
need to extrapolate the VAFs of the mutations in the primary tumour and in the 
relapse tumour. As a matter of facts, all the different tools available start, indeed, 
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from the VAFs and CNVs obtained through WES analysis of the samples, to 
recapitulate the composition of the tumour population of origin. Therefore, for 
each of the 10 solutions produced by our model, we produced nine files 
reporting information on the mutations, their coverage and VAFs, as follows: 
• 100 positions of the genome and corresponding base changes are extracted 
from a file containing all the mutations identified in our cohort of patients (this 
step was made only to resemble a plausible dataset from the clinical point of 
view); 
• to each position we then associate: 
 –  one of the mutations in the model (M), randomly; 
 –  the number of DNA copies present in the primary tumour exactly at that 
position (CNPT).  This number is extracted with a per base probability distribution 
determined by the analysis of all the CNVs detected in our samples; if this value 
differs from 2, then there is a random determination of the number of copies that 
are mutated (MCNPT)  
 –  the number of DNA copies present in the relapse tumour (CNRT ; as before, 
the probability distribution in the relapse is slightly different in this case)  
 –  the error rate at that position for every ”coverage” (err)  
 –  the coverage in the three samples (per primary tumour covPT, per remission 
covR, per relapse tumour covRT), extracted in the range [60-150X] as the majority 
of the positions in the samples we analysed present the same distribution (we 
avoided extreme coverage because sometimes it is associated to a bias in the 
capture or in the alignment phase)  
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• once that CNs, error and coverage were set for every position, we computed 
the number of reads for the following categories: reference (R) and alternative (A) 
coverage for the primary tumour, for the remission and for the relapse, 
respectively with the equations: 
 
Purity (purity) and error (err) are alternatively fixed to a neutral value, in order to 
create 9 datasets for every solution: 4 will have purity fixed to 100% and 
increasing error rate equal to 0, 0.01, 0.05, 0.09 or, vice versa, 5 will have error 
rate fixed to 0 and values of purity growing from 60% to 70%, 80%, 90% and 
100%. 
 
 
4.1.5.2 PyClone is the best performing clonal analysis decomposition tool on 
our benchmark 
We have now created a benchmark composed of 90 files, reporting observations 
referred to 10 tumour models based on varying error rate and purity of the 
sample. At this stage, we analysed all 90 datasets with four of the most used tools 
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for clonal reconstruction: Clomial, ExPaNds, PyClone and SciClone. As stated 
above, all these tools start from VAFs of single point mutations and CNVs data, in 
order to reconstruct the clonal composition of a tumour, generating as an output 
the number of clones forming the tumour population, their associated 
frequencies and the variants belonging to each clone or subclone. We could, 
therefore, evaluate the performance of each tool, comparing the results of the 
analysis of our benchmark dataset obtained with each tool to the model’s 
solutions. 
The first and easier task to be evaluated is the identification of number of clones. 
In Figure 4.19, for every tool, we show the total number of clones forming the 
tumour population as a red dot and the number of detectable clones (i.e. clones 
with VAF higher than 5%, i.e. VAF of heterozygous mutations 2.5%) with a blue 
dot. For every method, the boxplots are associated to the number of clones 
identified varying error rate and purity. Clomial always underestimates the 
number of clusters, failing in the assignment of clone identification. In contrast, 
Expands, PyClone and SciClone tend to approach the real number of clones. 
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Figure 4.19: Performances of four clonal composition analysis methods on our 
benchmark dataset. For each model and method is reported a boxplot of the number of 
clones identified varying error rate and sample purity. The total number of clones is 
represented with a red dot; the number of detectable clones (frequency > 5%) is 
depicted with a blue dot. The outliers are depicted as black dots. Boxes define the 25th 
and the 75th percentiles; horizontal line within the boxes indicates the median and 
whiskers define the 10th and the 90th percentiles.   
 
We, next, considered as reference for the number of clones, only the exact 
number of detectable clones in the model (i.e. clones with frequency >5%). We 
decided to exclude low frequency clones from further evaluations because, at low 
frequencies, it becomes really difficult to discriminate groups of mutations with 
similar behaviour. Moreover, we mostly care about grouping higher frequency 
mutations, because the assignment of low frequency mutations to subclones, 
though they might play a determinant role in relapse expansion, is a challenging 
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problem starting from WES data. Indeed, even mutations discovery at low 
frequency is challenging from WES data and the ones we detect are selected by 
chance from the low frequency mutations population. We used the reference 
number of clones to evaluate the number of times each method identifies the 
exact number of clones (Figure 4.20.a) or misses the exact result by maximum one 
clone (Fig 4.20.b): the higher is the bar associated to the method, the better it 
performs in the identification of the exact number of clones. PyClone results the 
best performing method, grasping the correct numerosity in 24/90 cases (27%) 
and missing the correct results by maximum one clone in 57/90 cases (63%). 
SciClone ranks after PyClone with 17 (19%) and 44 (49%) exact and almost exact 
results, respectively; Expands ranks third (14 and 37) and Clomial gives the worst 
results, catching at uttermost the 12% of the correct solutions (2 exact results and 
11 missed).  
Figure 4.20: Evaluation of the performance of the different methods in discerning 
the right number of clones. On the y-axis is reported the number of times each method 
is able to determine the exact number of clones in the tumour population (a), or misses 
the correct result by maximum one clone (b). 
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evaluated whether also the frequencies associated to each cluster approximate 
the real frequency. We calculated the distance of the frequency of each real clone 
from the nearest frequency identified by the tested tools. When the methods 
identified one clone less or one clone more than the real ones, we simply added 
its distance to the sum. Figure 4.21 shows, for each method, the sum of distances 
both not normalized (Figure 4.21.a) and normalized for the number of exact calls 
(Figure 4.21.b). Considering this parameter, SciClone is the tool that performs the 
best. 
Figure 4.21: Evaluation of the performance of each tool in the determination of 
clonal frequencies. For each method, when the number of clones identified was correct 
(plus or minus one), we computed the sum of the distance of the frequency of each real 
clone from the nearest frequency identified by the tested tools. Panel a. shows the 
absolute distance, panel b. the distance normalized for the number of exact calls. The 
impact of the normalization step becomes clear for Clomial, which fails to retrieve the 
exact number of clones in the majority of the cases and appears to have little absolute 
distance. However, after normalization, becomes the worst performing in the prediction 
of frequency. 
 
At first sight, the immediate conclusion from these results would be that SciClone 
gets closer to the real frequency, however, this is not correct. In this type of 
measurements mistakes are not uniform. Indeed, showing directly the 
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each method, it is clear that the method, in general, getting closer to the real 
frequencies is ExPands (Figure 4.22). In fact, in most cases, ExPands makes little 
mistakes and rarely misses completely the result. SciClone instead, has the bigger 
median error but it is less prone to big mistakes. PyClone, finally, has a median 
distance lower than SciClone but it allows for the biggest distances from the 
correct frequency. 
Figure 4.22: Distances from the correct number of clones grouped by method used 
for clone identification. The distribution of the distances of the frequency from the real 
reveals that SciClone, the method having overall little distances, counter intuitively has 
the highest distance values in the majority of cases. Boxes define the 25th and the 75th 
percentiles; horizontal line within the boxes indicates the median and whiskers define the 
10th and the 90th percentiles.   
 
In 70 of the 90 datasets produced for testing of the methods, we introduced 
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errors in the VAFs proportions, emulating an altered purity of the sample of origin 
or a deviation from the effective VAF of the variants. We, therefore, decided to 
quantify the effect of these errors on the performances of the tools, measuring 
again the distances from real frequencies. Indeed, the responses of the different 
methods to data variability are diverse (Figure 4.23). Datasets without noise are 
not always the easiest to deconvolute: SciClone, for example, has the broadest 
boxplot for the case with purity 1 (and standard deviation 0). We noticed that the 
specific dataset used for the analysis has a great impact on the performances of 
the methods, because two separate samplings with equal characteristics (i.e. 
purity 1 and standard error 0) always give different results. PyClone is highly 
affected by changes in the standard deviation and we observed growing 
distances associated to bigger standard deviations. For SciClone, Expands and 
Clomial is even impossible to produce the boxplots for some groups, indicating 
that they never get close to the exact number of clones for that specific condition. 
The best performing tools are Expands and PyClone, the former is more robust to 
all sources of error, the latter slightly outperforms the others in ideal conditions: 
sd < 0.05 and purity > 60%. 
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Figure 4.23: The impact of external sources of variation on the capacity to discern 
clonal composition. For every method the boxplot shows the distances from the real 
frequencies computed under different sources of noise. Expands is the more robust to 
external variability; on the contrary, SciClone has a fluctuating behaviour and PyClone is 
influenced by the standard deviation. Boxes define the 25th and the 75th percentiles; 
horizontal line within the boxes indicates the median and whiskers define the 10th and 
the 90th percentiles.   
 
Despite the source of variability in the dataset, a major challenge in clonal 
decomposition is played by the inner characteristics of the clonal population. 
Grouping together the results analysed with the four methods for each model 
derived in the construction of the benchmark, it is evident that the error has a 
minor effect compared to the variability among solutions (Figure 4.24). Indeed, 
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
0
25
50
75
Clomial Expands PyClone SciClone
Method
dis
ta
nc
e
error
ploidy0.6
ploidy0.7
ploidy0.8
ploidy0.9
ploidy1
sd0
sd0.01
sd0.05
sd0.09
error
purity0.6
purity0.7
purity0.8
purity0.9
purity1
sd0
sd0.01
sd0.05
sd0.09
	  148	  
some models are easier to be decomposed, for example model 1 and 10 have 
smaller boxplots, indicating that they have little median distance of the 
frequencies from real. On the other hand, model 6 and 8 have broader boxplots 
for the distances, probably reflecting a complex clonal composition. 
Figure 4.24: Boxplots of the distance from exact frequencies for couples solution-
error source. Regardless of the method used for the determination of clonal 
composition, we studied the association between errors and models and observed that 
the model have a great impact in the solution of the problem. Boxes define the 25th and 
the 75th percentiles; horizontal line within the boxes indicates the median and whiskers 
define the 10th and the 90th percentiles.   
 
In particular, analysing the distances in function of the models and the methods 
used for calling the tumour subpopulations, it is clear that all the methods behave 
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similarly in simple cases (models with a low number of clones or populations with 
very different frequencies; Figure 4.25, Model1 and Model 3). However, their 
behaviour is very different for the difficult cases (models with a complex clonal 
composition and where different clones have similar frequencies in the tumour 
population) and, in many cases, the methods fail even in identifying the number 
of clones present in the population (Figure 4.25, Model6 and Model9). Expands 
looks more robust, though we know that for standard deviation equal to 0.9, it is 
unable to produce results. PyClone always returns a result but, in difficult cases, it 
is far from the real value. 
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Figure 4.25: Robustness of the methods considering different complexity of the 
models. A boxplot of distances is reported for every couple model tool. The boxplot is 
produced only when the tool was able to ascertain the correct number (plus or minus 
one) of clones forming the population. For simple models the responses of the 
algorithms are very similar; complex situations show very heterogeneous results. Boxes 
define the 25th and the 75th percentiles; horizontal line within the boxes indicates the 
median and whiskers define the 10th and the 90th percentiles.   
 
 
The last property to assess with our analysis was the ability of the different tools 
to correctly group mutations, or, in other words, the ability of a tool to assign to 
the same clone the variants belonging to the same cell in the tumour population. 
In order to evaluate this ability, we used an “arm in arm” score build, multiplying 
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higher the “arm in arm” score is, the better the algorithms perform, because we 
consider the most populated intersections as correctly identified clones (i.e. 
regardless of the frequency assigned by the methods to each clone, we evaluate 
whether the methods are able to group in the same clone mutations that 
originally were together). Since it is more difficult to get a high intersection when 
the number of clones is high, we multiplied the value for the real number of 
clones. Surprisingly, Expands gives the worst results. Even if the number of clones 
and the frequency of clones identified by Expands are correct, the mutations are 
wrongly grouped (Figure 4.26). PyClone is slightly better than SciClone, but, 
concerning this aspect, the performances of the two methods are comparable. 
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Figure 4.26: “Arm in arm” score for the four methods. The boxplots reports the “arm 
in arm” score distribution for all the cases in which the method correctly identifies the 
number of clones. Boxes define the 25th and the 75th percentiles; horizontal line within 
the boxes indicates the median and whiskers define the 10th and the 90th percentiles.   
 
To summarize, a good method for clonal decomposition in a tumour population 
should be able to: i) determine the right number of clones, ii) determine the right 
frequency of the clones and iii) correctly group together the mutations belonging 
to each clone. From our analysis, performed using our benchmark dataset, 
PyClone emerged as the best compromise for our need. 
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underlined by the fact that the DREAM challenge organizers decided to dedicate 
a specific challenge to the Tumour heterogeneity and Evolution. The challenge 
results have not been published yet, however, the organizers made publically 
available a small training dataset, of which we took advantage to test the different 
methods. The dataset is composed by two tumours for which they provide: the 
files with the list of mutations (SNVs) and CNVs, information on the real purity of 
the sample, the number and frequency of the real clones and the list of mutations 
belonging to each clone. On this specific dataset we were able to test only 
Expands and SciClone because PyClone needs more than one sample for the 
same patient to work and Clomial does not give an output. Nor Expands neither 
SciClone predicts the correct number of clones.  The distances from the correct 
number of clones are 3 and 6 for SciClone and 5 and 6 for Expands (Table 4.7). 
Table 4.7: Number of clones identified using the DREAM challenge datasets. 
Number of clones identified by Expands or SciClone, compared to the numbers provided 
by the DREAM challenge (Real). 
 
Dataset Real Expands SciClone 
Tumour 1 5 11 2 
Tumour 2 2 7 8 
 
For every mutation we disposed of the cluster of membership and its frequency 
within the cluster, therefore, we were able to plot the correspondence between 
predicted and real clusters. We plotted the numbers of mutations as squares, 
where height and width of the squares are proportional to the number of 
mutations with those characteristics in the predicted and the real clones, 
respectively. Expands gives in output the frequency associated to the predicted 
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clones, while, for SciClone, we were able to identify a discrimination criterion. 
Therefore, we were able to determine which mutations were assigned to the right 
clusters (green squares in Figure 4.27). In many cases the real clusters were split 
or grouped in the prediction: for example, on the dataset tumour 1, Expands 
splits a single real clone at 0.7 frequency in 4 clones with frequency ranging from 
0.8 to 1 (we consider these results correct because the purity of the sample in 
tumour 1 was 0.7); on the other hand, SciClone groups together at frequency 
higher than 0.15 three clones with real frequencies ranging from 0.452 to 0.7. 
Even worst, excluding the correct predictions, we noticed that mutation 
belonging to one clone could be distributed among all the clones in the 
predictions (yellow squares in Figure 4.27). Since the proportion of yellow squares 
(i.e. wrong predictions) in the graph is considerably larger than the proportion of 
green squares (i.e. correct predictions), we conclude that the performances of 
SciClone and Expands on this dataset are not satisfactory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   155	  
Figure 4.27: Clone prediction on the DREAM challenge datasets. For each tumour 
dataset (TUMOUR 1 and TUMOUR 2) and for each method (Expands and SciClone), we 
compared the predictions for every mutation with the real clone. The square sides are 
proportional to the number of mutations belonging to each specific group. Green 
squares are mutations correctly classified; yellow squares are associated to wrong 
classifications.  
 
Reporting the results obtained on the same datasets by the teams that 
participated to the DREAM challenge we observed that the tested methods, 
compared to the group of publicly available ones we reported, perform better in 
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population (Table 4.8). On the other hand, the performances in the task of 
mutation assignment to subclones remain poor with the only exception of the 
team GuanLab_SMCHet on TUMOUR2.  
Table 4.8: Performances of the teams that participated to the DREAM challenge on 
Tumour1 and Tumour2. We reported the preliminary results obtained by the teams in 
their pre-submission round on the dataset previously described. For the three sub-
challenges reported (predicting number of clones, predicting subclone proportions and 
determining mutation assignment to subclones) a score of 1 is associated to perfect 
performances and measures respectively the difference between true and inferred 
number of clones, the mean absolute difference obtained comparing true and predicted 
cellular prevalence and the correlation between the true and predicted matrices 
clustering together the mutations belonging to the same clone. 
TUMOUR1 
Predicting Number of 
Subclones 
Predicting Subclone 
Proportions 
Determining Mutation 
Assignments to 
Subclones 
GuanLab_SMCHet 0.67 0.96 0.47 
Team Markowetz 0.67 0.91 0.19 
The overtaker 0.83 0.85 0.07 
SMC-Testers 0.33 0.69 0.05 
hacktumour 0.5 0.64 0.05 
GISL NA NA NA 
TUMOUR2 
Predicting Number of 
Subclones 
Predicting Subclone 
Proportions 
Determining Mutation 
Assignments to 
Subclones 
GuanLab_SMCHet 1 0.98 0.87 
Team Markowetz 0.67 0.93 0.61 
The overtaker 0 NA -0.49 
SMC-Testers 0.67 0.39 0.26 
hacktumour 0.67 0.39 0.26 
GISL 1 0.62 -0.06 
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4.2 Biological results 
The refinement of the methods described in the first part of our thesis had the 
main scope to have at our disposal the cutting edge bioinformatics tools that best 
adapted to the specific needs of our study. Our aim was, indeed, to analyse in 
depth, from the exomic point of view, a cohort of 30 patients affected by AML, in 
three phases of evolution of the disease: primary tumour, remission and relapse. 
We concentrated our efforts, in particular, on delineating the commonalities and 
the differences among our groups of samples, concerning single nucleotide, copy 
number variants and small insertion/deletions (indels).  
 
4.2.1 Patient’s characteristics 
The general characteristics of the patients of our cohort are reported in Table 4.9 
and schematized in Figure 4.28. Our cohort was balanced for gender: males and 
females were respectively 17 (57%) and 13 (43%). Half (15/30) of the patients 
presented a normal karyotype; all the others presented either complex karyotype 
(7/30, 23%) or specific chromosomal rearrangements (excluding one patient for 
which the karyotype information was not available). The majority of patients were 
diagnosed at ages between 50 and 70 years old (67%), however the range was 
between 18 to 73 years of age. 
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Table 4.9: General characteristics of the patients collected for our study. For every 
patient in our cohort we report gender, age at diagnosis and karyotype. 
PATIENT GENDER AGE KARYOTYPE 
BO1 M 32 NK 
BO2 M 42 (+8);t(2;10)(q33;p13) 
BO3 F 34 NK 
BO5 F 55 complex 
BO6 F 62 complex 
BO7 M 57 NK 
BO8 F 70 complex 
BO9 M 53 complex 
BO17 F 64 complex 
TO1 F 67 NK 
TO2 F 73 NK 
TO3 M 58 NK 
TO4 M 67 46, XY, +11 
TO6 M 70 t(8;21) 
TO7 M 70 NK 
TO8 F 61 NK 
UD1 M 33 (-6,-11) 
UD2 M 39 complex 
UD3 M 55 NK 
UD4 F 59 complex  
UD5 M 67 NK 
UD6 F 18 t(8;21) 
UD8 M 28 NK 
UD9 F 32 NK 
UD10 F 22 INV16 
UD11 M 62 NK 
UD12 M 57 t(10;11) 
UD13 F 54 NA 
UD14 M 67 NK 
UD15 M 68 NK 
 
 
 
 
 
 
 
 
	   159	  
Figure 4.28: Characteristics of our patient’s cohort. Distribution of our patients for 
gender (left pie chart), karyotype (right pie chart) and age at diagnosis (histogram).  
 
Concerning the clinical information, the risk stratification and the follow up of our 
patients, the data are reported in Table 4.10. The diagnosis was performed 
cytogenetically in 4 cases, molecularly in 11 and with both techniques in 4 
patients; only in one case it was done ematologically and for 10 cases we did not 
have this information. The majority of our AMLs belong to the FAB classification 
M1 (7/30, 23%); 3 AMLs were M0-M1, 5 were M5 and 4 M4; the remaining were 
M0 (3), M2 (2) and secondary (WHO classification, 2) (for 4 patients the FAB 
subtype was not available). We received the information about risk stratification 
for 25 patients: 13/25 (52%) had a high risk of relapsing, 3 (12%) intermediate risk 
and 9 (36%) standard risk. The treatments were heterogeneous, the doses and 
number of cycles varied a lot among patients, but the drugs used, in the vast 
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majority of the cases, were Fludarabine, Cytarabine, Idarubicin and Etoposide. 
Moreover, the post-induction strategies were adapted to patient’s response and 
characteristics. Finally, concerning the follow-up, we know that only 10 (33%) 
patients achieved second complete remission, while, unfortunately, the rest died 
of this pathology or complication related to transplants. 
Table 4.10: Clinical information of our cohort of patients.  For every patient, we report 
the FAB subtype detected at the first exordium of the tumour, the risk category (S: 
standard risk, I: intermediate risk, H: high risk), the type of diagnosis, the induction 
therapy, the consolidation therapy and, finally, the follow-up (CR, complete remission; D, 
deceased). The abbreviations used for treatments are the following: 
FLAI=Fludarabine+Cytarabine+attenuated-doses of Idarubicin; IDA=Idarubicin, 
ARAC=Cytarabine; 3+7=standard treatment; AZA=Azacytidine; E=Etoposide; 
DAUNO=Daunorubicin; HD=high doses; LD=low doses. NA, not available. 
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For the majority of the patients, the clinicians assessed the genetic status of FLT3 
and NPM1, the two main genetic variants and more commonly mutated genes in 
AML.  As discussed in the Introduction (paragraph 1.3.1) these two types of 
mutations are important markers for disease predictions. Therefore, the 
mutational status of FLT3 and NPM1 was used by the clinicians, not only to 
characterize the samples at diagnosis, but also after treatment, to assess the 
molecular remission of the disease. In our cohort, this information is available for 
all patients except for NPM1 in 1 patient at diagnosis, and only for a few patients 
in the remission and relapse phases of the disease (Table 4.11).  In the primary 
tumours 2 patients had a mutation in FLT3  (one of them had an elevated risk), 7 
had a mutation in NPM1 (4 had a standard risk and 3 high risk), other 2 presented 
both mutations together and they were classified as high risk. 
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Table 4.11: The mutational status of FLT3 and NPM1 in the three phases of the 
disease of our cohort of patients. The mutational status is reported as wild type (WT) if 
the mutation has been tested but was not detected; mutated (MUT, red cells) if it is 
present; if the test was not performed we reported the not availability symbol (NA, grey 
cells). 
 
PRIMARY REMISSION RELAPSE 
PATIENT FLT3 NPM1 FLT3 NPM1 FLT3 NPM1 
BO1 WT WT NA NA NA NA 
BO2 WT WT NA NA NA NA 
BO3 MUT MUT NA NA NA NA 
BO5 WT WT NA NA NA NA 
BO6 WT WT NA NA NA NA 
BO7 WT WT NA NA NA NA 
BO8 WT WT NA NA NA NA 
BO9 WT WT NA NA NA NA 
BO17 WT WT NA NA NA NA 
TO1 WT WT NA NA NA NA 
TO2 WT MUT NA WT NA MUT 
TO3 WT WT WT WT WT WT 
TO4 MUT WT WT WT NA NA 
TO6 WT WT NA NA NA NA 
TO7 MUT WT NA NA NA NA 
TO8 WT NA WT NA NA NA 
UD1 WT WT NA NA WT WT 
UD2 WT WT NA NA WT WT 
UD3 WT MUT NA WT MUT MUT 
UD4 WT WT WT WT NA NA 
UD5 WT MUT NA WT NA NA 
UD6 WT WT NA NA NA NA 
UD8 WT MUT WT WT WT MUT 
UD9 WT WT NA NA WT WT 
UD10 WT WT WT WT WT WT 
UD11 MUT MUT WT WT NA NA 
UD12 WT MUT WT WT WT NA 
UD13 WT WT WT WT WT WT 
UD14 WT MUT NA WT WT MUT 
UD15 WT MUT NA WT NA MUT 
 
Of the 10 patients analysed for FLT3 ITD both in the primary and in the relapse 
samples, 9 maintained their wild type status in the relapse and one gained the 
ITD in the relapse sample. The mutational status of NPM1 in the relapse, instead, 
is always identical to the mutational status detected in the primary tumours: 5 
cases remains mutated and 6 remains WT. Furthermore, the co-occurrence and 
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mutual exclusivity between the two mutations looks very similar both in the 
primary and the relapse samples, though the numerosity of the patients between 
the two groups is very different (Figure 4.29). 
Figure 4.29: The combinations of FLT3 and NPM1 mutations in the primary and 
relapse tumours is very similar. The number of patients in each group is very different 
because mutations are tested more rarely in the relapse samples than in the primary 
tumours. Despite the different numerosity, the landscape of combinations of the 
mutations looks very similar in the two groups. 
 
 
4.2.2 We subtracted the donor variants from the relapse samples 
obtained after allogeneic bone marrow transplant 
We noticed that four samples (UD1, UD4, UD11 and UD12) presented an 
aberrantly high number of mutations (median number of raw mutations per 
patient 15’635.5), considering all the mutations found in the primary and relapse 
samples of our cohort (30 patients, median of raw mutations per patient in the 
remaining 26 was 249). Moreover, we noticed a great disproportion in the 
number of SNPs compared to novel mutations (as shown in Figure 4.30) for these 
patients: they presented a rate of SNPs over 80%. We tested by Illumina MiSeq 
985 SNPs in the highly mutated samples and we validated 943 of them (96%). 
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Only 4 SNPs were present also in the primary sample of the same patients at 
frequencies between 1 and 38%. The validation of these mutations revealed that 
we were not witnessing a sequencing artefact.  
Figure 4.30: Proportion of variants overlapping with dbSNP. For every patient we 
divided the number of variants present in the dbSNP database for the total number of 
variants identified (in primary and relapse samples). 4 patients had almost 100% of the 
variants overlapping with SNPs (red bars).  
 
 
Very often AML patients undergo allogeneic bone marrow transplantation and, of 
course, this causes a contamination of the relapse leukaemias by cells coming 
from the donor that repopulated the bone marrow. In the four hypermutated 
samples, allogeneic transplantation preceded bone marrow collection at relapse, 
thus resulting in the presence of donor cells in the relapse. Since the DNA of the 
4 donors was available, instead of discarding these 4 contaminated samples from 
our dataset, we decided to proceed experimentally by sequencing also the donor 
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DNA and subtracting the SNPs identified for each donor from the corresponding 
contaminated relapse sample. After this subtraction, the number of mutations for 
the four samples dramatically decreased together with the fraction of SNPs in the 
samples. We identified a total of 47 mutations (28% already registered as SNPs) 
for UD1, 8 mutations (12% SNPs) for UD4, 19 mutations (68% SNPs) for UD11 and 
33 mutations (15% SNPs) for UD12. These are numbers of mutations and also 
SNP rates comparable to the ones observed in all other patients of our cohort 
(median of refined mutations per patient 39.5). 
 
4.2.3 The majority of SNVs and Indels are private for primary or 
relapse tumours. Common mutations affect mostly “landscaping” 
genes 
We started analysing the landscape of SNVs and small indels for the primary 
tumour and relapse samples of each patient, using MuTect and Pindel to identify 
these variants, respectively. In order to contextualize our results in the AML 
mutational landscape described in the Introduction section we characterized the 
variants identified for their known role in the development of the disease and 
their biological function. 
 
4.2.3.1 The number of primary and relapse specific mutations are similar, but 
the type of mutations are not the same 
The analysis of exomic variants and small insertions/deletions of the primary and 
	   167	  
the relapse tumour pairs show significantly different results in many patients, 
although the median number of variants (SNVs + Indels) per patient is very 
similar: 29 for the primary tumour (range: 9-69, average: 30.1) and 32 for the 
relapse (range: 8-98, average: 32.5). Indeed, the p-value of the t-test used to 
measure the equality of the means of the number of mutations in the two groups 
is not significant, suggesting that the two populations behave very similarly in 
terms of number of mutations or, alternatively, the two groups may be too small 
to exhibit their divergence (Figure 4.31). Nonetheless, 40% of the patients (12/30) 
show significant differences in the number of mutations detected in the primary vs 
the relapse samples. Such differences not always tend in the same direction: 5 
cases show significantly higher number of mutations in the primary tumour and 7 
in the relapse (Fig 4.31).  
Figure 4.31: The number of mutations detected per patient in 30 AML samples. a. 
For every patient is reported the number of SNVs and indels identified in the primary 
tumour (blue bar) and in the relapse (red bar). The stars indicate the p-values (see the 
legend) obtained testing the difference in the proportion of mutations in the primary and 
relapse with a statistical test on the proportions. b. The boxplot shows the distribution of 
the number of mutations in the two groups of samples. Boxes define the 25th and the 
75th percentiles; horizontal line within the boxes indicates the median and whiskers 
define the 10th and the 90th percentiles.   
 
Having a similar number of mutations does not necessarily imply that the 
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mutations are the same in the primary and relapse tumours. As a matter of fact, 
on average, only 54% of both the primary mutations (range 3-84%) and the 
relapse mutations (range 9-100%) are in common between the two groups and 
the remaining 46% are specific for one of the two samples (Figure 4.32). These 
results indicate that about half of the mutations disappear after chemotherapy 
and many others are generated. In particular, primary specific mutations were 
effectively killed by the treatment; at the same time we always observe in the 
relapse the withdrawal of a group of mutations present in the primary tumour, 
fostering the hypothesis that chemotherapy might overwhelm at least a part of 
the tumour population. Emblematic cases are: UD11 with no new mutations in the 
relapse; TO1 and UD6 with very few mutations (respectively 4 and 16%) in 
common between primary and relapse (Figure 4.32).  
Figure 4.32: Proportion of mutations unique or in common between primary and 
relapse samples. A stacked bar plot is reported for every patient with the proportion of 
mutations unique for one of the two samples (blue and red for primary and relapse 
tumours, respectively) or in common (green). The patients are ordered by decreasing 
number of common mutation in order to group patients with similar characteristics. 
 
As described in the Introduction (section 1.8), the reciprocal proportion of 
transitions and transversions can be associated to the mechanism that induced 
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such mutation types (Ding et al.133). Therefore, we inspected their numbers in our 
AML samples and, through a statistical test on equality of proportions; we tried to 
identify whether any particular type or more types of mutations were more 
frequent among the primary and the relapse samples. We found significantly 
more transitions in the primary tumours (in particular the A>G and C>T type of 
mutation) and more transversions in the relapse (T>A), confirming previous 
observations (Figure 4.33). While transitions are more common and they naturally 
occur in the genome, transversions have been associated to chemotherapeutic 
agents or other mutagens. Therefore, an augmented proportion of transversions 
in the relapse samples suggests that some chemotherapy-induced mutations 
have been fixed in the relapsing cells. 
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Figure 4.33: Mutations found in the primary tumours (top) and relapse tumours 
(bottom) gathered by base change. Colours in the red range are associated to 
transversions, colours in the green range are associated to transitions. If the results show 
significant differences between primary and relapse samples a star with the p-value is 
reported. 
 
4.2.3.2 Mutations in AML driver genes often persist after chemotherapy 
To understand the role of known AML driver mutations (as defined in Materials 
and Method, section 3.8), we investigated their presence in the primary and 
relapse samples and correspondent VAFs. We were able to divide the AML driver 
genes mutated in our cohort in 7 classes on the basis of their evolution in the 
samples (Figure 4.34): 
1. Genes that always persist: they are found always both in the primary and 
the relapse samples. These drivers probably resist to chemotherapy and 
lead to relapse expansion. DNMT3A, IDH2 and EZH2 are “landscaping”61 
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genes that belong to this class; their VAFs are similar or decreasing in the 
relapse samples, however, the difference in sample cellularity can be the 
reason for such a reduction; 
2. Genes that are found only in the primary tumour: these genes are always 
killed by chemotherapy, thus their presence could make the cells prone to 
respond to the treatment. This category includes 4 genes implicated in 
transcriptional regulation: PHF6 harbouring a zinc-finger domain, CTCF 
that binds chromatin, ASXL2 that is a putative polycomb protein and 
RBMX, which binds RNA regulating the processes that take place before 
and after transcription; 
3. Genes that are found only in the relapse: since we are looking at a group 
of AML driver genes, it is probable that they have been found in the 
primary tumour of other patients. Nevertheless, it is possible that they arise 
preferentially in a context of tumour predisposition or as a consequence of 
other mutations: certainly we are looking at single mutations but the 
mutational landscape underling the appearance of new mutations can 
already be pre-leukemic. Genes belonging to this group promote RNA 
polyadenilation (CSTF2T), splicing (U2AF2) and chromatin remodelling 
(ZBTB33); 
4. Genes that are never in common: despite these genes are sensitive to the 
therapy, probably they are important for tumour development and their 
presence is needed for a frank leukaemia. In this class, we found well 
known oncogenes as CBL, KIT, KRAS and PTPN11 that act in the signalling 
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pathway that promotes a proliferative advantage and that, at the same 
time, are fundamental for the oncogenic phenotype and make the cells 
more susceptible to the treatment; 
5. Genes that never appear newly in the relapse (see Figure 4.34): these 
genes are always common or primary only; the reasons for the absence of 
new mutations in the relapse samples for these genes are ambiguous and 
it is possible that on a larger cohort we could have observed also their 
emergence in the relapse samples. The relevant point is the fact that they 
are recurrently common (the numbers are higher than the previous groups) 
thus suggesting a possible cooperating role in relapsing tumours. This is a 
functionally miscellaneous class ranging from transcriptional (GATA2) and 
cell proliferation activating genes (NPM1), to genes that belong to the 
spliceosome (SF3B1) and the cohesin complex (SMC3); 
6. Genes that persist or appear in the relapse: these genes are always 
common or relapse specific and have characteristics more adherent to the 
“resistant” phenotype because when they are present in the primary 
tumour, at least in our cohort, they resist to therapy; at the same time they 
can also appear newly in the relapse. Furthermore, the VAFs associated to 
this class grow in the relapse sample describing an expansion of the 
relative clone. Interestingly CEBPA, which is generally associated to a 
favourable outcome, falls in this category, together with TET2 and TP53 
both described in the introduction for their known oncogenic role. 
7. Genes found in all categories: probably because they are mutated in many 
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patients, we could observe all the possible combinations. These are all well 
known leukaemia-associated genes and it is possible that their cooperation 
with other genes of the same or other classes contribute to therapy 
resistance.  
Figure 4.34: AML driver genes often persist after chemotherapy. a. For every AML 
driver gene mutated in our samples we report how many times it is uniquely mutated in 
the primary, in the relapse tumour or in common. We then divided the genes on the 
basis of their behaviour in this analysis. b. For every AML driver gene, the boxplot shows 
the VAFs identified in the primary (blue) and relapse tumours (red). Boxes define the 25th 
and the 75th percentiles; horizontal line within the boxes indicates the median and 
whiskers define the 10th and the 90th percentiles.   
 
 
4.2.3.3 DNA methylation and Cohesin complex mutations persist in the 
relapse, spliceosome mutations disappear after chemotherapy 
We then divided the mutated genes into functional categories according to the 
paper of the TCGA44. We observed three general trends (Figure 4.35): 
• Categories of mutated genes that persist in the relapse: it has been, 
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previously, hypothesized that “landscaping”61 mutations would escape 
chemotherapy. In fact, we identified the functional class of genes involved 
in DNA methylation common to the majority of cases. Also mutations that 
never occur in the relapse belong to this class, they can be ascribed to a 
very small cohort and they are frequently common between primary and 
relapse, suggesting that this classes of genes are able to survive the 
treatment (NPM1, cohesin complex); 
• Categories that are mostly not persistent: variants affecting the 
spliceosome machinery seem to be more susceptible to chemotherapy, 
however, they often appear in the relapse tumour with novel mutations; 
• Categories with no prevalent behaviour: in this class fall Tumour 
suppressors, Myeloid transcription factors, chromatin modifiers and 
Activated signalling genes; their heterogeneous presence in cells 
respondent or not to therapy together with their concomitant new 
emergence in relapse cells suggests that they either were already present 
in a minor fraction of cells at diagnosis that expanded after treatment or 
that they need the co-occurrence of other mutations to impart a 
phenotype. 
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Figure 4.35: DNA methylation and Cohesin complex mutations persist in the 
relapse, spliceosome mutations disappear after chemotherapy. For every functional 
category described by the TCGA, the graph reports the number of mutated genes 
identified uniquely in the primary (blue) or in the relapse tumours (red) or in common in 
the two groups (green).  
 
4.2.4 Common CNVs are very rare and poorly defined from a 
functional point of view 
Copy number variants were analysed in our cohort of patients using the Control-
FREEC tool on the WES data. We were able to perform this analysis only on 24 
patients, because the remaining 6 were sequenced after exome enrichment with 
two different kits for primary and relapse tumours. This resulted in an aberrantly 
high proportion of CNVs, very likely due to different coverage of the exonic 
regions of the genome by the two kits.  
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4.2.4.1 The CNVs are very variable among patients and samples and they are 
seldom retained 
We identified a median number of CNVs per patient of 81.5 (mean: 160.5) for the 
primary tumours and 122.5 (mean: 520.2) for the relapses, with ranges from 17 to 
723 and from 28 to 4944, respectively (Figure 4.36). In particular, two patients 
(BO2 and UD2) behave as outliers concerning the number of the CNVs in the 
relapse, which presents more than four thousands of variants each. These AMLs 
display a number of CNVs above average also in the primary tumour, suggesting 
that a complex genomic status in the primary tumour could degenerate in a 
catastrophic genomic event under the pressure of chemotherapy. In general, our 
patients revealed a great variability in terms of number of CNVs. All patients, with 
the exception of 5 patients (TO2, UD11, UD4, UD5 and UD9), have significant 
different number of CNVs when tested for the difference of proportions between 
variants identified in the primary tumour vs the relapse (Figure 4.36). Because of 
the great variability observed between primary and relapse tumours, we can 
detect a significant preponderance of CNVs accumulation in the relapse tumours 
compared to primary tumour within our cohort (p-value 1.678 X 10-9). 
Furthermore, no correlation has been identified between the number of 
nucleotide variants and copy number variants neither sample wise (ρ=0.013), nor 
patient wise (ρ=-0.14) (data not shown). 
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Figure 4.36: The variability in copy number abundance among patients is high. a. For 
every patient, we show the number of CNVs identified by Control-FREEC both in the 
primary (blue bars) and in the relapse tumour (red bars). b. We reported the boxplots of 
the number of CONVs identified per patient in the primary and relapse samples. The p-
value for the Wilcoxon-test comparing the means in the two populations is reported 
(Shapiro test was used to assess the normality within groups, resulting in a significant 
difference from the normal distribution both for the primary and relapse samples). Boxes 
define the 25th and the 75th percentiles; horizontal line within the boxes indicates the 
median and whiskers define the 10th and the 90th percentiles.   
 
We, next, categorized the aberrations of CNVs in losses and gains based on the 
number of copies present in the tumour compared to the control: losses if the 
tumour has fewer copies than the control; gains if the tumour has more copies 
than the control. In general, we observe slightly more gains than losses (188 gains 
vs 163 losses per patient, on average) (Figure 4.37). However, there is no 
statistical difference between the means of CN gains and losses between the 
primary and the relapse tumours considering all patients (p-values 0.35 and 0.36, 
respectively, with confidence intervals for the difference of the means of [-
543,198] and [-619,232]) and there is no statistical difference in the numbers of 
gains and losses between primary and relapse samples of each patient (Figure 
4.37). Finally, the CNVs detected in the two samples with an impressively high 
number of variants may be false positives. Indeed, all these CNVs are scored 
almost exclusively as gains for BO2 and as losses for UD2 (Figure 4.37). This may 
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be imputed to a misinterpretation of the data by the algorithm likely due to 
enrichment bias. 
Figure 4.37: In our cohort of patient there is no preponderance of CN losses or 
gains. We segregate CNVs in gains (GAIN) and losses (LOSS). The bars represent the 
number of CNVs detected in the primary (blue) and in the relapse tumours (red). 
 
In parallel with the analysis performed for the nucleotide variants, we wanted to 
understand how many of the variants scored in the primary tumours are 
maintained in the remission samples of the same patient. The proportion of CNVs 
retained after chemotherapy is quite variable but, in general, very low: in respect 
to the primary tumour on average 27% (ranging from 2 to 83%), the 42% of the 
primary tumours (10/24) has less than 20% of common mutations; in respect to 
the relapse they are on average 22% (ranging from 0.4 to 90%; Figure 4.38).  
Indeed, the vast majority (median 85%) of CNVs detected in the relapse are new 
(Figure 4.38). 
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Figure 4.38: A quite small proportion of CNVs detected in the primary tumour is 
retained in the relapse. For every patient, we report the number of CNVs identified 
uniquely in the primary (blue) or the relapse (red) or in common to both (green). 
 
 
4.2.4.2 The majority of driver genes involved in CNVs are not recurrent 
We then asked how many and which AML driver genes are affected by CNV gains 
or losses. From this point on, we decided to eliminate from our analysis the two 
patients (BO2 and UD2) that probably presented many false positives, in order to 
eliminate possible bias introduced in the analysis by the high number of gains 
and losses identified in either one of them. We detected 61 driver genes affected 
by CNVs, the majority of them (61%) were hit by only one CN gain or loss in our 
cohort. Only two genes were hit at least 3 times in our cohort: PTPRT, a signalling 
protein involved in cell growth and differentiation, with 3 gains and one loss, and 
EZH2, a transcriptional repressor, with 3 losses (Figure 4.39 and Figure 4.40); in 
both cases the CNV was found both in common and specifically in the primary or 
the relapse tumour of different patients. We performed our analysis on CNVs, 
BO
2
U
D
4
TO
4
U
D
1
U
D
2
TO
8
U
D
10
U
D
12
U
D
8
U
D
3
TO
2
TO
1
U
D
13
TO
3
TO
7
U
D
6
U
D
14
U
D
5
TO
6
U
D
15
BO
3
U
D
9
U
D
11
BO
1
N
um
be
r o
f C
N
Vs
 id
en
tif
ie
d
0
200
400
600
800
1000
primary
common
relapse
4245 5033 
	  180	  
considering separately gains and losses.  
As shown previously for SNVs, we divided the results in 7 groups based on the 
behaviour of the gains affecting the AML drivers in the different tumour phases 
(Figure 4.39). Genes belonging to a specific group, in this case, appear to have 
more mixed functions as compared to the results shown before for SNVs. Many of 
the genes mutated by CNVs that belong to Group1 and, therefore, maintained in 
common among primary and relapse tumours, are serine/threonine kinases 
(STK33, WEE1), GTPases (ADRBK1, TRIO) and oncogenes (CBL, MYB). Group5 
genes, in common or primary-specific, are mostly related to regulation of 
transcription (ARID1B, ETV3, PRPF3) and calcium binding (CACNA1E, TCHHL1). 
Figure 4.39: AML driver genes hit by CN gains in our cohort of patients. We report 
the number of times (CNV GAIN count per gene) each AML driver gene was hit by a CNV 
gain. The AML drivers were divided into groups as described for SNVs in Figure 3.32. 
The bars show the number of gains identified in each gene uniquely in the primary (blue), 
in the relapse tumours (red) or in common between the two groups (green). 
 
The same type of analysis on CV losses reveals that CNVs retained after 
chemotherapy (Group1 and Group7) include a tumour suppressors (WT1), 
landscaping mutations (HDAC2, EED interacting with EZH2), kinases (MAPK1) and 
phosphatases (PTPRT). Genes belonging to Group2 and Group4, never in 
common between primary and relapse samples of the same patient or primary 
specific, include many factors that regulate transcription (ASXL3, ETV6, IKZF1, 
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RUNX1) and signalling genes (DOCK9, FLT3 and PLXNA4) (Figure 4.40). 
Figure 4.40: AML driver genes hit by CN losses in our cohort of patients. In the plot 
is reported the number of times each AML driver gene falls in a region of CNV loss. The 
AML drivers were divided into groups as described for SNVs in Figure 3.32. The bars 
show the number of losses identified in each gene uniquely in the primary (blue), in the 
relapse tumours (red) or in common between the two groups (green). 
 
4.2.4.3 CNVs hitting AML drivers belonging to Activated signalling and 
chromatin modifiers functional classes are retained in the relapse 
Considering the classification of the AML drivers hit by CNVs into functional 
categories, as described above (paragraph 1.3.2.2) and in 44, it is worth noticing 
that tumour suppressors, myeloid transcription factors and spliceosome pathways 
appear rarely in common between primary and relapse, corroborating our 
previous evidences on mutated AML drivers, showing that transcription factors 
are often found uniquely associated to one of the two samples (Figure 4.41). 
CNVs in chromatin modifiers and factors activating signalling pathways can persist 
after chemotherapy, though the persistent CNVs are not preponderant among all. 
CNVs in NPM1 and cohesin complex components always appear in the relapse 
(Figure 4.41). 
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Figure 4.41: CNVs hitting AML drivers belonging to activated signalling and 
chromatin modifiers functional classes are retained in the relapse. For every 
functional category described by the TCGA, the graph reports the number of genes hit 
by CNVs identified uniquely in the primary (blue), in the relapse tumours (red) or in 
common between the two groups (green).  
 
 
4.2.5 Clonal analysis of the tumour populations in our patients’ 
cohort 
We performed clonal analysis for all 30 patients in our cohort using PyClone. In 
order to reconstruct the clonal composition of the tumour population, the Pyclone 
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algorithm requires as input the following parameters derived by WES analysis: i) 
the variants (SNVs + Indels) identified during the mutation calling phase; ii) the 
relative frequencies (VAFs) of each variant; iii) the number of copies (CNs), which 
has been set to 2 for all the regions without CNVs. From the analysis of each 
patient, PyClone generates a figure similar to the one shown in Figure 4.42 panel 
a, together with the specification of frequency of the clones and the list of the 
mutations belonging to each clone. As example of the output of the analysis, we 
show the results obtained for one of our patient, UD12 (Figure 4.42). For each 
patient, PyClone produces always two plots: the first is related to the primary 
tumour clones and the second to the relapse clones. Each clone in the plot is 
visualized as a “violin”, which, for each clone, depicts the probability of having a 
given cellular frequency in the tumour population. When the number of mutations 
within a clone is sufficiently high, the violin is small, indicating that the margin of 
error for the estimate of the frequency is low (clone 1, clone 5 and clone 6 in 
Figure 4.42.a). In some cases, the clones are represented by only one mutation; 
for those clones the difficulty to estimate the real cellular frequency is depicted by 
a large “violin” (clone 2 in Figure 4.42.a). However, if the frequency of the single 
mutation is quite high and, therefore, the probability of assigning a wrong 
frequency in the tumour population is low, again the violin is small (clone 4 at 
relapse in Figure 4.42.a).  For every cluster (i.e. clone) identified, we plotted the 
VAFs of all the mutations assigned to each particular cluster (Figure 4.42.b). First, 
we eliminated all the clones with a frequency lower than 10% in both samples 
because the determination of clonal origin at low frequencies is ambiguous and it 
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is probable that these clones contain new mutations belonging to any clone in 
the population; then, we classified the clones based on the different frequencies 
they displayed in the primary tumour vs the relapse tumour. Based on their VAFs 
in the two tumour populations, the clones were named as follows: 
• Primary only: if the frequency of the clone in the relapse was lower than 
2%; 
• Relapse only: if the frequency of the clone in the primary tumour was lower 
than 2%; 
• No change: if the frequency of the clone differed of less than 5 percent 
points in the two tumour phases; 
• Decreasing in relapse: if the difference in frequency was higher than 5 
percent points and the clone was more frequent in the primary tumour 
than in the relapse; 
• Growing in relapse: if the difference in frequency was higher than 5 
percent points and the clone was more frequent in the relapse than in the 
primary tumour. 
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Figure 4.42: PyClone analysis of patient UD12. a. Typical output plot made by 
PyClone. We highlighted in red an example of clone “not changing” and in blue an 
example of “relapse only” clone that was, however, eliminated from further analysis 
because its frequency was lower than 10% in both tumour phases. b. Plot of the 
frequencies of the mutations occurring in each listed gene in the primary (blue triangles) 
and the relapse (red dots) tumours grouped by their clonal membership.  
 
 
4.2.5.1 The majority of the patients show resistance to chemotherapy  
We investigated the clonal composition of all tumours for all patients except UD2, 
for which PyClone was unable to produce an output. Based on the clonal analysis 
performed as described for UD12, for every patient, we assigned each mutated 
gene to one of the classes of clonal membership listed above and we plotted the 
results in Figure 4.43.  We were able to identify 4 possible schemes of tumour 
evolution after chemotherapy (note that the numbers reported above the boxes 
in Figure 4.43 refer to the following schemes): 
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   Clone 1 “no change” (from 46 to 45% of frequency) 
	   	   Clone 6 is relapse specific (from ~0 to 5% of frequency) We will not consider it because its 
frequency is below 10% 
a. 
b. 
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1. CLONAL SELECTION (16, 55% of the patients): belonging to this class are 
tumours characterized by the presence of a quite high fraction of “no 
change”, “decreasing in relapse”, “growing in relapse” and “relapse-only” 
clones, accompanied by a small fraction of “primary only” clones. This 
clonal composition suggests us the possibility that the therapy affected 
some clones (those vanishing or diminishing), successively favouring the 
expansion of more fitted resistant clones that generated the relapse 
tumour; 
2. RESISTANCE (6, 21% of the patients): clones in primary and relapse 
tumours have similar frequencies (the tumours are mainly composed of “no 
change” clones), suggesting that a part of the tumour simply resisted to 
chemotherapy; 
3. NO COMMONALITIES (only one patient): primary tumour and relapse 
have no clones in common (all clones are “primary only” or “relapse only”). 
Only one tumour, TO1, belongs to this class. The two phases of the 
disease look as two different tumours with specific and independent clonal 
populations. It would be difficult to find an explanation for this behaviour, 
even because the time to relapse for TO1 was of about 12 months, that 
seems a quite short time to develop a new and separate leukaemia. 
Indeed, inspecting the VAFs of the variants manually, we are able to score 
the presence of one cluster with VAFs close to 0%, but not null, in the 
primary tumour, that slightly increases in frequency in the relapse, however 
never reaching the 10% threshold. So the result we obtain is due to 
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analysis thresholds, that are arbitrary, but we still observe a primary clone 
expanding at relapse; 
4. DECREASE OF COMMON CLONES (6, 21% of the patients): all clones 
present in the primary tumour decrease or disappear (the tumours are 
mainly composed of “relapse only” and “decreasing in relapse” clones). 
Even if we can not exclude that there might be some other mechanisms 
that influence relapse expansion or that the effect of chemotherapy is the 
introduction of new mutations, leading to relapse formation. This 
behaviour could partly be an artefact due to a problem of purity of the 
remission sample, used to call the mutations, impairing the mutation 
calling task because their presence in the remission challenges the 
probability to call a somatic mutation. 
Figure 4.43: Schemes of clonal evolution in our AML samples. For every patient we 
report the clonal membership of every mutation identified. The colours are referred to 
the labels assigned to each clone as reported in the Legend and described in the text 
(paragraph 4.2.5.1). The four boxes correspond to the evolutional behaviour described in 
the text: 1, Clonal selection; 2, Resistance; 3, No commonalities; 4, Decrease of common 
clones. 
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4.2.5.2 Many driver genes resist to chemotherapy  
As reported for all genes, we performed a clonal analysis considering only the 
AML driver genes, grouping them on the basis of the behaviour of the clones that 
harboured their mutations. They were classified as: “Resistant”, if they appear in 
clones that survived chemotherapy and in some cases expanded in the relapse; 
“Poorly resistant”, when, though they were present at relapse, the frequency of 
their clones decreased; “Not resistant”, if they were present in clones killed by 
the chemotherapy. Of course, when the mutation was not present or not 
detectable in the primary tumour, we were unable to categorize them and 
assigned them to the “Arising” category. “Resistant” drivers are mainly involved 
in chromatin organization (SUZ12, DNMT3A, KDM6A, EZH2) and positive 
regulation of biosynthesis (CEBPA, MAPK1, GATA2, NPM1, TP53, RUNX1). 
Functional annotation of resistant genes attributes them mainly to 
“landscaping”61 and cell proliferation pathways (Figure 4.44). The list of AML 
driver contains some fishy genes like, for example TTN; in our analysis we can 
recognize the passenger nature of TTN because we observe its presence in 
clones of many different types, thus suggesting that it is not the primary player for 
the resistance of those clones (Figure 4.44). 
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Figure 4.44: Many clones harbouring mutations in AML driver genes are resistant to 
chemotherapy. Each AML driver gene is assigned to a category based on the behaviour 
of the clones that harbour their mutations (see text). The same gene in different patients 
appeared in clones with different characteristics.   
  
4.2.5.3 Clones containing mutations in NPM1 or in genes that belong to chromatin 
modifiers, cohesin complex, and DNA methylation are resistant to chemotherapy  
If we consider, once again, the functional categories to which the driver genes 
belong (Figure 4.45), based on the classification of clonal segregation, we 
observe that the spliceosome and tumours suppressor genes functional 
categories disappear or are reduced after chemotherapy. NPM1, genes involved 
in DNA methylation and in cohesion complex look mostly unaffected, because 
they never disappear after treatment. Mutations in chromatin modification 
pathways reappear at the relapse always at the same or incremented frequency. 
Mutated genes belonging to activated signalling and myeloid transcription 
factors have, instead, a more varied behaviour, suggesting that genes in these 
categories can either be resistant or not, or that they might cooperate with drivers 
belonging to the same or other categories. 
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Figure 4.45: Clones containing mutations in NPM1 or in genes that belong to 
chromatin modifiers, cohesin complex, and DNA methylation are resistant to 
chemotherapy. For every functional category described by the TCGA, the stacked bar 
plots represent the number of clones belonging to the categories reported in the figure 
legend. 
 
 
4.2.5.4 The remission sample seldom is mutated at low frequency 
Indeed, the presence of driver mutations at remission has been already shown for 
AML (see paragraph 1.4); their importance is paramount both from the clinical 
point of view: they can underlie the presence of minimal residual disease, and for 
the bioinformatics analysis because they can challenge the variants call. To 
investigate the presence of mutations at low frequency in the remission sample, 
we isolated all the genes belonging to the “no change” and “growing in relapse” 
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classes as we can be confident that the genes belonging to these classes survived 
chemotherapy. After, we plotted their frequencies in the primary and remission 
samples; we thought that pathogenic genes would decrease in frequency in the 
remission and therefore we filtered only genes presenting lower VAF in the 
remission compared to the primary tumour (Figure 4.46). The final list contained 
386 genes. Among them we found many reasonable false positives: all the taste 
and olfactory receptors, mucins and keratins are families of genes having very 
similar sequences and high variability among individuals; the alignment in these 
positions is often tricky (DSPP, TAS2R46, KRT8, MUC2, TCHH, FAM186A, OR1L4, 
OR2L3, ANKLE1, KIAA0196, KRTAP9-4, OR2L8). At the same time we also found 
“landscaping”61 genes (EZH2, ASXL1, IDH1, RUNX1, TET2, SETD8), signalling 
genes (NPM1, NRAS, SIRPA), genes associated to poor outcome (FLT3, TP53) and 
to drug metabolism (ABCC12). 
In particular, we observed that four genes belonging to clones of the “no 
change” class, detectable in the remission sample, were AML drivers or were 
classified as cancer genes by the Cancer Gene Census (CGC). RUNX1 (identified 
in TO8) had a frequency of 40% in the primary tumour, almost disappeared at 
remission (1% VAF) and came back at relapse with 30% frequency. A similar 
behaviour was observed also for CCND2 (in TO8: 40% VAF at primary, 0.8% VAF 
at remission and 19% VAF at relapse). Finally, other two genes have similar 
trajectories but at lower VAFs: MLH1 (in TO4) from 4% VAF in the primary goes to 
0.4% in the remission and reappears in the relapse at 9%; HSP90AB1 (in BO8) 
from 5% VAF to 2% and reappears at 7% VAF in the relapse. Note that the VAF of 
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a gene can dissociate from the frequency of the clone it belongs to, therefore, 
genes belonging to the “no change” class can have VAF differences bigger than 
5 percentage points. All these observations underline the problem of remission 
determination: in the case of TO8, for example, the treatment was very likely not 
sufficient for the complete eradication of the disease; additional molecular 
markers for remission assessment would improve the confidence in molecular 
remission determination. 
Figure 4.46: “No change” and “growing in relapse” classes are seldom present in 
the remission sample. We plot for the mutations belonging to those classes, the VAFs in 
the primary and remission sample in order to detect their presence in the remission. We 
also isolated from them the group of mutations having lower frequency in the remission 
compared to the primary tumour and characterized that list of genes. The blue line 
bisects the plan, mutations having lower VAF in the remission compared to primary lay 
below the blue line.  
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The same analysis was performed on the “Relapse Only” mutation class and we 
observed that, although the majority of mutations were undetectable at 
exordium, many of them (119) were already present at remission (Figure 4.47). 
22/29 (76%) of the patients had “relapse only” genes detectable at remission; 
excluding 5 outliers with high VAF of 18%, 20%, 22%, 51% and 54%, at remission 
they had a median VAF of 3% and a maximum VAF of 15%. Nonetheless, many of 
them were present on probable drivers, and we could detect AML driver genes, 
invisible at exordium, mutated at remission only in 4 patients. The genes were 
U2AF2 (BO6), CRIPAK (BO9 and UD14) and RBMX (UD9). The possible 
explanations for this event are two: that mutation could be present at very low 
frequency in the primary tumour and expanded later or chemotherapy induced 
them. Analysing the primary tumour at deeper sequencing could provide better 
insights on these events. Since these genes were previously identified as mutated 
in AML but are not known as primary players in the disease (no NPM1 or FLT3 
mutations were found), it would be interesting to determine their presence in a 
wider cohort of patients. Moreover, we analysed the presence of known drivers 
from CGC (not strictly AML drivers) in our cohort: patient BO2 presented a 
“relapse only” mutation detectable at remission on GNAS, a CGC driver gene. 
UD14, besides CRIPAK (mutated at 5% VAF) had mutations on other driver genes: 
MN1 (12% VAF), NFKB2 (5.5% VAF) and TSC2 (4% VAF); this can be possibly 
explained with the presence of a clone that expanded at relapse, becoming 
~10% VAF (correspondent to 20% of cells, not the dominant clone). 
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Figure 4.47: “Relapse only” variants are often detectable at remission. We isolated 
the variants that were present at relapse but not detectable in the primary tumour and 
analysed their VAFs at remission.  
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experimentally defined as founder mutations the nucleotide variants with VAFs 
scoring in the ninth decile of all frequencies in the primary tumour and followed 
their evolution trough their abundance in the cells in the different phases of the 
disease (Figure 4.48). Surprisingly, we observed that the founder clone is not 
always retained at relapse. The emblematic example is the patient TO1, in which, 
confirming the results obtained by the analysis of clonal composition by PyClone, 
we observed the complete depletion of the founder clone at relapse.  
Figure 4.48: Founder mutations can be depleted at relapse. For every patient we 
plotted the frequencies of the founder mutations in the primary and relapse samples. In 
each plot, each line identifies a different founder mutation, selected as the mutations 
falling in the ninth decile of VAFs in the primary tumour.  
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4.2.6 We were unable to validate by MiSeq relapse specific 
mutation in primary tumour 
We next validated our SNVs using Illumina MiSeq sequencing platform: our idea 
was to take advantage of a deeper coverage to verify the presence of the 
detected mutations at lower frequencies compared to normal WES output. We 
therefore tested a group of variants identified in 12 patients (BO1, BO2, BO3, 
TO1, TO2, TO3, UD1, UD2, UD3, UD4, UD5, UD6). We choose to test 262 
variants with VAFs median 40% (average 28%), belonging to the five groups 
defined in paragraph 4.2.3 in order to cover all the possible evolutionary 
characteristics. Results are reported in Table 4.12. The overall validation rate is 
94% in the primary tumour (sum of “primary only”, “decreasing in relapse” and 
“no change” groups) and 89% in the relapse (sum of “relapse only”, “growing in 
relapse” and “no change” groups). We had the chance to test the same variants 
in both samples at the same time, thus we made some observations: 
• Private mutations (i.e. “primary only” and “relapse only”) have high 
validation rates: 95% and 87% in the primary and in the relapse samples, 
respectively; 
• Common mutations (i.e. “decreasing in relapse”, “no change” and 
“growing in relapse”) also showed a high validation rate in both samples: 
94% and 90% in primary and relapse samples, respectively; 
• Miseq recapitulates the classes defined through WES results having a 0% 
of validation of “relapse only” mutations in the primary tumour and 5% of 
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validation of “primary only” mutations in the relapse; 
•  The main expectation from this analysis was, in fact, to find some relapse 
mutations in the primary tumour of the patients at lower frequencies. 
However, the MiSeq platform increases the sequencing depth but does 
not overcome the limits of the sequencing error introduced by the Illumina 
technology, preventing to distinguish very low frequency variants from 
errors (0.05%). It is, thus, possible that a group of “relapse only” variants is 
present at the exordium of the disease at frequencies lower than the 
detectability threshold of the MiSeq technology (0.5%) and we would need 
to approach this problem with a different technological solution to be able 
to uncover them (e.g. duplex sequencing134); 
• the presence at low frequency of “primary only” mutations in the relapse 
sample, on the other hand, is the proof of the existence of a clonal 
heterogeneity of the tumour population, with the presence of mutations 
that survive chemotherapy but do not expand. 
Table 4.12. Validation of 262 mutations through Illumina MiSeq sequencing 
platform in the primary and relapse tumour samples. 
Group Tested Validated 
in primary 
Validation 
VAF > 10% 
Validation 
VAF < 10% 
Validated 
in relapse 
Validation 
VAF > 10% 
Validation 
VAF < 10% 
Primary only 65 62 (95%) 42 20 3 (5%) 1 2 
Decreasing in 
relapse 
38 37 (97%) 37 0 34 (89%) 12 22 
No change 87 80 (92%) 79 1 78 (90%) 54 23 
Growing in 
relapse 
5 5 (100%) 5 0 5 (100%) 5 0 
Relapse only 67 0 0 0 58 (87%) 34 24 
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5. Discussion 
In the fight against cancer, nowadays, we have two disposable winning skills: early 
diagnosis and targeted drug intervention. AML is characterized by a rapid 
development and its early diagnosis is usually impracticable; it can be identified 
only rarely at beginning stages in predisposed individuals (e.g. MDS patients). 
The conception of novel drugs, on the other hand, can be enhanced by a better 
knowledge of the specific mechanisms leading to the appearance and 
maintenance of the pathology.  
APL is the prime example of targeted therapy, advancing in about two decades 
from the identification of the characteristic translocation of the genes PML and 
RARalpha (t15;17)135, to the first clinical trial treating APL without 
chemotherapeutic agents136. Lo Coco et al. were able to achieve 100% of 
remissions (on 77 patients), obtaining even better results than the association of 
trans-retinoic acid to idarubicin that cured patients in 95% of the cases (75/79). 
For all the other AMLs, the mechanism leading to tumour development is more 
complex and great improvement would be accomplished by the determination of 
the causes of frequent therapy failures. In this thesis, endowed of the NGS 
technologies advancement, that revolutionized the approach for tumour 
investigation, we try to delineate the possible process of relapse formation with 
the aim, in the future, to be able to predict which patients are more susceptible to 
relapse. 
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5.1 The choice of methods for NGS analysis has to be 
evaluated to answer a specific question on a definite 
dataset 
The methods for the analysis of NGS data are still in a refinement phase, at 
present. Indeed the scientific community is still lacking the definition of a unique 
pipeline combining all the best methods, especially for the high level analysis that 
consist in the actual detection of variants and definition of their role in the 
pathogenesis. In general, in order to obtain good results, it is recommended to 
first investigate the methods that fit best for the specific purpose of the analysis 
and for the specific dataset to be analysed. In fact, different methods can start 
from disparate assumptions that sometimes can collide with the hypothesis of the 
study. Moreover, the characteristics of the dataset (e.g. mutation rate, genomic 
instability, WGS versus WES) need to be taken in consideration when choosing 
the methods to analyse them. 
For our project we broadly analysed the existing methods for the treatment of 
NGS data in order to determine those better fitting to our cohort of patients and 
purposes. In particular, we tested the performances of aligners, mutation callers, 
CNV callers and methods to reconstruct clonal composition of tumors. 
Occasionally, we had the possibility to choose the best tool meeting our 
investigative needs, discovering that other methods were valuable as well: the 
choice of BWA rather than Novoalign was driven mainly by an economical (BWA 
is not under license) aspect because the performances of the two methods were 
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similarly good. These results have been confirmed by the 2015 publication of 
Hwang et al.137, in which the authors compared the performances of 13 WES 
analysis pipelines on a gold standard dataset. Also in that case BWA and 
Novoalign followed by GATK downstream analysis showed similarly good 
performances. Indeed BWA is one of the most widely used aligners for WES 
reads. On the contrary, for mutation calling the scientific community is making an 
effort trying to fill the weaknesses of the methods combining their skills in a 
unique tool. For this reason the ICGC-TCGA SMC-DNA meta challenge aimed at 
the construction of a meta-pipeline incorporating mutation calls from multiple 
variant callers in order to make robust variant predictions. Teams who submitted 
their method to the challenge organizers, in the majority of the cases, obtained 
levels of prediction accuracy over 90%, confirming that the aggregation of 
different tool’s characteristics largely improves the variant detection. Despite the 
great advancements of the last years in the accurate identification of somatic 
mutations, many papers showed us evidences of intrinsic errors related to the 
sample preparation and analysis that challenge this task: errors introduced by 
PCR, imbalanced coverage138 and sample degradation131 can eventually result in 
false positive calls and many methods are nowadays under development to 
overcome this issue. 
Certainly, the CNV detection in WES samples is tricky due to many factors: GC 
content and repetitive regions are probably the two more known actors but also 
imbalance produced by the PCR process or exome capture and the fact that 
some sections of the genome (i.e. regulatory regions) are generally less covered, 
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impair CNV calling, particularly in low coverage regions139. In fact Hong et al. 
reported a very poor reproducibility in CNV calling even from two successive 
analyses of the same samples, underlining the need for a careful and wide 
evaluation of existing methods140. Control FREEC, selected as best performing 
method in our study, also in the literature resulted to be the one showing the 
highest sensitivity and specificity balance for WES data141. 
Concerning clonal composition reconstruction, we concluded that none of the 
tested methods was ultimately satisfactory. Indeed, the extrapolation of clonal 
composition of the tumour population from WES data is complicated by multiple 
factors: 
• the presence of very low frequency mutations: it is difficult to associate low 
frequency mutations univocally to one clone, because they can be recent 
mutation in any clone; 
• the number of copies relative to the specific position of the mutation is a 
fundamental information to assess the real frequency of the mutation and 
the determination of the combination of frequency and number of 
absolute copies is not always straightforward; 
• the variant frequencies are affected by the error given by the sampling of 
the DNA material from the whole tumour: selecting only a subset of DNA 
molecules from the original sample can result in overestimation or 
underestimation of variant frequency, especially for low frequency variants. 
The ICGC-TCGA-DREAM challenge provided the opportunity to improve clonal 
analysis decomposition tools though the preliminary results told us that some 
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improvements could be made. Therefore, we made the best possible choice 
among the tested tools, aware that the results had to be taken with a pinch of 
salt.  
 
5.2 The impact of relapse prediction in AML patients 
Aiming at the characterization of the genomic landscapes of relapsing AML 
patients, we sequenced the primary and relapse tumour of 30 patients, and 
compared them with the corresponding remission sample highlighting the 
mutations that were retained and eventually grew after the first remission. This 
would allow to understand the forces that interplay in the relapse formation and 
to unveil the scenario that best fits with the clinical observations. AML is able to 
rapidly evolve and adapt to the new environmental state, thanks to the plasticity 
given by a genetic alteration makeup that confers an advantage to win the 
“struggle for life”. There are many hypothetical evolutionary scenarios and it is 
possible that they could be overlapping for subgroups of patients. The first 
intriguing question is whether mutations characterizing leukemic clones are 
already present at diagnosis. The markers described in Paragraph 1.7 are not 
exhaustive for prediction of relapse formation and finding new genetic markers 
that can improve outcome assessment would have a great impact on the clinic. 
This would consequently make room for new therapeutic strategies and 
contemporary give to the patients the possibility to make an aware choice of the 
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treatment, reducing the costs for the National Health Systems and improving 
patients’ quality of life. 
Strictly related to the first question, we would like also to understand whether the 
relapse originated from the dominant clone, a sub-clone or possibly from a pre-
leukemic clone that eventually evolved acquiring new mutations. 
We observed that in the majority of the patients (76%) some relapse clones were 
already present in the primary tumour and reappeared at similar or augmented 
cellular frequencies at relapse. 21% of the patients carried clones that persisted at 
relapse at decreased frequency, suggesting that the therapy was not effective but 
the dominant clones at relapse did not originate from the more represented in 
the primary tumour. In a patient-wise scenario the mutations of primary and 
relapse tumours were different and the transition/transversion rate indicated two 
different mechanisms at the origin of mutations in the two groups. However at the 
gene level, mutation specific for the primary or relapse tumour in one patient 
could be common in other patients as well. The genomic landscapes of primary 
and relapse groups were similar and it was difficult to grasp a specific resistant 
genetic make-up from our cohort. Grouping genes by functional categories, we 
observed that genes belonging to DNA methylation pathway, cohesin complex 
and chromatin modifiers are prone to confer resistance to therapy. 
Also CNVs patient-wise were seldom retained and, excluding those with high 
false positive rates, the patients with many common CNVs had also common 
mutations (UD4, TO4, UD1 and TO8). Recurrent mutated AML drivers were few 
and CNV losses were generally retained at relapse. 
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These results partially recapitulate previous observations of persistent 
“landscaping”61 mutations at relapse; nevertheless we have noticed that cell 
types carrying driver mutations seldom survive chemotherapy and there is no 
functional category always killed by the treatment. Furthermore we remarked the 
fact that the founder mutations of the primary disease in some cases disappeared 
at relapse, posing a question mark on the origin of the clones that expanded at 
relapse. Indeed, at relapse we never observed clones that were completely 
unrelated with the primary leukaemia but the disappearance of the most frequent 
mutations was not compatible with the hypothesis of a hierarchical structure of 
tumour cells. The possible explanation for this occurrence can be either technical 
or biological: it is possible that the sampling made by the biopsy and sequencing 
does not catch the high complexity of the real situation or that the frequencies 
that we measure are not accurate enough to permit a reconstruction of evolution 
of the disease in time; from the biological point of view we can suppose that in 
some patients the mutations are not the founder events and can be preceded by 
other transforming events like CNVs, as we confirmed for two out of five patients 
lacking founder mutations in the relapse, or epigenetic changes.  
 
5.3 NGS technology provides new chances for a better 
remission assessment 
The characterization of resistant mutations in this context was tricky, probably 
because the cells surviving after treatment were not proliferating in the primary 
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tumour but owned a high proliferative potential. The typical traits of dormant cells 
are difficult to be defined. Indeed, we observed the emergence at relapse of 
clones already presented in the primary tumour, with no additional mutations at 
relapse; previous studies also reported this behaviour, suggesting that the 
dormancy phenotype of LSCs can lie outside the genetic make up of a cell. 
With the situation manifested, this study has a clinical repercussion on the 
molecular characterization of the remission sample rather than the primary 
tumour. In fact, in many patients we observed that some molecular lesions 
peculiar of relapse sample were detectable at remission, although they were not 
identified in the primary tumour. Because the remission samples consisted in 
blood cells, we hypothesize that a NGS analysis targeted on AML driver genes 
would help in driving the treatment to obtain better outcomes for patients. In 4 
out of 29 patients (14%) we were able to identify driver mutations at remission 
and in 22 out of 29 patients (76%) we detected “relapse only” mutations at low 
frequency in the remission sample; in these cases a targeted sequencing of the 
remission sample (preferentially performed through a technique allowing calling 
of variants at very low VAFs) would advice clinicians on the ineffectiveness of the 
therapy, thus allowing them to provide additional treatments when possible. A 
hypothetical NGS chip would contain all AML driver genes, other known drivers 
(CGC) and a refined list of “relapse only” mutations that we detected at 
remission. 
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5.4 Conclusion and future perspectives 
The circumstances that make chemotherapy ineffective for AML treatment are 
complex and probably interplay on various levels: mutations, genomic 
rearrangements, epigenomics and regulation of dormancy/proliferation. In this 
thesis we identified some functional categories more prone to resistance and 
particular genes (not notorious in AML) presenting growing VAFs at relapse. We 
noticed the presence of leukemic mutations in the remission sample at low 
frequency and advocated the introduction of more sophisticated diagnostic tools, 
based on NGS technologies, to guide clinicians in the treatment decision plan. 
We think that some naturally consequent steps will deepen the knowledge of 
relapse formation commenced in this study: 
• the sequencing of primary tumour at very high sequencing depth would 
reveal the eventual presence of relapse mutations in the primary tumour; 
• an additional cohort of AML patients that did not relapse in 5 years after 
the initial treatment would give better insights on the difference in the 
mutational landscapes of primary tumour that are more or less prone to 
relapse in the next five years (this cohort can be retrieved from the TCGA 
patients); 
• the model used to build the benchmark datasets to test clonal analysis 
composition tools can be improved to ask a biological question: in order to 
test for the possibility that the presence of a pool of quiescent and 
somatically heterogeneous cells would favour the relapse formation, we 
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can simply add to the model the characteristic “dormancy”, coupling it 
with diminished proliferation. 
In the long term all the results reported in this thesis will possibly support the 
development and progress of new therapeutic strategies for AML. 
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